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Rheumatoid Arthritis (RA) is a chronic inflammatory disorder that typically affects 
cartilage and bone of small and middle-sized joints. Inflammatory cells invade the 
otherwise relatively acellular synovium, which leads to hyperplasia and formation of 
pannus-tissue. This infiltration causes destruction of cartilage, erosion of the adjacent 
bone and ultimately loss of function of the affected joint. Involvement of larger joints 
may also occur. Systemic inflammation, often going in parallel, can affect several organs 
(e.g. lungs, vessels and the hematopoietic system) and has long-term impact on organ 
function. Combined with inevitable side effects of yearlong anti-rheumatic medication 
(e.g. glucocorticoids) and the psychological burden of facing early invalidity and social 
instability, RA has, if insufficiently treated, important socio-economic impact and causes 
a reduction in life-expectancy of 7 years in average 1, 2.
For the clinician, there is considerable heterogeneity in both clinical picture and course 
of disease. Next to the characteristic signs and symptoms of RA, overlap with other 
rheumatic diseases can be observed (e.g. mixed connective tissue disease (MCTD)). In 
addition, other autoimmune diseases (e.g. Sjögren’s syndrome, autoimmune thyroiditis) 
may accompany RA. For reasons largely unknown, the course of disease is highly vari-
able, ranging from mild cases with non-erosive, even sometimes spontaneously remit-
ting disease, to severe, rapidly progressive and destructive arthritis 3. Recent analysis of 
genetic risk factors and autoantibody responses together with data from clinical trials 
suggest, however, that the clinical entity RA might consist of pathogenetically distinct 
subgroups, which present with similar if not identical clinical phenotypes 4. Different 
treatment strategies may need to be applied to patients within these groups.
For the immunologist, RA is considered an autoimmune disease by most, implying 
breakdown of immunological tolerance towards self at a given moment in a patient’s 
life. The trigger initiating this breakdown is so far unknown 5. The presence of autoanti-
bodies and slowly rising C-reactive protein-levels several years before onset of clinical 
symptoms indicate that the inflammatory process may be well underway long before 
patients first consult a physician 6. Variations between ethnic groups in susceptibility to 
RA, heterogeneity of disease course and variations in clinical, radiological and labora-
tory findings within groups strongly suggest that multiple factors, both environmental 
and genetic, influence onset and progression of RA, presumably with different impact 
during different stages of disease development. Genetic variations, autoantibodies, cel-
lular immune responses, hormones and gene-environment interactions are among the 
most studied factors contributing to RA development.
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AutoAntiBoDies AnD theiR Role in the DiseAse PRocess in RA
An array of antibodies targeting self-antigens (e.g. collagen type II, calreticulin, 
cathepsin, BiP, CH65, etc.) has been described in patients with RA 7. Demonstrating 
pathogenetic relevance for any of these reactivity’s, however, has proven difficult, last 
but not least because the clinical and radiological phenotype of RA can also develop in 
the absence of any of the autoantibodies known so far.
Rheumatoid factor
The initial notion that mechanisms of autoimmunity might underlie RA pathogenesis 
came from the discovery of autoantibodies targeting the Fc-part of human IgG (so called 
“rheumatoid factors” (RF)) in the blood of affected patients 8, 9. RF, present mostly as 
IgM-RF, but detectable in subgroups of patients also as IgG- and IgA-RF, are thought to 
form immune complexes activating complement, which in turn leads to increased vas-
cular permeability and the release of chemotactic factors recruiting immune-competent 
effector cells to the joint 10. The mere presence of RF, however, is insufficient to initiate 
arthritis development, as RF are also found in infectious diseases, autoimmune diseases 
other than RA and in up to 15% of healthy, mostly elderly individuals. Thus, sensitivity 
and specificity of RF are, depending on the population studied, 60-70% and 50-90%, 
respectively. Despite this lack of specificity, RF are part of the former and new classifica-
tion criteria for RA 11, 12.
Anti Citrullinated Protein Antibodies (ACPA)
Citrullination is a process by which arginine residues in a given protein are post-transla-
tionally modified, in the presence of high calcium-concentrations, by an enzyme called 
PAD (peptidyl arginine deiminase). Under physiological conditions, it is believed that 
citrullination facilitates the degradation of intracellular proteins during apoptosis 13, 14. In 
1998, two antibodies present in serum of RA patients, anti perinuclear factor (discovered 
in 1964 15) and anti-keratin antibodies (first described in 1979 16) were found to recognize 
a common target: citrullinated fillagrin 17, 18. This observation, together with an unprec-
edented specificity of citrulline-specific antibodies for RA, has placed anti-citrullinated 
protein antibodies (ACPA) at the center of intense research efforts. Meanwhile, citrullin-
specific reactivities against several proteins (e.g. fibrinogen, collagen, vimentin, enolase, 
and others) have been identified, and by the use of optimized assays ACPA are now 
detectable in 60-70% of RA-patients, but hardly in other diseases or healthy subjects. 
Whether ACPA contribute to the disease process, and the possible pathogenetic mecha-
nism of such a contribution, is matter of intense debate. A number of clinical associations 
and an increasing amount of experimental data, however, point in this direction.
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Individuals with joint pain (arthralgia) that harbor ACPA in serum have an increased 
risk to develop arthritis 19. In patients with undifferentiated arthritis (UA), the presence 
of ACPA increases the risk for progression to RA, and lowers the chance for remission 20. 
ACPA positive RA patients suffer from more extensive joint destruction and more fre-
quent extra-articular organ involvement than their ACPA negative counterparts 21. Also 
histologically, synovial tissue differs between ACPA positive and negative patients 22. 
Patients with UA benefit from treatment with methotrexate if ACPA positive, as they 
develop significantly less joint destruction in the first year than untreated controls, and 
progress to RA less frequently. For ACPA negative UA patients, methotrexate treatment 
was without effect on these parameters compared to placebo 23, 24. A number of genetic 
factors, among which the so-called shared epitope (SE-) alleles, confer risk for RA de-
velopment only to ACPA positive individuals, whereas they do not seem to influence the 
pathogenic process in ACPA negative disease 25. In fact, SE-alleles, a set of HLA-DRB1 
molecules with a shared amino acid sequence formerly regarded as strong risk factors 
for RA, are risk factors only for the development of ACPA, without an independent risk 
effect on the development of RA itself 26.
Taken together, these observations support a model in which ACPA positive RA de-
velops on a different pathogenetic background than ACPA negative RA 4. The ACPA 
immune response broadens shortly before onset of clinical disease, with an increasing 
number of citrullinated epitopes recognized and more ACPA isotypes generated 27, 28. The 
question arises, however, as to the available scientific evidence that ACPA are the actual 
factors driving the disease process. This all the more, as patients can undergo complete, 
drug-free remission despite persistent, high ACPA serum titers.
ACPA pathogenicity
Citrullinated antigens are found in RA synovium, which is an important prerequisite for 
local ACPA pathogenicity 29, 30. At the same time, ACPA levels are elevated in synovial 
fluid as compared to serum 31. In the mouse, antibodies to a citrullinated B-cell epitope 
of collagen type II (CII), which cross-react with citrullinated CII in human joints, were 
found to be arthritogenic 32. Monoclonal antibodies against citrullinated fibrinogen were 
found to enhance arthritis in a mouse model of pre-existing collagen-induced arthritis 33, 
and citrullinated human fibrinogen, but not unmodified fibrinogen, was able to induce 
arthritis in HLA-DRB1*0401 (DR4-IE) transgenic mice 34. In the latter experiment, no 
induction of arthritis was seen in wild-type mice lacking the transgene.
In the human, first evidence for ACPA-specific pro-inflammatory effects came from 
studies that observed stimulation of macrophages by ACPA-containing immune com-
plexes 35. In addition, ACPA were found to activate the complement system 36. More 
recently, in vitro activation of basophils by ACPA of the IgE isotype was described 37. In 
addition, associations were noted between IgE and FcεRI expression on synovial mast 
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cells, histamine levels in synovial fluid and ACPA positivity. As synovial mast cells are 
an important source of the proinflammatory cytokine IL-17, ACPA stimulated mast cell 
degranulation and cytokine production could contribute to local inflammation 38. More 
recent work has demonstrated in vitro activation of human osteoclasts by antibodies to 
citrullinated vimentin, with increased bone loss in mice injected with these antibodies 39. 
This latter observation, which was not noted for non-specific IgG, so far most closely 
links ACPA to the pathological correlate of RA: bone erosions.
In summary, both clinical associations and an increasing number of experimental data 
support the hypothesis that ACPA contribute to synovial inflammation and joint destruc-
tion. The observation that RA can remit despite the presence of ACPA indicates, however, 
that the quality rather than the quantity of the ACPA immune response determines its 
pathogenicity. One important aspect of the immunogenicity of antibodies is determined 
by Fc-linked glycans.
AntiBoDy GlycosylAtion AnD its functionAl consequences
Human antibodies are glycoproteins with carbohydrate structures attached to the con-
stant and, in some cases, to the variable region of the molecule. These glycans strongly 
influence the in vitro and in vivo biological characteristics of an antibody, such as serum 
half-life, binding to Fc-receptors, complement activation and interaction with lectins 40, 41. 
Glycans attached to the Fc-tail of IgG-molecules have most extensively been studied.
Fc-glycosylation of human IgG
The Fc-tail of human IgG carries two complex-type N-glycans, each attached to one 
heavy chain at position 297 (asparagine) in the CH2 domain of the protein backbone (Fig-
ure 1A). The sugar chains are intercalated between the heavy chains, with which they 
non-covalently interact at several positions. This interaction maintains the three dimen-
sional structure of the Fc-tail, which changes conformation and loses its function once 
the glycans are enzymatically removed 42-44. The glycan chains consist of a conserved 
biantennary, heptasaccharide core structure of N-acetylglucosamine (GlcNAc) and man-
nose residues (Figure 1B). Core fucose, additional (bisecting) GlcNAc, galactose, and a 
terminating sialic acid residue further modify this sequence. In total, these modifications 
yield more than 30 possible variants per glycan chain, of which glycoforms carrying 
either zero, one or two galactose residues (termed G0, G1, G2 glycoforms) are most 
abundantly found on human IgG (20–35%, 35%, and 16% of all glycoforms, respec-
tively). The degree to which Fc-linked glycans on IgG are sialylated, galactosylated, 
fucosylated or carry bisecting GlcNAc residues in a given individual depends on various 
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factors such as age, hormonal status, and the type of immune response during which the 
IgG molecule is produced 45-47.
Functionally, the Fc tail interacts with Fc receptors and binds the complement com-
ponent C1q. In addition, it is the target of rheumatoid factors and as such involved 
in immune complex formation. Absence of galactose residues (G0) on the Fc-linked 
glycans is associated with concomitant absence of sialic acid residues and increases the 
affinity of the Fc tail for activating Fc gamma receptors (FcγR) expressed by immune 
cells 49, 50. In addition, agalactosylated glycoforms on the Fc tail enhance the formation 
of IgG-containing immune complexes 51. Mainly for these reasons, a high abundance of 
G0-glycoforms on IgG is thought to correspond to pro-inflammatory properties of the 
molecule. In contrast, presence of galactose (G2) and sialic acid residues is believed to 
favor anti-inflammatory effector functions. Moreover, absence of core fucose residues 
leads to high avidity of the Fc-tail for binding to FcγRIIIa, which is based on a unique 
interaction of the afucosylated Fc-glycan with carbohydrates of the receptor 52. This in-
teraction enhances antibody dependent cellular cytotoxicity (ADCC) by up to 100-fold, 
a finding exploited by glycoengineerd therapeutic monoclonal antibodies 52-54.
The in vivo effects of different IgG Fc-linked glycoforms can be studied using re-
combinant monoclonal IgG molecules of defined specificity or by employing IgG mol-
ecules purified from pooled human plasma of healthy individuals. Such polyclonal IgG 
preparations (termed intravenous immunoglobulin, IVIG) are known for their important 










figure 1: (A) Three dimensional structure of a human IgG1 molecule with the two heavy chains de-
picted in dark and light grey. The glycan chains are intercalated in between the heavy chains (modified 
from 48). (B) Schematic depiction of a monosialylated glycan attached to one of the heavy chains at posi-
tion 297. The dotted line shows the conserved core structure, which can be modified by fucose, galac-
tose and sialic acid residues. Also disialylated glycoforms and glycans carrying an additional, bisecting 
N-Acetylglucosamine (GlcNAc) residue can be found (not shown).
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diseases 55. Using IVIG, a number of studies have proposed an important role of terminal 
sialic acid residues for IgG-mediated effector functions. In fact, removal of terminal 
sialic acid residues from IVIG-associated glycans has been reported to abrogate its anti-
inflammatory activity in mouse models of autoimmunity 49, 56, 57. Conversely, enrichment 
of IVIG for sialylated molecules enhanced this property. In fact, it has been postulated 
that only a minor fraction of IgG molecules (~ 1-3%) within IVIG carries terminal sialic 
acid residues on their Fc-linked glycans and that this small fraction might account for 
the therapeutic effects observed 49. Accordingly, enrichment of the sialylated fraction 
by lectin affinity chromatography using Sambucus nigra agglutinin (SNA) or in vitro 
sialylation was found to result in a reduced dose requirement for the in vivo activity of 
IVIG. In line with this, a fully recombinant human IgG1 molecule with Fc-linked glycans 
terminating in sialic acid-galactose linkages recapitulated the in vivo anti-inflammatory 
activity of intact IVIG and enhanced its effect by 35-fold, compared with the activity of 
conventional IVIG 56.
It is important to note, however, that several aspects of the studies on IVIG described 
above are currently under debate. This is mainly based on the observation that lectin 
chromatography with SNA does not enrich for Fc-linked sialylated IgG, but for IgG 
molecules carrying sialic acid containing glycans in the Fab portion 58, 59. In addition, the 
studies employed human IgG molecules to study effects in mice, indicating that it might 
not be possible to directly translate the findings to the human situation. Thus, although 
the relevance of the Fc-glycan for interaction of IgG molecules with FcγR is undisputed, 
the specific role of terminal sialic acid residues in this context requires further study.
In addition to FcγR mediated effects, Fc-glycans are also required for and modu-
late IgG-mediated complement activation 60. Although the ability of IgG to activate 
complement strongly depends on the IgG subclass, C1q binding to IgG1 and subsequent 
activation of the classical pathway was found to be most effective in the presence of G2-
glycoforms 61, 62. Mannose-binding lectin (MBL), on the other hand, binds to exposed, 
terminal mannose, fucose and GlcNAc residues on agalactosylated (i.e. G0 containing) 
IgG molecules in vitro, thereby initiating the lectin pathway of the complement cas-
cade 63. Debate exists, however, as to the in vivo relevance of this finding with regard 
to IgG pathogenicity in autoimmune diseases, as IgG-G0 molecules in MBL-null mice 
(genetically deleted for MBL) did not lose their inflammatory potential in mouse models 
of immune-thrombocytopenia and arthritis, whereas their effects were abrogated in FcγR 
deficient mice 50.
IgG Fc-glycosylation in RA
In RA, early work has demonstrated aberrant glycosylation of the Fc-tail of serum IgG, 
which mainly lacks galactose and sialic acid residues as compared to IgG in healthy 
individuals 64. This hypogalactosylation (i.e. predominance of the G0 glycoform) and, 
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as a consequence, hyposialylation, of the Fc-tail associates with disease activity and can 
revert to normal levels during effective treatment, for example with tumor necrosis factor 
alpha inhibiting agents 65, 66. A similar decrease in G0 content was observed in female 
RA-patients during pregnancy 67. The hypogalactosylation of IgG molecules in RA is 
likely to be regulated on the B cell level, rather than a result of enzymatic release of 
galactose residues post-secretion, as reduced expression of β-1,4-galactosyltransferase, 
the enzyme responsible for adding galactose residues to the Fc-linked glycan, was noted 
in B cells of patients with RA 68.
These observations raise the question whether the disease activity dependent variation 
of IgG Fc-glycosylation in RA actively contributes to disease, or whether it merely reflects 
the inflammatory environment in which the IgG molecules are produced. Arguments for 
the latter concept are fuelled by the finding that hypogalactosylation of human IgG-Fc is 
not specific for RA, but also characterizes other autoimmune diseases and can even occur 
in the context of infectious diseases 69. The hypothesis of an active modulation of disease 
by G0-containing IgG, however, is supported by studies on the anti-inflammatory effects 
of sialic acid containing IVIG described above, and by animal studies. Specifically, in 
a murine passive transfer model of arthritis, agalactosylated IgG induced more severe 
arthritis than IgG without glycan modification, indicating that Fc-linked G0 glycoforms 
can indeed increase inflammation in this context 67, 70. Moreover, deglycosylation of 
the Fc-tail abrogated arthritogenicity of monoclonal, collagen-specific murine IgG in a 
similar model 44. More recent data showed that the increase in IgG G0 glycoforms in RA 
could be detected several years before diagnosis 71, a finding that supports, but does not 
prove, the concept of a pro-inflammatory effect of G0 in human RA.
In summary, glycans on the Fc tail of human IgG have a strong influence on its biological 
function. Intriguing aberrations of Fc-linked glycans are noted in RA. Until now, it is un-
certain whether these glycosylation changes are cause or consequence of inflammation.
the Role of ReGulAtoRy t cells in RA
Regulatory (Treg) T cells represent an important mechanism by which the immune sys-
tem can control the development of autoreactivity. This is crucial, as autoreactive T- and 
B-lymphocytes can escape the classical checkpoint of central tolerance in bone marrow 
or thymus, which functions as the main barrier to eliminate autoreactive lymphocytes 
during their development. Accordingly, severe autoimmunity including arthritis devel-
ops in the absence of regulatory T cells, both in mice and humans 72, 73.
The population of CD4 expressing human Treg cells is heterogeneous; it comprises 
a subset with imprinted regulatory functions (“naturally occurring” Treg cells) derived 
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from the thymus, and a set of peripheral T cells that can acquire them (“adaptive” or 
“inducible” Treg cells) 74. Both types are considered to be “regulatory” based on the 
capacity to effectively inhibit proliferation and cytokine secretion of effector T cells in 
culture. CD4+ Treg cells are classically identified based on the expression of high levels 
of CD25 and the transcription factor FoxP3, and of low levels of the α-chain of the 
IL-7 receptor (CD127). The expression of FoxP3 is stable in natural Treg cells due to 
epigenetic imprinting, while inducible Treg cells express FoxP3 transiently 75, 76. More 
recently, the transcription factor and regulator of FoxP3 expression Helios was identified 
as phenotypic and functional marker of natural, but not adaptive, Treg cells 77. In vitro, 
Treg cells are characterized by low proliferation rates, low production of IL-2 and by 
secretion of TGF-β, IL-10, IL-35, perforin and granzymes 78, 79.
Regulatory T cells in RA
The role of Treg in RA pathogenesis is unclear. Unlike in the mouse, human natural 
and adaptive Treg are difficult to differentiate from activated T cells without regulatory 
functions, as markers such as CD25 and FoxP3 are inducible upon stimulation. Because 
of this, the number and functional integrity of regulatory T cells in RA are subject to 
debate 80. In the mouse, depletion of CD25+ FoxP3+ Treg can enhance arthritis, while 
adoptive transfer of Treg can ameliorate disease 81, 82. As these experiments, together 
with arthritis development in Treg deficient mice and humans shows the general capacity 
of Treg to modulate arthritis, both functional Treg deficiency or resistance of effector 
cells to Treg-mediated suppression could operate in RA.
As CD25 and FoxP3 expression in human T cells cannot be equalized with suppressive 
function, reports on Treg in RA range from decreased numbers to increased frequen-
cies, and from impaired to enhanced suppressive functions 83-86. In addition, differences 
were reported between Treg cells in peripheral blood and synovial fluid 85. Elegant flow 
cytometric studies combined with functional and epigenetic data have shown that human 
Treg cells can be subdivided in resting naïve and activated effector Treg cells based on 
the expression of CD25 and CD45RA, and in a population of FoxP3 expressing, CD25+ 
but CD45RA− non-Treg cells 87. This more subtle delineation of Treg cell populations, 
however, has not been used in most studies.
Of interest, impaired Treg cell function has been reported under the influence of 
TNF-α, which was reversible by anti-TNF treatment 84, 88. This observation is plausible, 
as Treg cells express TNFR-II, which makes them susceptible to the deleterious effects 
of TNF-α. In fact, treatment with TNF-antagonists gave rise to a newly generated, 
functionally distinct Treg-cell population that secretes TGF-β and IL-10. However, more 
recent data suggest that also this notion might be debatable, as TNF was also found to 
promote Treg cell function 80.
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Taken together, it is currently unclear to what extent Treg cells are defective in RA, or 
why functional Treg are insufficient to control the disease.
outline of this thesis
Based on the observations and considerations described above, this thesis investigates 
several aspects of immunological disease mechanisms that are of relevance to the in-
flammatory immune response in rheumatoid arthritis. Specifically, three main research 
questions triggered the experiments presented and form the outline of this thesis:
1. Do regulatory T cells feature anti-inflammatory properties besides the inhibition of 
effector T cells, which could help explain their therapeutic effectiveness in a murine 
model of established arthritis?
2. Are there specific features of the ACPA immune response that could contribute to 
inflammation in RA, and can analysis of these features help in understanding the 
characteristics of ACPA producing B cells and their development?
3. Do certain genetic variants that associate with RA susceptibility contribute also to 
disease progression, as evidenced by the rate of joint destruction in RA?
Part i was triggered by the observation that adoptive transfer of regulatory T cells during 
the effector phase of murine collagen-induced arthritis significantly decreased inflamma-
tory disease activity, without affecting the levels of circulating antibodies 82 (chapter 2). 
This was unexpected, as effector T cells, the primary target of Treg cells, were thought 
to be involved primarily in the initiation phase of this otherwise antibody-driven disease 
model 89, 90. At the same time, this finding suggested that Treg cells possess means to 
dampen inflammation beyond the inhibition of effector T cell function. In the light of the 
role of TNF-α in RA, our studies revealed that Treg cells can express and shed a soluble 
receptor for TNF-α, TNFRII. This TNFR-shedding was capable of inhibiting an early, 
TNF-mediated inflammatory response in the mouse, which demonstrated the in vivo 
relevance of this functional aspect of Treg. Importantly, the feature of TNFR-shedding 
could be shown for murine as well as human Treg cells. In conclusion, the first part of 
the thesis demonstrates the identification of a mechanism underlying anti-inflammatory 
properties of regulatory T cells.
Part ii is dedicated to the quality of the ACPA immune response and its potential contri-
bution to inflammation in RA (chapters 3 – 6). As described above, ACPA are detectable 
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in similar levels in patients with active and inactive disease 91, 92, indicating that the qual-
ity rather than the quantity of the ACPA immune response determines its pathogenicity. 
We studied both features of the ACPA Fc tail as well as characteristics related to antigen 
binding via the variable region.
Based on the observation that the Fc tail of IgG molecules in RA lacks galactose and, 
consequently, sialic acid residues, and that Fc-linked glycans can modulate immune 
responses, we hypothesized that ACPA might differ from non-specific IgG molecules in 
their Fc glycosylation profile and thereby have the potential to enhance inflammation. 
To study Fc glycosylation antigen-specifically, we first developed a method for isolating 
ACPA from small quantities of human serum and combined it with a high throughput 
analysis of Fc glycopeptides by mass spectrometry (chapter 3). This methodology al-
lowed us, for the first time, to study glycan residues linked to the ACPA Fc tail, and to 
compare them to those found on the Fc tail of non-specific total IgG of the same patient. 
When applied to serum and synovial fluid samples of ACPA positive RA patients, the 
analysis revealed that ACPA indeed exhibit a specific, pro-inflammatory glycan profile 
in that they significantly lack sialic acid and galactose residues (chapter 4). Importantly, 
we found differences in the Fc glycosylation profile of ACPA in serum and synovial fluid 
within the same patient, which was not the case for non-specific IgG. In line with the ini-
tial hypothesis, ACPA in synovial fluid were highly agalactosylated. As such, this finding 
represents evidence for qualitative differences of ACPA in different compartments, and 
indicates that ACPA producing B cells might possess specific functional characteristics, 
which are distinct from “conventional” B cells.
In this context, little is known on the origin and development of ACPA-specific B cells. 
Most B cells mature in germinal centers, where they receive help from follicular helper 
T cells to undergo class switch recombination and affinity maturation 93. ACPA of all Ig 
isotypes have been detected in patient sera, supporting the notion that ACPA producing 
B cells originate from germinal center reactions 28, 37. Importantly, during conventional 
immune responses, only B cells with B cell receptors of high affinity for the antigen 
receive appropriate survival signals required to differentiate into memory B or plasma 
cells. To gain further insight into specific features of ACPA that might relate to aberrant 
B cell development, we studied the avidity of ACPA in comparison to the avidity of 
antibodies against recall antigens such as tetanus (chapter 5). Surprisingly, ACPA were 
found to be mainly of low avidity, irrespective of the degree of class switch recombina-
tion that the ACPA specific B cells had undergone. Also during the course of 5 years, we 
did not detect affinity maturation within individual patients. This observation supports 
the notion of a developmental difference between “conventional” and ACPA producing 
B cells, but the underlying mechanism remains unknown.
Finally, another aspect of ACPA pathology relates to the antigens recognized. The 
ACPA response is polyclonal and generates multiple specificities that recognize various 
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citrullinated proteins 94. This has fuelled the hypothesis that certain reactivity’s might 
be more specific for, or more relevant to the disease process than others. As most cur-
rently used detection assays use citrullinated antigens designed to detect as many ACPA 
positive individuals as possible, yielding high sensitivity of the assay, these do not take 
into account potential subgroups of patients in which the ACPA recognition profile 
might associate with clinical features of the disease. As destruction of the affected joint 
is the prominent feature of RA, we addressed this issue by analyzing whether certain 
fine specificities exist within the repertoire of citrullinated antigens that are specifically 
pathogenic by promoting enhanced joint destruction over time (chapter 6). Of interest, 
no fine-specificity associated with the rate of joint destruction within the ACPA positive 
subgroup, indicating that recognition of citrullinated antigens in itself, but not the recog-
nition of specific citrullinated proteins, is of primary relevance to RA disease pathology. 
Moreover, it suggests that analysis of the ACPA recognition profile within ACPA positive 
individuals does not identify patients specifically at risk for progressive disease.
Part iii, in keeping with risk factors for joint destruction, analyzes the contribution of 
genetic variants located in the 6q23 region to the rate of joint destruction in RA (chap-
ter 7). This region had previously shown association with RA susceptibility in several 
studies, but the underlying mechanism for this effect, as for many genetic risk factors, 
remained unknown 95-97. Of interest, the association was only found in the ACPA positive 
subgroup, in line with observations on other RA-associated risk factors including the 
shared epitope alleles. The variants are located close to the gene encoding TNFAIP3, a 
negative regulator of NFκB involved in TNF-receptor mediated signaling. In our study, 
we observed that carriers of two single nucleotide polymorphisms displayed increased 
joint destruction over time. This observation refines the understanding of potential ef-
fects mediated by this genetic locus and represents the first description of a risk factor 
outside the HLA-region that could be linked to disease outcome.
chapter 8 provides a summary of the work presented and a discussion of the results in 
the context of current literature.
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ABstRAct
CD4+CD25+ regulatory T cells (Treg cells) play an essential role in maintaining toler-
ance to self and non-self. In several models of T cell mediated (auto-) immunity, Treg 
cells exert protective effects by inhibition of pathogenic T cell responses. In addition, 
Treg cells can modulate T cell-independent inflammation.
We now show that CD4+CD25+ Treg cells are able to shed large amounts of TNF recep-
tor II (TNFRII). This is paralleled by their ability to inhibit the action of TNF-α both 
in vitro and in vivo. In vivo, Treg cells suppressed IL-6 production in response to LPS 
injection in mice. In contrast, Treg cells from TNFRII-deficient mice were unable to do 
so despite their unhampered capacity to suppress T cell proliferation in a conventional in 
vitro suppression assay.
Thus, shedding of TNFRII represents a novel mechanism by which Treg cells can inhibit 
the action of TNF, a pivotal cytokine driving inflammation.
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intRoDuction
Current understanding of basic processes that control immune tolerance has been fuelled 
by identification of CD4+CD25+ regulatory T (Treg) cells3 as an important component of 
self-tolerance. CD4+CD25+ T cells have been shown to regulate peripheral self tolerance, 
to protect against autoimmunity and to suppress immune responses to autoantigens, al-
loantigens, tumor antigens and infectious agents 1-4.
Despite accumulating evidence for immunoregulatory properties of CD4+CD25+ Treg 
cells, the mechanism by which CD4+CD25+ Treg cells inhibit T cell-independent inflam-
mation is not well defined. CD4+CD25+ Treg cells are anergic to TCR-stimulation in 
vitro and capable of inhibiting proliferation and cytokine production of other T cells by 
secretion of anti-inflammatory cytokines (e.g. IL-10 and TGF-β) and a mechanism that 
depends on CTLA-4 and membrane-bound TGF-β 5, 6.
We previously showed that adoptive transfer of Treg cells decreases levels of acute 
phase proteins such as serum amyloid P component (SAP) in mice that had been injected 
with CFA (unpublished observation) or that underwent total body irradiation 7. For that 
reason, we hypothesized that Treg cells shed a soluble mediator that can inhibit the 
induction of acute-phase responses. TNF-α is one of the most prominent initiators of the 
acute-phase reaction which can, via the action of IL-6, promote the release of several 
acute-phase proteins from the liver 8-10. Here, we describe a novel mechanism by which 
Treg cells can counteract the action mediated by TNF-α.
MAteRiAls AnD MethoDs
Mice
C57BL/6 mice and TNFRII KO mice on a C57BL/6 background (B6.129S2-
Tnfrsf1btm1Mwm/J) were maintained at LUMC animal facility in accordance with national 
legislation under supervision of the University’s animal experimental committee.
Isolation of murine Treg cells and culture
Murine CD4+CD25+ and CD4+CD25− T cells were isolated from spleen and LN of 
6-14 week old mice by positive selection of CD4+ T cells (MACS), fluorescent label-
ing (anti-CD4, anti-CD25) and subsequent FACS-sorting (FACS-ARIA cell sorter, BD 
Biosciences) on the basis of CD25 expression. Purified T cell subsets were activated in 
the presence of Dynabeads mouse CD3/CD28 (Dynal Biotech) and 50 IU/ml IL-2.
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Isolation of human Treg cells and culture
Isolation of human CD4+CD25high or CD4+CD25− T cells from buffy coats of healthy hu-
man donors was performed as previously described 11. FACS-sorted CD4+CD25high and 
CD4+CD25− cells were cultured in the presence of 1 µg/ml anti-CD28 (CLB-CD28/1, 
Sanquin), 5 µg/ml plate-bound anti-CD3 (OKT-3, BD Biosciences) and 100 U/ml IL-2 
for up to 5 days. Metalloproteinase-inhibitor marimastat was added to cultures where 
indicated at a final concentration of 10 µg/ml.
Suppression assay
After 3 to 4 days of in vitro activation, CD4+CD25− and CD4+CD25+ T cells were 
cultured with equal numbers of freshly isolated splenocytes in the presence of 1 µg/ml 
PHA. 3H-thymidine incorporation of triplicates was measured 3-4 days later. Suppres-
sion assays were performed for each sorted population of CD4+CD25+ cells to ensure the 
suppressive capacity of isolated Treg cells.
Flow cytometry
Murine cells were stained using mAb against CD4, CD25, CD120b (TR75-89), FoxP3 
(FJK-16S, eBiosciences) or an isotype control. Human cells were stained using mAb 
against CD4 (RPA-T4), CD25 (2A3), CD120b (MR2-1, AbD Serotec and 22235, R&D 
Systems), CCR7 (3D12), HLA-DR (L243), CD45RO (UCHL1), CD45RA (HI100) 
and CD62L (Dreg 56). Intracellular FoxP3-staining was performed using eBiosciences 
FoxP3-staining kit (PCH101 or appropriate isotype control). Antibodies were purchased 
from BD Biosciences unless otherwise stated.
TNFRI and TNFRII secretion
sTNFRI and sTNFRII in culture supernatants were measured using standard ELISA-kits 
(Hycult Biotechnology for murine and R&D Systems DuoSet for human sTNFR).
Bioactivity of sTNFR
In vitro activity of sTNFR was measured using TNF-α sensitive WEHI 164 clone 13 
cells as previously described 12. In vivo activity was determined by injecting mice i.v. 
with 1x106 Treg or control cells (CD4+CD25− T cells) of either WT animals or TNFRII 
KO animals after 4 days of in vitro activation. As a control, mice were injected i.v. with 
250µg Etanercept, a TNFRII-Ig fusion protein. 1 hour later mice were injected i.p. with 
150µg LPS (S. typhosa, Sigma). 4 and 6 hours after LPS-injection blood samples were 
collected to determine serum levels of IL-6 using BD Biosciences Mouse IL-6 ELISA 
set.
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Results AnD Discussion
Shedding of sTNFRII by murine CD4+CD25+ Treg cells but not by CD4+CD25− cells
Adoptive transfer of CD4+CD25+ Treg cells can inhibit the induction of acute-phase 
responses in mice 7. As TNF-α stimulates acute-phase responses 8-10, we hypothesized 
that CD4+CD25+ Treg cells could directly inhibit TNF-α. FACS-analysis revealed that 
CD4+CD25+ Treg cells, as opposed to CD4+CD25− T cells, strongly express TNFRII 
(data not shown), leading us to predict that Treg cells may be able to shed sTNFRII. 
Therefore, we activated purified CD4+CD25+ and CD4+CD25− T cell populations in vitro 
and analyzed supernatants of these cultures for presence of sTNFR. While no sTNFRI 
could be observed (data not shown), sTNFRII was detectable in culture supernatants 
of CD25+ cells from day 1 onwards (Figure 1). No TNFR-shedding was noted in the 
presence of IL-2 only (data not shown), indicating that TCR-triggering is required for 
TNFR-shedding.
figure 1: CD4+CD25+ T cells shed TNFRII
Levels of soluble TNFRII in cell culture supernatants. CD4+CD25+ and CD4+CD25− cells were cultured 
with anti-CD3/anti-CD28 coated beads and IL-2. Supernatant was analyzed for the presence of TNFRII 
by ELISA (* P<0.05, ** P=0.0001). Depicted is one representative experiment out of 3.
Although sTNFRs were also detected in cultures of activated CD4+CD25− cells, this T 
cell subset produced far less sTNFR. CD4+CD25− T cells proliferate more vigorously 
than CD4+CD25+ Treg cell populations, resulting in 8-10 times higher cell numbers after 
6 days of culture. When corrected for cell numbers, CD4+CD25+ Treg cells produced 
approximately 50 times more sTNFR than their CD4+CD25− counterparts on a per cell 
basis (data not shown).
CD4+CD25+ Treg cell-derived sTNFRII inhibits the action of TNF-α in vitro
We next wished to examine the biologic activity of Treg cell-derived sTNFRII. For 
this purpose we performed a bioassay using TNF-α sensitive WEHI cells 12. Survival 
of WEHI cells was measured after incubation with ranging amounts of rTNF-α in the 
presence or absence of culture supernatants derived from activated CD4+CD25+ and 
CD4+CD25− T cells. Supernatant from CD4+CD25− T cells induced ~ 50% WEHI cell 
death without addition of rTNF-α, reflecting increased shedding of TNF-α by activated 
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CD25− effector T cells as compared to CD4+CD25+ Treg cells. TNF-α-induced death of 
WEHI cells was largely prevented, however, when, next to titrated amounts of rTNF-α, 
culture supernatant of CD4+CD25+ Treg cells was added to the wells. (Figure 2A). To 
confirm that the inhibition of cell-death was indeed mediated by sTNFRII, we next 
isolated CD4+CD25+ Treg cells from TNFRII KO mice. No inhibition of cell-death was 
observed after addition of culture supernatant from activated CD4+CD25+ cells derived 
figure 2: Biological activity of Treg cell-derived sTNFRII.
(A) sTNFRII in the supernatant of CD4+CD25+ T cell cultures can prevent TNF-α induced cell death. 
CD4+CD25+ and CD4+CD25− cells were activated in vitro for 4 days. Supernatant was added to cultures 
of WEHI cells in the presence of varying amounts of rTNF-α. Depicted is the percentage of WEHI cells 
surviving the culture for 20 hours. (B) TNFRII shed by Treg cells is required to prevent TNF-α induced 
cell death. CD4+CD25+ cells from naïve WT or TNFRII-KO mice were isolated and supernatant of 
cell cultures was used in the WEHI cell bioassay in the presence of 0.5 pg/ml rTNF-α (* P<0.001; Et. 
= Etanercept). Representative data from 11 independent experiments are shown in (A) and (B). (C) 
CD4+CD25+ cells from TNFRII KO and WT mice are equally capable of suppressing effector T cells. A 
conventional T cell suppression assay was performed as control for Treg activity using CD4+CD25+ T 
cells from WT or TNFRII KO mice as suppressor cells. Percentages depict percent inhibition of prolif-
eration. Representative data from 9 experiments are shown.
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from TNFRII KO mice (Figure 2B). Nonetheless, these cells were at least as potent as 
CD4+CD25+ cells from control WT animals in a conventional in vitro T cell suppression 
assay, indicating that CD4+CD25+ cells from TNFRII KO animals were bona-fide Treg 
cells with the ability to suppress effector T cells (Figure 2C). Addition of Etanercept, 
a soluble TNFRII-Ig fusion protein used clinically to treat rheumatoid arthritis, had 
comparable effects on the survival of WEHI cells (Figure 2B). These data indicate that 
the ability of Treg cells to inhibit T cell proliferation is unaffected in TNFRII KO mice 
and further show that Treg cell-derived sTNFRII is functional as it is able to prevent the 
action of TNF-α in vitro.
CD4+CD25+ Treg cell-derived sTNFRII modulates LPS-induced IL-6 production in 
vivo
TNF-α modulates the kinetics of IL-6 expression following LPS-injection in mice 13, 14. 
IL-6, in turn, induces the expression of acute phase proteins. Thus, we reasoned that the 
reduction of the acute phase response observed previously 7 could be due to Treg cell 
derived sTNFRII. To analyze this possibility, we injected mice i.p. with LPS one hour 
after injection of CD4+CD25+ Treg cells from either WT or TNFRII KO mice. Serum 
IL-6 levels were analyzed at different time-points following LPS-injection.
At 4 and 6 hours after LPS-injection, treatment with Etanercept significantly reduced 
the amount of IL-6 produced in response to LPS, confirming that, indeed, TNF-α is 
involved in the induction of IL-6 following LPS injection (Figure 3). Likewise, adoptive 
transfer of CD4+CD25+ Treg cells isolated from WT animals significantly decreased 
figure 3: Treg cells inhibit LPS-induced IL-6 production through TNFR-shedding.
CD4+CD25+ cells were isolated from either WT animals or TNFRII-KO animals and activated in vitro 
for 4 days as described. 1x106 cells were injected into mice receiving 150 µg of LPS i.p. one hour later. 
Serum IL-6 levels were determined 4 and 6 hours after LPS-injection. One representative experiment 
out of 4 is shown (Et. = Etanercept).
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IL-6 production. In contrast, CD4+CD25+ Treg cells isolated from TNFRII KO animals 
lacked this ability, indicating that Treg cell derived TNFRII is involved in the inhibi-
tion of the IL-6 response following injection of LPS. Together, these data show that 
CD4+CD25+ Treg cells can inhibit the action of TNF-α and dampen inflammation by 
releasing sTNFRII.
TNFR-shedding by human CD4+CD25high T cells
Given the potential implications of our findings with murine Treg for the treatment of 
TNF-mediated inflammatory disorders, we next investigated whether TNFR-shedding 
would also be a feature of human Treg.
We first analyzed TNFRII-expression on freshly isolated human CD4+ T cells. 
TNFRII-expression was found to be highest on CD4+CD25high T cells, but could also 
be detected on CD4+CD25intermediate and on a minor fraction of CD4+CD25− T cells 
(Figure 4A). In line with this, TNFRII-expression was highest on, but not exclusively 
confined to, CD4+FoxP3+ T cells. Phenotypic analysis using markers relevant for T cell 
function revealed that CD4+TNFRII+ T cells were largely CD45RO+CD45RA− (Figure 
4B). While CD4+TNFRII− T cells uniformly expressed CCR7, no HLA-DR and were 
mostly CD62Lhigh, CD4+TNFRII+ T cells exhibited a more heterogeneous expression of 
these markers. Interestingly, FoxP3-expression was restricted to TNFRII+ T cells. Thus, 
figure 4: Phenotype of TNFRII-expressing human CD4+ T cells.
(A) Cell surface expression of TNFRII on freshly isolated human PBMC from healthy donors. TNFRII 
expression is highest on CD4+CD25high cells that coexpress FoxP3. (B) Phenotypical analysis of 
CD4+TNFRII+ (open line) vs. CD4+TNFRII− (filled line) T cells. Gating was based on an appropriate 
isotype control. Data are representative of 4 independent experiments.
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CD4+CD25highFoxP3+ T cells that display both effector and central memory markers 15 
constitutively express TNFRII and have in part lost expression of homing receptors 
CD62L and CCR7.
Similar to the experiments performed in mice, CD4+CD25high and CD4+CD25− T 
cells were subsequently purified by FACS-sorting and activated in vitro for up to 5 
days. TCR-stimulation induced strong upregulation of TNFRII surface expression on 
CD4+CD25high and, to a lesser extent, on CD4+CD25− T cells during 5 days in culture 
(Figure 5A). Cultures were performed in the presence or absence of marimastat, an 
inhibitor of metalloproteinases such as TNF-α converting enzyme (TACE, ADAM17), 
the enzyme responsible for cleavage of TNFRs from the cell surface. Inhibition of 
TNFR-shedding by marimastat led to a strong accumulation of TNFRII on the cell 
surface of CD4+CD25high T cells as determined by an increase in mean fluorescence 
intensity (MFI) of the TNFRII-staining. Activation of CD4+CD25− T cells under the 
same conditions, however, led to an only weak increase in TNFRII-MFI, indicating 
lower shedding activity. In line with this observation, large amounts of sTNFRII were 
detectable in culture supernatants of CD4+CD25high T cells, with much lower levels be-
ing produced by CD4+CD25− T cells (Figure 5B). sTNFRI was almost undetectable in 
cultures of both cell types (data not shown). The difference in TNFRII-levels was even 
more prominent when adjusting TNFRII-levels in supernatants for cell counts, taking 
into account the stronger proliferation of CD4+CD25− T cells. In addition, calcula-
tion of the amount of TNFRII shed from day to day revealed that shedding activity of 
CD4+CD25− T cells reached a peak between day 3 and 4, whereas TNFRII-shedding of 
CD4+CD25high T cells still increased (Figure 5C). It is unlikely that the sTNFRII-levels 
determined originate from activated effector T cells contaminating the CD4+CD25high 
T cell population, as FACS-sorting and subsequent activation of CD4+CD25intermediate 
T cells led to substantially lower amounts of sTNFRII in culture supernatants than ac-
tivation of CD4+CD25high T cells (data not shown). Interestingly, surface staining with 
HLA-DR of CD4+CD25high T cells from two donors activated in the presence or absence 
of marimastat revealed that CD4+CD25highHLA-DR+ T cells had substantially higher 
shedding capacity than CD4+CD25highHLA-DR− T cells (Figure 5D). Within the Treg 
cell compartment, HLA-DR has previously been described to define a population with 
enhanced suppressive ability. Our data indicate that the TNFR-shedding capacity differs 
between these two subsets. This might be relevant for the in vivo function of Treg cells 
and further emphasizes that human Treg cell populations are composed of functionally 
distinct subsets 16.
In summary, we here describe a new mechanism of action of CD4+CD25+ Treg cells. 
Our results are in line with recent observations describing that TNF-α can transiently 
silence the suppressive activity of Treg cells through signaling via TNFRII 17, 18. Interest-
ingly, suppressive function was found to be restored after several days 18. Our findings 
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showing that TNFRII is shed several days after activation of Treg cells fit well with these 
observations, as shedding of TNFRII would allow Treg cells to counteract the action of 
TNF-α, thereby circumventing its inhibitory effect on Treg cell function. This way, Treg 
figure 5: Characteristics of TNFRII-shedding by human CD4+CD25high T cells.
(A) Mean Fluoresence Intensity (MFI) of TNFRII-staining after culture in the presence or absence of 
marimastat (Mst.). The inset depicts the increase in MFI on marimastat-treated cells CD25high or CD25− 
cells as the area between the respective curves. (B) Levels of sTNFRII in supernatants of cells after acti-
vation (* P<0.05, ** P<0.01). (C) Levels of sTNFRII produced from day to day adjusted for cell count. 
Cells were manually counted at each time point in duplicates. The amount of sTNFRII produced from 
one day to the next was divided by the average cell number present in the wells at these time points using 
the formula: (conc. sTNFRII dayx+1 – conc. sTNFRII dayx) / (1/2 * (cell-count (x10
5) dayx + cell count 
(x105) dayx+1)) (* P<0.05). Results presented in A-C are representative of 5 independent experiments. D) 
Increase in MFI of TNFRII-staining on CD4+CD25highHLA-DR+ and CD4+CD25highHLA-DR− T cells 
from two separate donors after 5 days of activation in the presence and absence of marimastat. Increase 
in MFI of HLA-DR+ cells was normalized to 100 in order to account for overall differences in HLA-DR 
expression levels between donors.
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cells could regain their suppressive ability to regulate the function of effector T cells and, 
at the same time, suppress the effects of TNF-α, a crucial mediator of acute and chronic 
inflammation.
We have previously shown that CD4+CD25+ T cells can be used effectively in the treat-
ment of collagen induced arthritis (CIA), a model for systemic arthritis in mice 7, 19. CIA 
is primarily an antibody driven disease 20, 21, the role of T cells is, most likely, restricted 
to the provision of help to B cells that produce collagen type II (CII) specific antibodies. 
As CD4+CD25+ Treg cells are able to reduce arthritis severity in the effector phase of 
the disease without affecting circulating anti-CII antibodies, it is likely that the shedding 
of sTNFR by adoptively transferred Treg cells is involved in the inhibition of arthritis.
Finally, our data obtained with human Treg cells indicate that the mechanism we show 
in mice is essentially similar in the human setting. Although constitutive TNFRII-expres-
sion is not confined to Treg cells, human CD4+CD25high T cells exhibit a much stronger 
and more sustained shedding activity upon activation when compared to CD4+CD25− T 
cells. This is of potential interest in the context of TNF-mediated autoimmune diseases 
such as rheumatoid arthritis, in which TNFRII-Ig fusion proteins are used effectively in 
therapeutic settings. Together, these data provide a rationale for the therapeutic use of 
Treg cells in systemic autoimmune diseases.
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ABstRAct
In several autoimmune disorders, including rheumatoid arthritis (RA), autoantibodies 
are thought to be the driving force of pathogenicity. Glycosylation of the Fc-part of 
human immunoglobulins is known to modulate biological activity. Hitherto, glycosyl-
ation of human IgG-Fc has been analyzed predominantly at the level of total serum IgG, 
revealing reduced galactosylation in RA. Given the pathogenic relevance of autoantibod-
ies in RA, we wished, in the present study, to address the question whether distinct 
Fc-glycosylation features are observable at the level of antigen-specific IgG subpopula-
tions. For this purpose, we have developed a method for the micro-scale purification 
and Fc-glycosylation analysis of anti-citrullinated peptide antibodies (ACPA). ACPA 
represent a group of auto-antibodies that occur with unique specificity in rheumatoid 
arthritis patients. Their presence associates with increased inflammatory disease activity 
and rapid joint destruction. Results indicate that ACPA of the IgG1 subclass vary con-
siderably from total serum IgG1 with respect to Fc-galactosylation, with galactosylation 
being higher on ACPA than on serum IgG1 for some patients, while other patients show 
higher galactosylation on serum IgG1 than on ACPA. Using this method, studies can 
be performed on the biological and clinical relevance of ACPA glycosylation within 
rheumatoid arthritis patient cohorts.
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intRoDuction
Human immunoglobulin G (IgG) occurs in four subclasses, which share a conserved N-
glycosylation site in their Fc region. Notably, Fc-N-glycosylation is very different from 
Fab N-glycosylation, the latter occurring in the variable regions of approximately 20% 
of the polyclonal IgG population from human serum. Fab N-glycans show a high degree 
of galactosylation and sialylation whilst Fc-N-glycans are predominantly non-sialylated 
and truncated structures (i. e., biantennary N-glycans lacking galactose residues). This 
difference has been found for IgGs from the human circulation 1, 2 as well as for mono-
clonal IgGs expressed in mammalian cell culture 3-6.
Fc-glycosylation varies much between individuals: Fc-N-glycan galactosylation shows 
a pronounced age dependency, with a rather low degree of galactosylation for young 
children, a maximum of galactosylation around age 25, and a decrease in galactosylation 
at higher age 7-9. During pregnancy the degree of IgG Fc-galactosylation increases and 
drops again after delivery 10-12, and various inflammatory diseases including rheuma-
toid arthritis (RA) and tuberculosis are associated with decreased galactosylation of 
IgG 10, 12, 13.
Fc-glycosylation modulates various biological activities of IgG: first, fucose-deficient 
IgG1 is binding with higher affinity to the Fcγ receptor IIIA than its core-fucosylated 
counterpart 14, 15. Sialylation does likewise influence the binding of the various IgG 
subclasses to different activating and inhibitory Fcγ receptors 16. This modulation of 
the interaction with Fcγ receptors by IgG Fc-glycosylation features strongly influences 
the efficacy of IgGs in antibody dependent cellular cytotoxicity (ADCC) assays 14, 17-20. 
Second, in a mouse model, sialylation of the Fc-part N-glycan has been shown to be 
involved in the anti-inflammatory properties of human IgG 16, which seems to be at the 
basis of the beneficial effects of donor IgG (intravenous immunoglobuline; IVIG) for 
the treatment of various inflammatory and autoimmune diseases. In this study Kaneko 
et al. showed in a mouse model that a change in total IgG Fc-glycosylation character-
ized by an altered sialylation is underlying the pro- versus anti-inflammatory activity of 
antibodies 16.
Most studies on IgG glycosylation have analyzed N-glycans released from total human 
serum IgG, which includes Fc N-glycans and Fab N-glycans. IgG glycosylation, however, 
is different for the Fc-part and the Fab part 1-6, and varies between IgG subclasses 12. Only 
recently, Mehta et al. have for the first time analyzed IgG glycosylation at an antigen-
specific level 21, while all the other studies have not addressed the occurrence of possible 
specific glycosylation features of antigen-specific subpopulations of IgG.
In order to obtain a deeper insight into antibody glycosylation, we decided to analyze 
the Fc N-glycans of antigen-specific subpopulations of serum IgG. We chose for ana-
lyzing the Fc-glycosylation of anti-citrullinated peptide antibodies (ACPA), which are 
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autoantibodies of predominantly the IgG1 subclass that occur in RA-patients with high 
specificity 22-24. For this purpose, we have established a micro-scale capturing assay for 
ACPA from serum followed by monitoring of Fc-glycosylation at the glycopeptide level 
in an IgG-subclass specific manner. Our results clearly indicate that ACPA IgG1 differs 
from total serum IgG1 in the degree of galactosylation of the Fc N-glycan.
MAteRiAls AnD MethoDs
IgG purification from total human serum
Protein A-Sepharose beads (GE Healthcare, Eindhoven, The Netherlands) were washed 
three times with 10 volumes of PBS. 15 μl of beads per well were applied to a 96-well 
filter plate (Multiscreen Solvinert, 0.45 μm pore-size low-binding hydrophilic PTFE; 
Millipore, Billerica, MA). The volume was brought to 150 μl with PBS, and 2μl of serum 
was applied per well. The plate was sealed with tape and incubated on a shaker for 1 h. 
The beads were washed 5x with 200 μl PBS under vacuum (approximately 100 mbar). 
After washing 2x with 200 μl water, immunoglobulins (IgG1, IgG2, and IgG4) were 
eluted with 100 μl of 100 mM formic acid (p. a. for mass spectrometry; Merck, Darm-
stadt, Germany) into a V-bottom microtiter plate (Nunc, Roskilde, Denmark). Samples 
were dried by vacuum centrifugation.
Purification of anti-citrullinated peptide antibodies (ACPA)
Sera for the isolation of ACPA were chosen based on their reactivity against a second 
generation citrullinated peptide antigen (CCP2) in a commercially available ELISA 
system (Immunoscan RA Mark 2; Euro-Diagnostica, Arnhem, The Netherlands). For 
purification, sera of ACPA-positive and ACPA-negative RA-patients were diluted 1:10 
in dilution buffer (provided with the ELISA kit) and incubated in CCP2-coated ELISA 
plates for 1 hour at 37°C. Supernatants were discarded and plates were washed 2x with 
PBS followed by 2x washing with 25 mM ammonium bicarbonate (Merck, Darmstadt, 
Germany). ACPA were then eluted using three different approaches:
1. Elution with sodium-isothiocyanate: After washing, samples were incubated with 100 
µl 5M sodium-isothiocyanate for 15 min at room temperature. Eluates were collected 
from the ELISA plate and immediately dialyzed (dialysis membranes with molecular 
weight cut-off 12-14 kD, cat.-no. 551300; Thermo Fisher Scientific, Waltham, MA) 
over night at 4°C against PBS. ACPA IgG was purified from PBS using Prot A beads 
(see 2.1) and subjected to trypsin treatment (2.4) and Fc-glycosylation analysis (2.5).
2. In-plate tryptic digest: After washing, 30 µl of 25 mM ammonium bicarbonate buf-
fer containing 200 ng of sequencing grade modified trypsin (Promega, Leiden, The 
Netherlands) was added to each well of the ELISA-plate. Plates were incubated for 
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30 min on a shaker at room temperature followed by over night incubation at 37°C. 
Samples were subjected to Fc-glycosylation analysis (2.5).
3. Elution with 100 mM formic acid: After washing, 50 µl 100 mM formic acid was 
added to each well to achieve antibody elution. Plates were incubated for 15 min at 
room temperature. Eluates were transferred to 96 well V-bottom microtiter plates, 
dried in a vacuum centrifuge, and subjected to trypsin treatment (2.4) and Fc-
glycosylation analysis (2.5).
For comparison of the methods, the isolation procedures 2 (in-plate tryptic digest) and 3 
(formic acid elution) were performed in parallel on one plate in order to avoid inter-assay 
variation.
Enzyme-linked immunosorbant assay (ELISA)
Detection of human IgG: Human IgG was detected using an antibody-based sandwich 
ELISA system. In brief, 96 well flat-bottom microtitration plates (Maxisorb; Nunc, Co-
penhagen, Denmark) were coated with polyclonal rabbit anti-human IgG (Dako A0423; 
Glostrup, Denmark) diluted 1:5000 in coating buffer (50mM sodium bicarbonate buffer 
pH 9,6) for 2 hours at 37°C. Plates were blocked with PBS containing 1%BSA for 30 
min at 37°C. Samples and standard (pooled normal human serum) were added to the 
wells diluted in PBS containing 1%BSA and 0.05% Tween and incubated for 30 min at 
37°C. Biotinylated goat F(ab’)2 anti-human IgG diluted 1:40000 (Biosource Interna-
tional AHI1309, Camarillo, CA) in PBS containing 1%BSA and 0.05% Tween was used 
for detection. Plates were subsequently incubated with poly-horse radish peroxidase 
labeled with streptavidine (diluted 1:750 in PBS containing 1%BSA and 0.05% Tween) 
(Sanquin M2051, Amsterdam, The Netherlands) and bound IgG was visualized using 
2,2’-azinobis 3-ethylbenzthiazoline-6-sulfonic acid (ABTS; Sigma). Color signal was 
measured at an optical density of 415nm using a conventional ELISA reader. Plates were 
vigorously washed between each step with PBS containing 0.05% Tween 20. Antibody 
dilutions were optimized by serial titrations for detection of the standard IgG prior to 
performance of the assay.
Detection of ACPA: ACPA were detected using a second generation ELISA-kit (Im-
munoscan RA Mark 2; Euro-Diagnostica) according to the manufacturer’s instructions.
IgG digestion with trypsin
A 20 μg aliquot of trypsin (sequencing grade; Promega, Leiden, The Netherlands) was 
dissolved in 4 ml of 25 mM ammonium hydrogencarbonate. Within 1 min after prepara-
tion, 40 μl of this mixture was added per well to the dried purified antibodies. Samples 
were shaken (1 min), incubated overnight at 37°C, and stored at -20°C until usage.
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Nano-LC-ESI-ion trap-MS
Prior to analysis, microtitration plates containing tryptic digests of IgG were subjected 
to centrifugation (10 min at 3000 g). 0.2 μl aliquots of trypsinized Protein A eluates (cor-
responding to IgG1, IgG2, and IgG4 from 10 nl of serum) and 2 μl aliquots of trypsin-
ized samples obtained from the various ACPA purification procedures were applied to a 
reverse-phase column (C18 PepMap 100Å, 3 μm, 75 μm x 150 mm; Dionex/LC Packings, 
Amsterdam, the Netherlands) using an Ultimate nano-LC, a Famos autosampler, and a 
Switchos trap-column system (Dionex/LC Packings). The column was equilibrated at 
room temperature with eluent A (0.1% formic acid in water and 0.4% acetonitrile) at a 
flow rate of 150 nL/min. After injection of the samples, a gradient was applied to 25% 
eluent B (95% acetonitrile, 5% water containing 0.1% formic acid) in 15 min and 70% 
eluent B at 25 min followed by an isocratic elution with 70% eluent B for 5 min. The 
eluate was monitored by UV absorption at 215 nm.
The LC system was coupled via an online nanospray source to an Esquire HCT ultra 
ESI-IT-MS (Bruker Daltonics, Bremen, Germany) equipped with an electron transfer 
dissociation module (PTM Discovery System™) and was operated in the positive ion 
mode. For electrospray (1100-1250 V), capillaries (360 μm OD, 20 μm ID with 10 μm 
opening) from New Objective (Cambridge, MA, USA) were used. The solvent was 
evaporated at 165°C employing a nitrogen stream of 7 L/min. Ions from m/z 600 to m/z 
1800 were registered. For glycosylation profiling, the mass spectrometer was used in 
the MS mode. The HPLC method resulted in a resolution of the glycopeptides based on 
the peptide moiety with IgG1 glycopeptides eluting first, followed by IgG4 and IgG2 
glycopeptides. Moreover, glycopeptides with neutral glycan moieties tended to elute 
earlier than glycopeptides with antennae sialylation, as described before 12. For both the 
neutral and the acidic glycopeptides of each IgG subclass, average mass spectra were 
generated over a 1 min elution range.
Results
Purification of anti-citrullinated peptide antibodies (ACPA) was achieved using commer-
cially available ELISA plates which contain immobilized citrullinated peptide antigens. 
Sera from rheumatoid arthritis patients that were previously tested as ACPA-positive or 
ACPA-negative (controls) were diluted in PBS and added to the ACPA ELISA plate wells 
in order to allow binding to the immobilized citrullinated peptide antigens. Unbound 
serum IgG as well as other serum components were washed away, and IgGs bound to the 
ACPA plates were analyzed using three different procedures, as schematically presented 
in Figure 1.
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In a first attempt, antibodies bound to the ACPA plates were eluted using sodium 
isothiocyanate. For this experiment sera were used from four ACPA-positive rheumatoid 
arthritis patients and four ACPA-negative rheumatoid arthritis patients, as determined by 
ELISA (Fig. 2A). Sodium isothiocyanate was removed by dialysis against PBS, and the 
amount of captured IgG was quantified for the 8 sera using an IgG-ELISA (Fig. 2B). The 
results showed the presence of captured IgG for the 4 ACPA-positive RA patients. For 
the ACPA-negative RA-patients no IgG was detected after dialysis, i. e., no unspecific 
co-purification of non-ACPA IgGs was detected. These results indicate the successful 
purification of ACPA with high specificity using an affinity capturing approach at the 
ELISA plate format. Virtually no background level of unspecifically bound IgG was 
detected.
The obtained amounts of ACPA were sufficient for Fc-glycosylation analysis by nano-
LC-ion trap-MS at the tryptic glycopeptide level (Fig. 3B) using a recently described 
method 12. The results obtained for patient RA10 are shown in Fig. 3B. Next to ACPA 
IgG1 glycosylation profiles, the Fc-glycosylation profiles of IgG1 from total serum were 
registered after Prot A capturing and trypsin treatment (Fig. 3B). IgG1 Fc glycopeptides 
were identified based on their specific tryptic peptide moiety (E293EQYNSTYR301), 
which allows to distinguish them from glycopeptides of other IgG subclasses based on 
the resulting glycopeptide masses and elution positions 12. Interestingly, the obtained 
glycosylation profile of ACPA IgG1 differed from the profile obtained for total IgG1 
of the same patient (Fig. 3A): whilst total IgG1 exhibited a typical rheumatoid arthritis 
glycosylation profile with a low degree of galactosylation (high G0; glycoform at m/z 
878.7), ACPA of RA10 showed a much higher degree of galactosylation, with G1 as 
the major glycoform (m/z 932.8). Moreover, sialylation was slightly higher in ACPA 
¥  elution of ACPA with  
  sodium isothiocyanate 
¥  dialysis 
¥  Protein A capturing 
¥  elution of ACPA with  
  100 mM formic acid 
¥  samples dried down 
¥  tryptic digest 
¥  tryptic digest 
  on CCP-plate 
¥  elution of ACPA 
  (glyco-)peptides 
¥  binding of ACPA: 
  incubation of diluted serum on CCP-plate 
¥  2 washes with PBS 
¥  2 washes with 25 mM ammonium bicarbonate 
ACPA IgG Fc glycosylation analysis by LC-ESI-MS 
2 1 3 
IgG detection by  ELISA 
¥  tryptic digest 
figure 1: Schematic representation of the three strategies which were evaluated for purification of anti-
citrullinated peptide antibodies (ACPA).
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compared to total serum IgG, with a relatively higher signal for the core-fucosylated 
biantennary monosialylated glycoform (triple protonated species at m/z 1083.8).
In a next step we wished to confirm that the glycosylation profiles obtained from the 
eluates of the capturing plate were reflecting total ACPA. We wanted to be sure that 
specific ACPA glycosylation features were not missed due to the possible depletion for 
high-affinity ACPA which might not be eluted from the capturing plate with the applied 
sodium isothiocyanate treatment. We addressed this point by comparing the elution pro-
files obtained by strategy 1 (Fig. 3B) with ACPA glycosylation profiles obtained by tryptic 
digest of the captured IgG1 directly on the capturing plate (strategy 2). This comparison 
was performed for 4 sera from ACPA-positive RA patients and for 2 sera from ACPA-
negative RA patients. No IgG glycopeptides were registered for the ACPA-negative RA 
patients, whilst the Fc-glycosylation profiles of the ACPA-positive patients obtained by 
strategy 2 (on-plate tryptic digest; shown for patient RA10 in Fig. 3C) were very similar 
to those obtained by strategy 1 (sodium isothiocyanate elution; shown for patient RA10 
































figure 2: Demonstration of ACPA purification by ELISA.
Eight sera from rheumatoid arthritis (RA) patients were assayed for ACPA by ELISA, which revealed 
4 ACPA-positive and 4 ACPA-negative RA patients (A). ACPA were purified following strategy 1 (Fig. 
1), followed by the measurement of IgG in the eluates by ELISA (B). The results show that ACPA were 
successfully purified, and no background levels of non-ACPA IgG were detected.
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figure 3: IgG Fc-glycosylation analysis of total serum IgG1 of patient RA10 (A) and of ACPA of the 
same patient purified following strategy 1 (B), strategy 2 (C), and strategy 3 (D).
Nano-LC-MS signals are shown for the glycopeptides with neutral N-glycan chains (left panels) and 
acidic N-glycan chains (right panels). Triple protonated signals were registered throughout. Signals rep-
resenting a fucosylated glycoform are labeled with filled triangles, whilst signals of non-corefucosylated 
glycoforms are labeled with open triangles. *, non-glycopeptide signal or irrelevant adduct.
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figure 4: IgG Fc-glycosylation analysis of total serum IgG1 and ACPA IgG1 of patients RA9 (A), RA14 
(B), RA18 (C), and RA30 (D).
Nano-LC-MS signals are shown for the glycopeptides with neutral N-glycan chains (left panels) and 
acidic N-glycan chains (right panels). Triple protonated signals were registered throughout. Signals rep-
resenting a fucosylated glycoform are labeled with filled triangles, whilst signals of non-corefucosylated 
glycoforms are labeled with open triangles. *, non-glycopeptide signal or irrelevant adduct.
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in Fig. 3B). The rationale for using strategy 2 was that all ACPA adsorbed to the captur-
ing plate would be hydrolyzed by trypsin, and the observed glycosylation profiles would 
reflect with great certainty total ACPA Fc-glycosylation. Because the obtained ACPA 
Fc-glycosylation profiles were virtually identical, both on-plate tryptic digest and sodium 
isothiocyanate elution are suitable for ACPA Fc-glycosylation profiling.
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While the direct tryptic treatment on the ACPA capturing plate provided a sensitive and 
rapid manner for ACPA Fc-glycosylation profiling, these samples showed a rather high 
level of background signals. Therefore, we decided to evaluate another, simple method, 
which involves ACPA elution with 100 mM formic acid, drying of the samples in a 
vacuum centrifuge, and tryptic digestion of ACPA (strategy 3, Fig. 3D). The obtained 
ACPA Fc-glycosylation profiles were again very similar to the one obtained following 
strategies 1 and 2 (shown for patient RA10 in Fig. 3D). Due to its simplicity and the good 
quality of the data, strategy 3 was selected for further analysis of ACPA Fc-glycosylation.
In addition, the Fc-glycosylation profiles of total IgG1 (upper panels) and ACPA IgG1 
(lower panels) were analyzed for 4 additional ACPA-positive RA patients (Figure 4), 
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figure 5: Relative expression levels of glycoforms of IgG1 from total serum and ACPA for 5 RA pa-
tients.
Relative intensities are given for the triple-charged ions of the various glycoforms (Fig. 3A and B). Total 
serum IgG1 and ACPA IgG1 for patient RA10 were measured three times and seven times, respectively, 
and average relative intensities as well as standard deviations are given for the fourteen glycoforms 
which were registered (A).
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RA18 (not included in Fig. 2). The glycosylation data for these four patients are rep-
resented in histograms (Fig. 5B-E), together with the data for patient RA10 (Fig. 5A). 
A comparison of the total IgG1 Fc-glycosylation profiles for the five patients showed 
marked differences. The major differences were in the degree of galactosylation (upper 
panels of Fig. 4A-D). Moreover, some differences in sialylation were observed. Notably, 
the ACPA Fc-glycosylation profiles observed for the 4 RA patients (lower panels Fig. 
4A-D) differed from the profiles obtained for total IgG1. RA10 showed a much higher 
degree of galactosylation for ACPA compared to total IgG1 (Fig. 3; Fig. 5A). RA9 and 
RA14 likewise showed a higher degree of galactosylation, though less prominent. RA30, 
in contrast, showed a rather high degree of galactosylation for total IgG1 and a much 
lower galactosylation of ACPA. ACPA of RA18 likewise showed a lower degree of ga-
lactosylation than total serum IgG1 of RA18. Next to the differences in galactosylation, 
some small variations in sialylation were observed between ACPA and total serum IgG1.
In conclusion, ACPA Fc-glycosylation profiles can be monitored efficiently with the 
protocol established in this study. The observed glycosylation patterns show differences 
in galactosylation and sialylation between individual RA patients. Moreover, these first 
analyses indicate that ACPA glycosylation may be very different from total IgG1 glyco-
sylation.
Discussion
In several autoimmune disorders autoantibodies are thought to be of crucial pathogenetic 
relevance. Understanding their mode of action might greatly enhance our perception of 
disease pathogenesis. We here describe an assay which allows the detailed analysis of 
IgG Fc-glycosylation at the level of autoantigen-specific IgG subpopulations from human 
serum. The assay makes use of a commercially available ELISA plate with covalently 
attached citrullinated peptide antigens, which allows the capturing of anti-citrullinated 
peptide antibodies (ACPA). ACPA are auto-antibodies that are often of the IgG1 sub-
class and are highly specific for rheumatoid arthritis (RA) 22-24. ACPA are continuously 
produced by B-cells, and have been implicated in disease pathogenesis 25, 26. Antibodies 
are eluted from the capturing plate using a low pH step, followed by trypsin cleavage 
and profiling of the Fc glycopeptides by nano-LC-ESI-ion trap-MS. This method was 
found to be highly specific, as no background IgG signals could be detected for RA-
patients which were judged to be ACPA-negative on the basis of ELISA results. First 
results obtained for a limited set of ACPA-positive RA patients indicate differences 
between ACPA IgG1 Fc-glycosylation and total IgG1 Fc-glycosylation. In particular, 
ACPA IgG1 appear to be remarkably different from total serum IgG1 with respect to 
galactosylation, with some patients showing higher galactosylation for ACPA than for 
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total serum IgG1 and other patients showing higher galactosylation on serum IgG1 than 
on ACPA. Moreover, some difference between ACPA and total serum IgG1 was found 
in the degree of sialylation. The latter difference may possibly represent a secondary 
effect: in the IgG glycosylation process in the Golgi, the attachment of less galactoses 
means less acceptor structures for sialyl transferases, which may explain the reduced 
sialylation to a large extent. Notably, for fucose and sialic acid, which are known to 
exhibit acid-labile glycosidic bonds, no hydrolysis was observed with the applied elution 
conditions: for a monoclonal antibody, no differences were observed in the degree of 
Fc glycopeptide sialylation and fucosylation with and without treatment with 100 mM 
formic acid followed by vacuum centrifugation (data not shown). Hence, the registered 
values for fucosylation and sialylation are not expected to be influenced by hydrolysis 
during sample preparation.
ACPA Fc-glycosylation does not appear to feature a particularly high percentage of G0 
glycoforms. Hence, the high degree of G0 found for IgGs of many RA patients does not 
seem to be caused by a very high degree of G0 on ACPA. It may be speculated, therefore, 
that the low degree of Fc-galactosylation in IgG of RA patients may occur rather on a 
broad population of IgGs with various antigen specificities and might not be the result of 
particularly high G0 of RA-associated autoantibodies. However, to be able to draw firm 
conclusions on the specific features of ACPA glycosylation and its biological and clinical 
information content, ACPA Fc-glycosylation will have to be analyzed in future studies 
within large clinical cohorts.
The establishment of a sensitive method for the analysis of ACPA Fc-glycosylation 
is an important step towards analyzing and understanding IgG glycosylation at an 
antigen-specific level. With the large variation shown in these first analyses, ACPA fulfill 
an important prerequisite for a biomarker candidate (large spreading of values which 
reflects information content). Analyses in various clinical RA cohorts will be performed 
to evaluate the diagnostic potential of ACPA glycosylation and reveal whether it indeed 
represents a marker for disease activity or disease progression / prognosis.
Recently Metha et al. 21 have analyzed IgG heavy chain glycosylation of anti-alpha-
Gal IgGs from serum of hepatitis C virus-infected persons with fibrosis and cirrhosis and 
have found increased levels of galactose-deficient glycoforms (IgG-G0) compared to 
anti-alpha Gal IgGs from healthy controls. Anti-Gal IgGs and ACPA are hitherto the only 
antigen-specific IgGs studied for Fc-glycosylation. Efforts should be made to analyze the 
glycosylation of IgGs directed against other auto-antigens, xeno-antigens, vaccines, and 
infectious agents. For this purpose more assays for the Fc-glycosylation analysis of other 
antigen-specific IgG subpopulations will have to be established in the future. The appli-
cation of these assays to large study populations should provide a deeper insight into the 
complexity and regulatory potential of IgG glycosylation at the antigen-specific level, 
which may represent important, hitherto neglected, immunological parameters. Based on 
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the results of Kaneko et al. 16, it will be interesting to compare Fc-glycosylation profiles 
for different phases of antibody responses and B-cell development. Next to population 
studies, more functional studies in animal models will be necessary to understand the 
regulatory events which make B-cells produce antibodies with a certain Fc-glycosylation 
profile. In addition, the effects of the differences in IgG Fc-glycosylation on ADCC and 
complement-mediated cytotoxicity need further attention. These combined efforts should 
provide us with a deeper understanding of antibody-mediated immunological effects and 
may reveal new rationales for modulating the immune response in various diseases.
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ABstRAct
objective: Anti-citrullinated protein antibodies (ACPA) exhibit unique specificity for 
RA. Whether and how ACPA contribute to disease pathogenesis, however, is incomplete-
ly understood. The Fc part of human IgG carries two N-linked glycan moieties which are 
crucial for the structural stability of the antibody and modulate its binding affinity to Fcγ 
receptors and its ability to activate complement. We have purified ACPA from serum and 
synovial fluid and analyzed Fc glycosylation profiles in a specific manner.
Methods: ACPA were isolated by affinity purification using cyclic citrullinated peptides 
as antigen. IgG1 Fc glycosylation was analyzed by mass spectrometry. ACPA glycan 
profiles were compared to glycan profiles of total serum IgG1 obtained from 85 well-
characterised patients. Glycan profiles of paired synovial fluid and serum samples were 
available from 11 additional patients.
Results: Compared to the pool of serum IgG1, ACPA IgG1 lack terminal sialic acid resi-
dues. In synovial fluid, ACPA are highly agalactosylated and lack sialic acid residues, a 
feature that was not detected for total synovial fluid IgG1. Moreover, differential ACPA 
glycan profiles were detected in RF-positive versus -negative patients.
conclusion: ACPA IgG1 exhibit a specific Fc-linked glycan profile which is distinct from 
total serum IgG1. Moreover, Fc glycosylation of ACPA differs markedly between syno-
vial fluid and serum. As Fc glycosylation directly affects the recruitment of Fc-mediated 
effector mechanisms, these data could further our understanding of the contribution of 
ACPA to disease pathogenesis.
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intRoDuction
Antibodies relevant to tissue pathology in autoimmune diseases are identified based 
on antigen binding specificity of the variable region. Only very few autoantibodies, 
however, mediate pathology by direct interaction with the antigen. In most other cases, 
the constant region (Fc part) determines antibody-mediated effector functions such as 
complement activation, antibody-dependent cellular cytotoxicity (ADCC) and engage-
ment of activating or inhibitory Fc receptors. These Fc-mediated effects are influenced 
by the Fc part’s amino acid sequence (i.e. antibody isotype and sub-class) and by Fc-
linked carbohydrate structures. The latter are located in the Cγ2 domain of the heavy 
chain in close vicinity to amino acids that interact with Fc receptors and the complement 
system. Accordingly, Fc-linked carbohydrate structures have recently received increas-
ing attention, as modification of Fc-linked glycan residues of therapeutic antibodies has 
been shown to strongly influence the antibodies’ therapeutic potential 1-6.
The Fc part of human immunoglobulin G (IgG) carries two N-linked, highly heteroge-
neous glycan moieties interposed between the heavy chains. These carbohydrate struc-
tures are crucial for the stability of the antibody and influence its biological activity 7-9. 
Attached to amino acid Asn297 of each heavy chain is a conserved, biantennary glycan 
backbone of N-acetylglucosamine (GlcNAc) and mannose residues, which is modified 
by core fucose, additional N-acetylglucosamine, galactose and terminating sialic acid 
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figure 1: (A) Schematic depiction of a monosialylated glycan chain linked to Asn297 of the IgG heavy 
chain and legend for symbols used in this article (box). The dotted line indicates the conserved sequence 
of glycan residues. An additional sialic acid residue can be attached to the second galactose residue, and 
an additional N-acetylglucosamine residue (‘bisecting GlcNAc’) to the central mannose (not depicted). 
(B, C) Typical mass-spectrometry profiles of IgG1 tryptic glycopeptides obtained after isolation of ACPA 
from serum (B) and synovial fluid (C). Sum mass spectra of the elution range of the IgG1 glycopeptides 
with neutral glycans are shown 34. pep: peptide moiety.
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are characterized by presence or absence of galactoses, so called G0 (no galactose), 
G1 (one galactose) and G2 (two galactoses) glycoforms, which make up around 20-
35%, 35% and 16% of all IgG Fc-linked glycoforms in healthy subjects, respectively 9. 
Lack of galactose residues results in a concomitant lack of terminal sialic acid residues 
and increases the affinity for activating Fcgamma receptors (FcγR) 10, 11. In contrast, 
presence of the fully processed glycan structure terminating in sialic acid residues has 
anti-inflammatory effects 3, 4. Presence of an additional, bisecting GlcNAc residue and 
absence of core fucose residues was found to enhance ADCC through high-avidity in-
teraction with FcγRIIIa 1, 12-14. Hydrolysis of the entire glycan backbone by glycosidase 
treatment or mutational deletion of the entire Asn297 N-linked glycosylation site leads to 
a change of the Fc part’s quartenary structure. This yields a non-immunogenic antibody 
unable to interact with FcγR and, consequently, to elicit significant cytokine release 5, 6, 8. 
Of interest, immune complexes containing such aglycosylated IgG fail to be eliminated 
rapidly from the circulation 15.
In line with these structural observations, both human and murine studies indicate a 
strong impact of Fc-linked glycan variants on the pathogenic potential of IgG antibod-
ies in inflammatory disorders such as rheumatoid arthritis. Early studies have demon-
strated a predominance of IgG-G0 glycoforms in sera of RA patients that correlates with 
disease activity and reverses to normal levels in patients who undergo (spontaneous) 
remission 16-19. Removal of galactose residues from murine IgG by β-galactosidase 
treatment resulted in increased arthritogenicity of transferred IgG in a murine arthritis 
serum transfer model 20. Likewise, pregnancy-induced remission in the pristane-induced 
arthritis model was paralleled by a decrease of IgG-G0 glycoforms, while the postpar-
tum period was accompanied by a respective increase in agalactosylated glycoforms 21. 
While these studies have narrowed the focus on the presence or absence of galactose 
residues, more recent studies indicate that not a lack of galactose residues itself, but 
rather the concomitant absence of terminal sialic acid residues may be responsible for 
the enhanced inflammatory activity exerted by G0 glycoforms 3, 4. Indeed, a receptor 
specifically recognizing IgG Fc-linked sialic acid residues has newly been described 
on a population of murine regulatory splenic macrophages, a cellular subset that may 
be involved in downregulation of inflammatory responses 22. While these latter findings 
await confirmation in the human system, relevance of sialic acid residues for modulat-
ing immune responses is demonstrated by the finding that intravenous immunoglobulin 
preparations (IVIG) completely lose their immunosuppressive capacity upon removal 
of sialic acid residues by neuraminidase treatment 3, 4. Together, these findings underline 
the importance of IgG Fc-linked glycan structures for antibody-mediated inflammatory 
responses.
Anti-citrullinated protein antibodies (ACPA) are highly specific autoantibodies for a 
subgroup of rheumatoid arthritis patients that suffer from severe erosive disease. A body 
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of evidence points to a crucial role for ACPA in disease pathogenesis, but the pathogenic 
potential of ACPA and the mechanism by which ACPA could cause tissue pathology 
are ill-defined. ACPA are present in serum years before the onset of clinical symptoms, 
ACPA production has been detected in synovial membrane explants, and increased 
ACPA levels were found in synovial fluid as compared to serum 23-25. ACPA-positive RA 
patients suffer from more severe disease than patients without a citrulline-specific im-
mune response, and presence of ACPA favours the development of overt RA in patients 
with undifferentiated arthritis 26-29. Intriguingly, however, ACPA levels do not or only 
moderately correlate with disease activity, and depletion of CD20+ B cells improves 
clinical symptoms while ACPA levels are only moderately affected 30, 31. The observa-
tion that ACPA can be present without signs of inflammation, both before and during 
disease, raises the possibility that the quality rather than the quantity of the ACPA im-
mune response influences disease. So far, studies have focussed on ACPA fine-specificity 
and isotype usage, but data on ACPA Fc-linked glycan residues have not been obtained. 
In light of the strong influence of Fc-linked glycans on the inflammatory potential of 
antibodies, we have recently developed a technique that allows analysis of Fc-linked 
glycans in an antigen specific manner 32. We have now used this technique to analyze 
Fc glycosylation of IgG1-ACPA in serum and synovial fluid of early arthritis patients in 
order to further characterize the immune response to citrullinated antigens.
PAtients AnD MethoDs
Serum and synovial fluid samples
Serum samples of 85 clinically well-defined, ACPA-positive arthritis patients participat-
ing in the Leiden Early Arthritis Clinic (EAC) were collected following informed con-
sent of study participants and study-approval by the local institutional review board. 
The Leiden EAC is a population-based inception cohort that includes patients with 
self-reported symptom duration of ≤ 2 years 33.
Paired serum and synovial fluid samples were collected from 11 additional ACPA-
positive rheumatoid arthritis patients. 7 samples originated from the outpatient clinic 
of the Department of Rheumatology and Clinical Immunology at Charité Hospital in 
Berlin (Germany), 4 samples were collected at the respective outpatient clinic of the 
Department of Rheumatology of Leiden University Medical Center (The Netherlands).
ACPA positivity was determined based on reactivity of sera against a second gen-
eration cyclic citrullinated peptide (CCP2) in a commercially available ELISA system 
(Immunoscan RA Mark 2; Euro-Diagnostica, Arnhem, The Netherlands). Serum and 
synovial fluid samples were aliquoted and stored at -80°C until further use.
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Isolation of ACPA and total IgG from serum and synovial fluid samples
ACPA were isolated from total human serum and synovial fluid as previously described 32. 
In brief, sera and synovial fluid samples were incubated in CCP2-coated ELISA plates 
(Immunoscan RA Mark 2; Euro-Diagnostica, Arnhem, The Netherlands) for 1 hour at 
37°C. Supernatants were discarded and plates were washed thoroughly. Bound antibod-
ies were eluted from the plates by adding 100mM formic acid (p.a. for MS; Merck 
Darmstadt, Germany) for 15 min at room temperature. Eluates were collected in 96-
well V-bottom plates, dried in a vacuum centrifuge and subjected to tryptic digest by 
adding 200ng trypsin (sequencing grade; Promega, Leiden, The Netherlands) in 40µl 
ammonium bicarbonate to each well followed by incubation at 37°C overnight. Digested 
samples were stored at -20°C until further use. Purity of eluted ACPA was verified by 
subjecting ACPA-negative control sera to the same isolation procedure. Non-trypsinized 
eluates of ACPA-negative samples were tested for the presence of human IgG by ELISA. 
None of the ACPA-negative eluates contained detectable amounts of IgG, indicating 
that only citrulline-specific IgG-molecules were eluted from the CCP2-plates (data not 
shown; for methodological details see 32).
Purification of total IgG was achieved by incubating serum or synovial fluid samples 
with Protein A-sepharose beads (GE Healthcare, Eindhoven, The Netherlands) in 96-
well filter plates (Multiscreen Solvinert, 0.45 µm pore-size low-binding hydrophilic 
PTFE; Millipore, Billerica, MA) on a shaker for 1 hour. Beads were thoroughly washed 
and bound IgG-molecules (IgG1, IgG2 and IgG4) were eluted into a 96-well V-bottom 
plate using 100mM formic acid. Samples were dried by vacuum centrifugation, digested 
with trypsin and stored at -20°C until further use 32, 34.
Fc glycoslylation analysis
Analysis of Fc-linked N-glycans was performed as previously described 32, 34. In brief, 
trypsinized samples obtained from the ACPA and total serum IgG isolation procedures 
were applied to a RP column (C18 PepMap 100 Å, 3 µm, 75 µm x 150 mm; Dionex/
LC Packings, Amsterdam, The Netherlands) using an Ultimate3000 nanoLC (Dionex/
LC Packings). The LC system was coupled via an online nanospray source to an Esquire 
HCTultra ESI-IT-mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped 
with an electron transfer dissociation module (PTM Discovery System™) and was oper-
ated in the positive ion mode. Ions from m/z 600 to m/z 1800 were registered. The HPLC 
method resulted in resolution of the glycopeptides based on the peptide moiety with IgG1 
glycopeptides eluting first, followed by IgG4 and IgG2 glycopeptides. Glycopeptides 
with neutral glycan moieties tended to elute earlier than glycopeptides with antenna 
sialylation. Average mass spectra were generated over a 1 min elution range for both the 
neutral and the acidic glycopeptides of each IgG subclass.
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As the most frequent isotype in ACPA-positive RA patients is IgG1, only IgG1 Fc-
linked N-glycans were analyzed in this study. Furthermore, it is important to note that 
also the Fab-fragment of IgG-molecules can carry N-glycans 35. Most previous studies 
have analyzed N-glycans released enzymatically from total human serum IgG, which 
results in a mixture of both Fc-linked and Fab-linked N-glycans. However, Fab-linked 
glycoforms can differ considerably from Fc-linked N-glycans, and vary between IgG 
subclasses 36. In our approach, the specific mass of the Fc peptide portion obtained after 
tryptic cleavage of the IgG molecule allows to exclusively analyze Fc-linked N-glycans, 
whilst Fab-linked glycopeptides exhibit a heterogeneous group of signals that do not 
interfere with Fc glycosylation analysis at the glycopeptide level. Due to the exclusive 
analysis of Fc-linked N-glycans, the total number of glycoforms detected was lower than 
that of previous reports, and some glycoforms were not detected at all.
Statistical analysis
In order to account for measurement variability, the relative peak intensity of the glyco-
form containing one galactose residue (G1) identified by mass spectrometry was deliber-
ately set to 1, and peak intensities of all other glycoforms were normalized accordingly. 
Frequencies of individual glycoforms are reported as percent of the total number of 
detectable glycoforms based on this normalization procedure. Differences in frequencies 
of glycoforms obtained from different samples were evaluated for statistical significance 
using the non-parametric Kruskal-Wallis test (in case of unpaired samples) followed 
by Dunn’s post hoc test to adjust for errors introduced by multiple testing. Dunn’s test 
generalizes the Bonferroni adjustment procedure for multiple testing to maintain the 
probability of a type-I error at ≤ 5%. For glycoforms of paired serum/synovial fluid 
samples groups were compared using the non-parametric Mann-Whitney rank-sum test. 
This is indicated where appropriate. P-values <0.05 were considered statistically signifi-
cant. Data were analyzed using SPSS version 16.0.2 and GraphPad Prism Software 4.0.
Results
Fc-linked galactosylation of ACPA IgG1 isolated from human serum
Specific Fc glycosylation profiles of ACPA IgG1 and respective profiles of total serum 
IgG1 were obtained from 85 ACPA-positive Dutch early arthritis patients (mean age 52.6 
± 14.4 years; 69.4% female). Based on previous observations reporting a predominance 
of agalactosylated glycoforms in patients with rheumatoid arthritis, we first analyzed 
frequencies of IgG1 Fc-linked galactose residues (Figure 2). A median of 25.4% (IQR 
19.8-32.3) of serum IgG1 molecules were found to lack galactose residues, consistent 
with previous reports (Figure 2A) 16. ACPA IgG1 contained slightly higher frequencies 
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of G0-glycoforms as compared to total serum IgG1 (29.8% (IQR 20.9-38.8)), a nominal 
difference that did not remain significant after correction for multiple testing. Almost two 
thirds (62.4%) of patients carried ACPA IgG1 that exhibited higher G0-frequencies than 
their respective serum IgG1. Patients of whom these ACPA were isolated did not differ 
significantly in age (data not shown), but did have slightly higher ESR than those with 
ACPA G0-frequencies below those of serum IgG1 (median ESR 32.0 mm/1h (IQR 21.5 - 
65.0) vs. 24.5 (IQR 15.5 - 40), p = 0.06). This is in line with a linear correlation between 
the frequency of ACPA G0-glycoforms and ESR (Spearman ρ = 0.54; p<0.0001; Figure 
2B). A similar correlation, although weaker, was found for G0-glycoforms of serum IgG1 
(Spearman ρ = 0.38; p<0.0003) and has been reported previously 19. Importantly, the 
frequency of ACPA G0-glycoforms did not correlate with ACPA-titres (p = 0.28; data not 
shown). Furthermore, no significant difference was noted between ACPA IgG1 and total 
serum IgG1 with respect to the presence of G1- or G2-glycoforms. Taken together, we 
observed a trend towards more agalactosylated glycoforms on ACPA IgG1 than on serum 
IgG1 that did not reach statistical significance at the available sample size.
ACPA-specific Fc-linked sialylation and fucosylation patterns
Given the reported impact of sialic acid and core fucose residues on the biological activ-
ity of antibodies, we next determined the frequency of IgG1 Fc-linked terminal sialic acid 
and core fucose residues (Figures 3 & 4). Absence of sialic acid residues increases the 
affinity for activating FcγR, while presence of sialic acid accounts for anti-inflammatory 
effects, as has been shown for IVIG 3, 10. The frequency of sialic acid residues attached 
to ACPA IgG1 was found to be significantly reduced as compared to serum IgG1 for both 
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figure 2: Fc galactosylation of ACPA and serum IgG1.
(A) Frequencies of G0-, G1- and G2-glycoforms for ACPA and serum IgG1 in percent of all detected 
glycoforms. Lines represent medians (B) Correlation between the frequency of ACPA-G0 glycoforms 
and erythrocyte sedimentation rate (ESR). Broken lines represent the 95% confidence interval of the 
linear regression (solid line).
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4G1- (Figure 3A; ACPA median 1.73% (IQR 1.36-2.16), serum median 2.16% (IQR 1.94-2.53); p<0.001) and G2-glycoforms (Figure 3B; ACPA median 5.47% (IQR 3.94-8.96), 
serum median 7.43% (5.82-10.44); p<0.001). As terminal sialic acid residues require 
galactose residues for linkage, sialic acid can only be detected on G1- or G2-, but not on 
G0-glycoforms. We did not detect glycoforms carrying two sialic acid residues in our 
samples.
Fucosylation strongly influences ADCC by modulating the Fc part’s binding avidity to 
FcγRIIIa. In the absence of core fucose residues ADCC is significantly increased 12, 14, 37. 
The vast majority of IgG1-antibodies analyzed here contained core fucose residues with 
no significant overall difference between ACPA IgG1 and total serum IgG1 (Figure 4; 
ACPA median 93.9% (IQR 92.5-95.3); serum median 94.0% (IQR 92.1-94.9), p=0.66).
Overall, these data indicate that the glycosylation profile of ACPA IgG1 differs consid-
























figure 3: ACPA-specific Fc-linked sialylation patterns.
Frequencies of monosialylated G1- (A) and G2-glycoforms (B) for both ACPA and serum IgG1. No Fc-









figure 4: ACPA-specific Fc-linked fucosylation patterns.
Overall frequency of fucosylated ACPA (G0+G1+G2) versus fucosylated serum IgG1 (G0+G1+G2) gly-
coforms. Lines represent medians.
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Fc-linked glycosylation of ACPA isolated from synovial fluid
RA is primarily characterized by synovial inflammation and progressive joint destruc-
tion. ACPA are thought to be involved in this process. However, the origin of ACPA 
circulating in serum is still unknown, and it remains to be determined to what extent 
serum ACPA contribute to synovial inflammation in the joint. In fact, ACPA titres in sy-
novial fluid (SF) exceed those in serum, and accumulating evidence suggests that ACPA 
can also be generated locally by plasma cells within the synovial membrane 24. So far, 
however, qualitative differences between serum ACPA and ACPA in SF have not been 
determined. In order to investigate whether Fc glycosylation differs between ACPA in 
SF and ACPA circulating in serum, we isolated ACPA from serum and synovial fluid of 
11 paired samples. ACPA IgG1 glycosylation profiles were compared to profiles of total 
IgG1 isolated from the same compartments. In contrast to ACPA in serum, ACPA isolated 




















































figure 5: ACPA-specific Fc glycosylation in serum versus synovial fluid.
G0-, G1- and G2-glycoforms of ACPA (A) and total serum IgG1 (B) isolated from serum and synovial 
fluid of 11 paired samples. Lines represent medians. (C) ACPA and total serum IgG1 G0-frequencies 
per individual patient in serum and synovial fluid. Significance levels were determined by comparing 
individual groups using the non-parametric Mann-Whitney rank sum test.
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27.4% (IQR 21.7-37.6), SF-ACPA: G0 median 47.0% (IQR 34.9-60.1), Mann-Whitney 
p = 0.008). This finding was specific for ACPA IgG1, as no such predominance of G0-
glycoforms was observed for the pool of total synovial fluid IgG1 (Figure 5B; serum 
IgG1: G0 median 27.5% (IQR 15.6-35.0); SF-IgG1: G0 median 31.4% (IQR 17.6-43.2), 
Mann-Whitney p = 0.5). Increased frequencies of ACPA G0-glycoforms in synovial fluid 
as compared to serum were observed in all 11 patients analyzed (Figure 5C). In contrast, 
G0-frequencies of total synovial fluid IgG1 were higher than in serum for some patients, 
but lower in others. Due to the lack of galactose residues, SF-ACPA also exhibited a 
significantly lower degree of sialylation (data not shown). All glycoforms examined in 
SF exhibited a high degree of fucosylation (up to 100%) with no significant difference 
between ACPA and total IgG1 (data not shown).
In summary, ACPA IgG1 in synovial fluid differ from ACPA IgG1 in serum in terms of 
Fc glycosylation. Synovial fluid ACPA are highly agalactosylated and lack terminal sialic 
acid residues. This differential glycan profile appears to be a specific feature of ACPA, 
as no significant difference in Fc glycosylation was observed for total IgG1 isolated from 
the same compartments.
Differential ACPA IgG1 Fc glycosylation profile in RF-positive and -negative patients
Previous studies indicate that specificity and positive predictive value of ACPA for RA 
are increased in the presence of rheumatoid factors (RF) 25. Individuals with both ACPA 
and IgM-RF are significantly more likely to develop RA than those who test positive for 
ACPA only, suggesting that ACPA and RF directly or indirectly interact 38, 39. Intriguingly, 
RF binding sites include the Cγ2 domain of the Fc part of human IgG which is in close 
proximity to amino acid Asn297 to which the carbohydrate chains are attached. There-
fore, it has been suggested that Fc glycosylation could influence RF-binding to IgG-Fc, 
and indeed fractions of RF exhibiting high affinity for agalactosyl IgG have been identi-
fied in RA patients 40, 41. Based on these observations, we were interested in investigating 
whether ACPA Fc glycosylation differs between IgM-RF-positive and -negative patients 
(Figure 6). We observed a significant predominance of ACPA IgG1 G0-glycoforms in 
RF-positive (n = 61; G0 median 31.6% (IQR 24.4-39.3)) as compared to RF-negative 
patients (n = 24; G0 median 19.1% (IQR 13.7-31.3), Figure 6A). This RF-dependent dif-
ference was only observed for ACPA, but not for total serum IgG1 (Figure 6B). In order 
to exclude that the observed difference could be due to the co-elution of agalactosylated 
RF bound to ACPA during the ACPA isolation procedure, we also isolated ACPA from 
RF-negative/ACPA-positive sera after mixing them with RF-positive/ACPA-negative 
sera. Fc glycan profiles of ACPA isolated from these mixing experiments did not differ 
from the profiles obtained without additional RF (data not shown), making it unlikely 
that our results are confounded by RF bound to ACPA.
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We also noted a significant lack of the sialylated ACPA-linked G2-glycoform in RF-
positive patients (RF-positive: median 5.2% (IQR 3.6-6.5), RF-negative: median 8.6% 
(4.4-11.1), p = 0.038), while the sialylated G1-glycoform was equally frequent in both 
subgroups (data not shown). No difference within these subgroups was observed for core 
fucosylation. Of note, RF-positive and -negative subgroups did not differ significantly in 
age or the degree of ESR-/C-reactive protein elevation (data not shown).
Discussion
N-glycans are crucial determinants of IgG Fc-mediated antibody effector functions. 
Modification of the Fc-linked carbohydrate backbone by addition of galactose, sialic 
acid, fucose and N-acetylglucosamine residues has differential impact on Fc-mediated 
immune responses both in vivo and in vitro 10-14, 20. Serum IgG molecules of RA patients 
have long been known to lack Fc-linked galactose residues when compared to serum 
IgG molecules of age-matched healthy controls, but whether antibodies of defined an-
tigenic specificity differ in their degree of Fc glycosylation remained undetermined in 
these patients. Given recent insights in RA pathogenesis based on the identification of 
anti-citrullinated protein antibodies, we sought to determine whether these RA-specific 
autoantibodies exhibit specific Fc glycosylation profiles that would help to elucidate 
their role in disease pathogenesis.
Comparing Fc-linked glycosylation profiles of ACPA IgG1 to the pool of total serum 
IgG1 in early arthritis patients, we found a significant lack of sialic acid residues on 
ACPA IgG1 molecules. Furthermore, we observed a non-significant trend towards a 


























figure 6: Differential ACPA Fc glycosylation in RF+ versus RF- patients.
Galactosylation profiles for ACPA (A) and total serum IgG1 (B) molecules in IgM-RF-positive and 
-negative patients. Lines represent medians.
Glycan profiling of ACPA 77
4
lower degree of ACPA-galactosylation which could result in an additional reduction in 
sialic acid residues. This finding points to an increased inflammatory potential of ACPA 
IgG1 and is in line with the recent observation that sialic acid residues rather than galac-
tose residues determine the anti-inflammatory activity of human IgG 3. Sialylated IgG 
molecules have reduced affinity to activating FcγR and, at least in the mouse, have been 
described to bind to a specific receptor on regulatory macrophages in the spleen 22. Like-
wise, a complete lack of Fc-linked sialic acid residues favours the pathogenic potential 
of IgG as demonstrated by the loss of anti-inflammatory activity of IVIG upon treatment 
with neuraminidase 3. Thus, ACPA IgG1 circulating in human serum exhibit, based on 
functional data from murine studies, a more pro-inflammatory Fc glycosylation profile 
than the pool of total serum IgG1.
With regard to core-fucosylation, we found that ACPA IgG1 G0-glycoforms were high-
ly fucosylated, an observation previously reported for total serum IgG G0-glycoforms 
of RA patients when compared to healthy controls 42, 43. Based on in vitro studies this 
high core fucose content is associated with a low potential to induce ADCC 12, but the 
functional relevance for RA pathogenesis is currently unclear and warrants further study.
Extending our ACPA-specific glycan analysis to synovial fluid we observed both a re-
duction in ACPA IgG1-linked galactose residues as well as concomitant absence of sialic 
acid residues. This lack of galactose and sialic acid residues was specific for ACPA, as no 
such difference in Fc glycosylation was observed for the pool of total IgG1. Although this 
finding is suggestive of an increased inflammatory potential of SF-ACPA as compared to 
serum ACPA, we cannot conclude that this ACPA Fc glycosylation profile is cause rather 
than consequence of inflammation. Despite this limitation, our observations demonstrate 
for the first time that ACPA in serum and in synovial fluid are not only quantitatively 
but also qualitatively different. Fc-linked glycan residues are unlikely to be enzy-
matically modified post-secretion in SF, as such modifications would be independent 
of antigen specificity and also affect the pool of total IgG in SF. Therefore, differential 
ACPA Fc glycosylation in SF as compared to serum suggests that SF-ACPA originate 
predominantly from specific B cell subsets in synovial tissue. Such ACPA-specific B 
cells could be under the influence of local cytokines that regulate glycan processing 
in plasma cells susceptible to the respective cytokine signal. Local ACPA-production 
has been postulated previously and is in line with the histological presence of germinal 
centers in synovial tissue of RA patients 23, 24, 44. RA B and T cells are known to exhibit 
reduced enzymatic activity of β-1,4 galactosyltransferase, the enzyme responsible for 
adding galactose residues to terminal GlcNAc residues in N-glycans 45, 46. Whether even 
more complex differences in N-glycan processing exist among B cell subsets in different 
compartments in RA is unknown.. In the context of RA and other autoimmune disorders 
such as SLE, it would be of particular interest to investigate whether newly generated 
and long-lived plasma cells differentially process Fc-linked N-glycans.
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We noted differential ACPA Fc glycosylation profiles in IgM-RF-positive versus 
-negative patients. Serum-ACPA of RF-positive patients lacked galactose residues when 
compared to ACPA isolated from RF-negative patients. This differential Fc glycosylation 
profile was only observed for ACPA but not for total serum IgG, the latter being in line 
with previous results 47. Our finding is intriguing, as it fuels the hypothesis of an interac-
tion between ACPA and RF. ACPA associate with RA independently of RF, but the risk 
to develop RA increases markedly (>30 fold) if RF are additionally present. In contrast, 
IgM-RF alone do not seem to associate with RA in the absence of ACPA 38. RF binding 
sites have been mapped to the Cγ2 and Cγ3 domains of human IgG. Not all RF recognize 
the same antigenic determinant, but at least one binding site involves Asn297 which 
carries the Fc-linked N-glycans 41. Thus, it has been postulated that Fc glycosylation 
can influence RF-binding affinity, and indeed RF with high affinity to agalactosyl-
ated IgG were repeatedly identified in RA patients 40, 41. Moreover, IgG aggregrates in 
synovial fluid of RA patients were found to contain high amounts of agalactosylated 
IgG, suggesting that a lack of galactoses facilitates association of IgG molecules 48. It is 
conceivable that lack of galactose residues leads to a conformational change in IgG-Fc 
structure 7 which could favour high affinity RF binding and even reveal novel epitopes 
that promote the generation of high affinity RF. So far, binding activity of IgG-RF was 
found to increase with decreasing RF Fc galactosylation (and -sialylation), compatible 
with the idea that Fc-glycosylation influences “antigenicity” of the Fc-tail 49. Whether 
RF directly or even preferentially also bind to ACPA that lack galactose residues cannot 
be concluded from our data, but our data suggest that the IgG recognized by RF exhibits 
a similar glycosylation profile than the one detected on ACPA. Thus, it is intriguing to 
speculate that ACPA G0-glycoforms help in the generation of RF with high affinity for 
agalactosylated IgG, thereby facilitating immune complex formation and complement 
activation.
Finally, as others before, we observed a strong correlation between the frequency of 
serum IgG-G0 glycoforms and ESR as well as age (data not shown). This association 
was even more pronounced for ACPA-G0 glycoforms (Figure 2). Of note, we accounted 
for these correlations in our subgroup analyses, rendering it unlikely that our results are 
influenced by these confounding factors.
In summary, we describe a detailed analysis of Fc-linked glycosylation profiles spe-
cific for ACPA. Fc glycosylation profiles differ between antibodies of different antigenic 
specifities and between antibodies isolated from different compartments. These data 
enhance our understanding of the citrulline-specific immune response and may open up 
novel strategies for therapeutic interventions.
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ABstRAct
objectives: Anti-Citrullinated Protein Antibodies (ACPA) are highly specific for Rheu-
matoid Arthritis (RA) and have been implicated in disease pathogenesis. Recent ongoing 
evidence indicates that the ACPA-response broadens before precipitation of full-blown 
RA as indicated by a more extensive isotype usage and an increased citrullinated epitope 
recognition profile. Nonetheless, the evolution of the ACPA-response is still poorly un-
derstood and might intrinsically differ from the protective responses against pathogens.
Methods: We analyzed the avidity and the avidity maturation of ACPA in relation to the 
avidity of antibodies against recall antigens.
Results: The avidity of ACPA was significantly lower compared to the avidity of anti-
bodies to the recall antigens Tetanus Toxoid (TT) and Diptheria Toxoid (DT). Moreover, 
ACPA did not show avidity maturation during longitudinal follow-up and ACPA avidity 
was relatively low also in patients that displayed extensive isotype switching.
conclusions: These observations indicate that the natural evolution of ACPA differs 
from the development of antibodies against recall antigens. Moreover, these data indicate 
that ACPA avidity maturation and isotype-switching are disconnected whereby exten-
sive isotype switching occurs in the setting of restricted avidity maturation. Intrinsic 
differences between RA specific autoantibody system and protective antibody responses 





Rheumatoid Arthritis (RA) is a chronic autoimmune disease that mainly affects the 
joints. The identification of anti-citrullinated protein antibodies (ACPA) represents an 
important breakthrough in the field of RA 1, 2. ACPA recognize post-translationally modi-
fied proteins, in which arginines have been modified into citrullinated residues by pepti-
dylarginine deiminase (PAD) enzyme during inflammation. Therefore it is hypothesized 
that citrullination of proteins in the joint may create epitopes that can serve as targets 
of ACPA, ultimately leading to inflammation and arthritis. Indeed several observations 
implicate ACPA in disease pathogenesis as it has been shown that the presence of ACPA 
predicts the emergence and outcome of RA 3-5. Moreover, ACPA have been implicated in 
disease pathogenesis by the observations that ACPA can induce and aggravate arthritis 
in mice 6, 7 and can activate human immune effector mechanisms, such as triggering of 
cellular Fc receptors 8 and activation of the complement system 9.
During a B cell response, isotype switching and affinity maturation typically occurs 
in the germinal center. Following somatic hypermutation, different B cell clones will 
compete for antigen on follicular dendritic cells (FDC). The B cells expressing surface 
immunoglobulins with a higher avidity will acquire the signals necessary for survival and 
proliferation. As a result, the total avidity of the immune response increases because low 
avidity B cells will not be stimulated and will eventually disappear from the population.
By definition, antibody affinity is the strength of interaction between a single antigen 
binding sites and soluble monovalent antigens in solutions. However, in reality antibod-
ies are multivalent and contain 2 (IgG) to 10 (IgM) antigen binding sites. In addition, 
also the antigens are often multivalent and/or nonsoluble. Therefore antibody avidity 
which is defined as the overall binding strength of polyclonal antibodies to a multivalent 
antigen provides a better measure for the strength of antibody responses.
Extensive information has been obtained regarding the avidity maturation of antibody 
responses against recall antigens, mostly following vaccination 10-12. Interestingly, in 
the mouse it was recently described that B-cells producing arthritogenic antibodies are 
relatively short lived plasmablasts that are different from the long lived plasma cells 
typically producing protective antibodies 13.
Given the implicated role of ACPA in RA, we have now investigated ACPA-avidity 




Sera of 92, ACPA positive, patients with early arthritis were selected from the early 
arthritis clinic (EAC), an inception cohort of recent onset arthritis previous described 14. 
Sera for longitudinal analysis were selected from available samples at baseline, 1 year 
and 5 year follow-up. Characteristic of patients in our cohort were as follows: 65.2% 
are female, age at inclusion is 51.7(17.0-82.3) years, disease duration is 7.71(0.2-36.13) 
months, 80.4% are RF positive and 66.3% have erosion at baseline. These individuals 
were not vaccinated with TT and DT for the purpose of this study. We also studied ACPA 
avidity at baseline during active disease and at remission in 5 RA patients with complete 
drug free remission. From 15 randomly selected RA patients we analyzed paired serum 
and synovial fluid samples. Disease duration of these patients is 8.27 (1-21) years. The 
collection and use of patient samples was approved by the local medical ethics commit-
tee in compliance with the Helsinki declaration.
Avidity assays for ACPA and recall antigens
To determine the avidity of ACPA IgG and IgG antibodies against recall antigens we 






































figure 1: Characteristics of the avidity assay.
(A) The appropriate serum dilution for the avidity assay was determined by performing a dose response 
study. The serum dilution was chosen as to obtain a 50% of maximal binding (arrows). Three representa-
tive samples for anti-CCP2 reactivity are presented.
(B) The relative Avidity Index (AI) is defined as the ratio of the amount of residual antibodies bound to 
the coated antigen after NaSCN elution (indicated by the vertical dotted line) relative to the amount of 
binding antibodies in the absence of NaSCN, expressed as percentage. The horizontal line indicates the 
50% elution profile which is used to calculate the concentration NaSCN that is necessary to elute 50% 
of the antibodies. Three representative samples for anti-CCP2 are presented.
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For ACPA the appropriate serum dilution was first determined by performing a titra-
tion using a CCP2 ELISA (Immunoscan RA Mark 2, Euro-Diagnostica, Arnhem, The 
Netherlands) with minor modifications, now using 2,2’-azino-bis-3-ethylbenzthiazoline-
6-sulphonic-acid substrate. The serum dilution at which the response was 50% of maxi-
mum was considered ‘optimal’ and a minimal dilution we used is 1:25. In addition, after 
developing the plate for 1 hour the absorbance at 415 nm had to be between 0.5-2.0 to 
allow optimal detection (figure 1A).
To determine the avidity of the anti-CCP2 antibodies, plates were incubated with the 
appropriate serum dilutions in PBS-Tween 1% BSA (PTB), for 1 hour at 37°C. After 
washing, the wells were incubated with increasing concentrations of the chaotropic agent 
sodiumthiocyanide: NaSCN at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 and 5M, for 15 minutes 
at RT. The wells were washed and bound antibodies were detected using HRP-labeled 
goat-anti-human IgG (DAKO, Denmark). The amount of antibody bound to the plate 
without elution and the amount that resisted elution by NaSCN were determined relative 
to a standard curve.
No difference in avidity was detected where ACPA avidities were measured on com-
mercial plates or on in house plates coated with CCP2 peptide (data not shown).
The “relative avidity index” (AI) was calculated 17. The AI is defined as the ratio of 
the amount of residual antibodies bound to the coated antigen after NaSCN (1M) elution 
to the amount of binding antibodies in the absence of NaSCN, expressed as percentage 
(figure 1B).
AI = remaining antibodies at 1M NaSCN (AU/ml) X 100
 binding antibodies at 0M NaSCN (AU/ml)
To determine the avidity and levels of antibodies against citrullinated human fibrinogen 
(cit Fib) we used a plate bound assay as described before 18 with minor modifications.
To determine the avidity of antibodies against modified citrullinated vimentin (anti MCV) 
we used a commercial ELISA (ORGENTEC Diagnostica GmbH, Mainz, Germany).
To determine the avidity of anti-TT IgG and anti-DT IgG we used an in-house 
ELISA 19, 20. In short, plates were coated with 100 ul/well of TT (1.5 Lf/ml in 0.05 M 
carbonate buffer, pH 9.6) or DT (0.75 Lf/ml in carbonate buffer, pH 9.6) both from 
RIVM (Bilthoven, The Netherlands).
Avidity of anti cit Fib, anti MCV, anti-TT IgG and anti-DT IgG antibodies were deter-
mined as for anti-CCP2 antibodies.
In all cases, conditions used for each of the assays were optimized to allow maximal 
antibody binding. The buffers used for coating antigens are washed away before avidity 
measurement and thus will not impact on the avidity measurement. After the antibodies 
have bound to their different antigens, the plates are washed with the same buffer and 
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eluted with elution buffer, and subjected to a similar detection of the residual antibody 
binding to the plate. In this way, this assay allows the comparison of avidities of antibod-
ies binding to different antigens 12.
Since the presence of Rheumatoid Factor (RF) could potentially influence our ob-
servations, we analyzed the occurrence of RF in the low and high avidity groups. No 
correlation between RF positive status and ACPA avidity was observed (data not shown). 
In addition, we measured avidity of RF IgM and IgG in three patients and observed also 
for RF a low avidity compared to avidity of anti-TT and anti-DT (data not shown).
Isotype measurements were performed as described elsewhere 21.
Statistical analysis
Differences between groups were analyzed with the Mann-Whitney test or ANOVA, and 
correlation was determined by the Spearman’s correlation coefficient with GraphPad 
Prism 4.0 software (GraphPad Inc, San Diego, CA, USA) or SPSS for Windows (release 
16.0, SPSS, Chicago, IL, USA). In all tests, P < 0.05 was considered significant.
Results
The avidity of ACPA is low compared to the avidity of antibodies against recall-antigens
As the avidity of antibodies towards antigens can have important implications for the 
biological effects mediated, we wished to determine the avidity of the ACPA response in 
RA patients and compared the avidity of ACPA IgG to the avidity of IgG against recall 
antigens.
In an initial group of 8 patients we analyzed the avidity of antibodies directed against 
three citrullinated antigens; the CCP2 peptide and two citrullinated proteins; cit-Fib and 
MCV, as well as the avidity of antibodies against the T cell dependent - recall protein 
antigens TT and DT. As shown in Figure 2A we observed, within the same patients, a low 
avidity for antibodies directed against all three different citrullinated antigens and a high 
avidity for antibodies against recall antigens TT and DT. To study this phenomenon in a 
larger cohort we focused on CCP2 and cit-Fib versus TT and DT. As shown in Figure 2B, 
in the cohort as a whole, the avidity of anti-CCP2 antibodies is generally low (median 
19%), with most patients displaying an avidity with an AI lower than 40% (Figure 2B). 
Next we also analyzed the avidity of antibodies directed against cit-Fib, an entire citrul-
linated protein, similar results were obtained. In sharp contrast, the avidity of antibodies 
against the recall antigens TT and DT (medians 74% and 61%, respectively) are of high 
avidity (Figure 2B), with most individuals displaying an AI of more than 40%. This is 
significantly higher than the avidity of ACPA (P<0.0001). Thus our data show that these 
ACPA are of low avidity as compared to antibodies against recall antigens.
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ACPA IgG avidity in sera represents overall avidity of ACPA
To control for the possibility that the overall avidity of ACPA ,as detected in serum, is 
influenced by retention of high avidity ACPA in the inflamed joint, we next analyzed 
ACPA avidity of patients during active disease and compared it to the avidity of ACPA 
of the same patients during complete drug free remission (N=5). We did not observe an 
increase in the overall avidity of ACPA indicating that ACPA avidity is not influenced by 
disease activity and that there is no evidence for a retention of high avidity antibodies in 
the inflamed joint (figure 3A). Likewise, we have analyzed if there is a difference in the 
avidity of ACPA IgG between patients that are only IgG positive to patients that are also 
positive for IgA and / or IgM ACPA. There was no difference in the IgG ACPA avidity 
depending on the presence of either IgM or IgA ACPA (data not shown). Furthermore we 
purified IgG from serum that was positive for IgG, IgA and IgM ACPA and compared 




           
































figure 2: The avidity of ACPA IgG is lower than the avidity of IgG against recall antigens.
(A) Avidity of ACPA IgG, anti-CCP2, anti-cit Fib and anti-MCV were compared to the avidity of IgG 
against recall antigens TT and DT in 8 patients. The data of the elution profiles are presented as mean +/- 
SEM. (B) Avidity of ACPA IgG, anti-CCP2 and anti-cit Fib, were compared to the avidity of IgG against 
the recall antigens TT and DT in 67 patients and is expressed as relative AI. The avidity of ACPA IgG is 
significantly lower than the avidity of IgG to recall antigens (P-value < 0.0001).
92 Chapter 5
avidity. Together these data indicate that the other isotypes had no impact on the avidity 
measurement of ACPA IgG (data not shown).
We also compared the avidity of anti-CCP2 in synovial fluid to the avidity of anti-
CCP2 in paired sera. Avidity of anti-CCP2 in synovial fluid was comparable to avidity 
of anti-CCP2 in sera (Fig.3B,C). Together, these data indicate that the avidity of ACPA 
as measured in serum does provide a good representation of the overall ACPA avidity.
The diversity of avidities of ACPA differs from the avidity diversity of recall antigens
So far we have depicted the avidity as avidity index (AI), a measure of the percentage 
of antibody still bound after elution with 1M NaSCN. However, since it is possible that 
elution profiles differ while having a similar AI, we also analyzed the elution profiles. 
Different antibody elution patterns for ACPA in comparison to IgG against recall antigens 
within one subject were observed (figure 4). For example, as presented in figure 4, the 
avidity of anti-CCP2 IgG present in the sample analyzed displayed a rather homogenous 
response, with over 80% of the antibodies eluting in the first 3 elution steps (Figure 
4A). In contrast, a wide distribution of avidities is observed for IgG against TT (Figure 
4B). Interestingly, the antibody response to recall antigens displays a wider distribution 
of avidity, whereas the avidity distribution of the ACPA response is, in general, narrow 
(Figure 4C). The absence of heterogeneity within the avidity-profile of ACPA, further 
indicates limited avidity maturation of the ACPA response.
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figure 3: Avidity of ACPA IgG in serum is not influenced by disease activity and is similar to ACPA 
IgG in synovial fluid.
(A) Comparison of the avidity of ACPA IgG in serum measured in RA patients during active disease at 
baseline to complete absence of disease activity at drug free remission. The avidity of ACPA measured 
in serum is not influenced by disease activity. (B) Avidity of ACPA in sera compared to avidity of ACPA 
in paired samples of synovial fluid. (C) Correlation between avidity of anti-CCP2 in sera (x-axis) and in 
paired synovial fluid (y-axis).
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Dynamics of ACPA IgG avidity
To evaluate whether there is affinity maturation of the ACPA IgG response over time 
following onset of arthritis, we next determined the avidity of ACPA in a longitudinal 
fashion, by comparing samples from the same patients at baseline and at 1 and 5 years 
follow up. We did not observe a correlation between ACPA avidity and baseline clinical 
characteristic such as age of onset, sex, DAS or CRP (data not shown). We observed 
no increase in ACPA IgG avidity over time in the patients analyzed (Figure 5A). As 
expected, the result for avidity measurements of anti-cit Fib antibodies in time confirms 
this observation (Figure 5B). In addition we did not observe a change in the high avidity 
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> 50% Ab eluted at 0.5M NaSCN
> 50% Ab eluted at 1.0M NaSCN
> 50% Ab eluted at 1.5M NaSCN
> 50% Ab eluted at 2.0M NaSCN













   
   Anti-CCP2      Anti-TT
figure 4: Different elution profiles between ACPA and IgG against recall antigens.
Different patterns of elution between anti-CCP2 IgG (A), and anti-TT IgG (B) following NaSCN elu-
tion. Percentage of antibody that was eluted after each consecutive step of NaSCN elution is expressed 
in bars and the percentage of antibody still bound after NaSCN elution is presented as a linear graph. 
The elution profiles of anti-CCP2 IgG and anti-TT IgG of one representative patient are shown. (C) The 
proportion of patients that have different elution profiles for the indicated antibody response.
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indicate that during disease progression the ACPA response does not undergo extensive 





















































A B    Anti-CCP2 Anti-cit Fib
figure 5: No avidity maturation of ACPA IgG during 5 year follow-up.
The avidity of ACPA in serial samples at baseline, 1 and 5 years follow-up were analyzed. Anti-CCP2 
avidity was analyzed in 16 RA patients (A) and anti-cit Fib avidity was analyzed in 9 RA patients (B). 





Low IgG IgM IgA IgG1 IgG2 IgG3 IgG4
I X X X X X X X
II X X X X X X
III X X X X X X
IV X X X X
V X X X X
VI X X X X X
VII X X X
VIII X X X X X
Broad ACPA isotype usage in low avidity ACPAE
Anti-CCP2























































































figure 6: ACPA avidity maturation, titers and isotypes.
Correlation between the levels and avidity of ACPA IgG; anti-CCP2 (A) and anti-cit Fib (B), and IgG 
against recall antigens; anti-TT (C) and anti-DT (D). (E) Broad ACPA isotype usage also in patients with 
low avidity of ACPA IgG. Shown are the 8 patients with the lowest avidity (numbered I – VIII) with their 
use of isotypes in the ACPA response (X indicates positivity for an isotype).
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ACPA avidity maturation, titers and isotypes
We determined the relation between antibody levels and avidity of both ACPA and IgG 
against recall antigens (Figure 6A-D). The data indicate that the avidity of IgG against 
recall antigens can be high even if the titer is low, confirming previous results. More im-
portantly, however, patients with a high titer of ACPA IgG still display only a relatively 
low avidity. This contrasts to antibodies against recall antigens which have a high avidity 
in case of a high titer.
Likewise, the isotype usage of ACPA was assessed in relation to the avidity of ACPA 
IgG. Unlike the distribution of the isotype usage of anti-TT antibodies, which is pre-
dominated by IgG1 (data not shown)19. We analyzed isotype usage in 8 patients with the 
lowest ACPA avidity and observed that there is broad usage of isotypes even in these 
patients (Figure 6E). Together these data reveal poor avidity maturation of ACPA IgG, 
despite high antibody titers and extensive isotype switching.
Discussion
In this study the ACPA response is generally of a much lower avidity than the recall 
responses and in our limited longitudinal study we did not obtained evidence for avidity 
maturation during the course of established disease. These data indicate that the regula-
tion of the RA-specific autoimmune response against citrullinated antigens differs from 
the regulation of recall-responses.
Currently, only limited information is available on the endogenous citrullinated an-
tigens recognized by ACPA. Therefore, we have used three different antigens for the 
determination of ACPA-avidity; the CCP2 peptide and two citrullinated proteins. The 
CCP2 ELISA is the most commonly used for the detection of ACPA 22, whereas the 
proteins cit-Fib and MCV have been shown to be present in the sera, synovial fluid and 
synovium of RA-patients 23, 24 and are recognized by ACPA of most RA-patients 25. We 
made similar observations for all three systems analyzed, providing internal confirma-
tion of the results.
To exclude the possibility that the observed low avidity of ACPA detected in serum 
was a reflection of preferential retention of high avidity antibodies in the inflamed joint 
we analyzed ACPA avidity during active disease and complete drug free remission, 
where all clinical activity was absent. These studies indicate that there is no change in 
the avidity of ACPA detected in serum comparing active disease to remission. As we 
also did not observe a different in ACPA avidity in paired samples of SF and serum, we 
consider it unlikely that the preferential retention of high avidity antibodies in the joint 
due to the presence of citrullinated epitopes explains the low avidity of ACPA, although 
this possibility can not formally be ruled out.
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The difference in the ACPA response as compared to ‘conventional’ B cell responses 
studied (i.e. B-cell responses against recall antigens) might be due to the nature of the 
antigen where citrullinated antigens are likely to be presented constantly in the body at 
multiple site, where recall antigens are presented for a short amount of time at a localized 
site. This would lead in a relative abundance of citrullinated antigens in the body and, 
as a consequence, the absence of competition for antigens by different B-cell clones in 
the germinal center as to be expected for recall antigens, absence of affinity maturation 
and hence low-affinity antibodies. Unlike isotype switching, avidity maturation not only 
critically depends on the presence of antigen, but most likely also on proper amounts 
of antigen in the germinal centers 26. This will result in an antibody response that does 
undergo isotype switching but does not display avidity maturation as we observed both 
at baseline and at follow-up. We favor this explanation over other possibilities such as, 
for example, lack of adequate T cell help on a limited amount of time passed after antigen 
exposure. The ACPA response is characterized by extensive isotype switching, including 
IgA and IgE 18, 21, 27. The generation of these isotypes appears T-helper cell-dependent as 
patients suffering from hyper IgM syndrome (caused by a gene defect in CD40Ligand) 
do not develop IgA responses 28, 29. Moreover, the HLA alleles predisposing to RA, only 
predispose to ACPA-positive RA and not to ACPA-negative disease 30 also indicates the 
involvement of CD4+ T helper cells in the formation of ACPA. Likewise, avidity matu-
ration of antibody responses against recall antigen takes place within weeks, whereas the 
disease duration of most RA patients is much longer.
Our data indicate that ACPA producing B cells behave differently as compared to 
‘conventional’ B cells. Recently it was shown in mice that rituximab specifically depletes 
B cells producing the autoantibodies, while sparing the ‘conventional’ plasma cells 
producing the protective antibodies 13. Therefore therapies targeting the crucial biologi-
cal mechanisms underlying ‘conventional’ B cell responses may not work similarly on 
ACPA producing B cells. In this respect, a possible interaction that could be of relevance 
is a therapy targeting the survival factors B-cells compete for during the germinal center 
reaction 31.
In conclusions, our data indicate that the ACPA response is different from antibody 
responses against recall protein antigens. The ACPA response can be of high titer, can 
use all isotypes yet is of low avidity that contrasts to antibodies against recall antigens 
that are of high avidity. These and possibly other differences between ACPA and recall 
responses are likely reflecting differences in the underlying B cells response. Under-
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ABstRAct
objectives: HLA shared epitope (SE) alleles are associated with joint destruction, the 
presence of anti-citrullinated protein antibodies (ACPA) and the ACPA fine-specificity 
repertoire in rheumatoid arthritis (RA). A large variation in joint destruction is seen 
within the ACPA-positive patient population, and it is conceivable that certain ACPA 
reactivities contribute to radiological damage. Here, we investigated whether ACPA 
fine-specificities, which are formed under the influence of SE-alleles, associate with the 
extent of radiographic joint damage.
Methods: Antibodies recognizing six citrullinated epitopes were determined in sera 
of 330 ACPA-positive RA patients genotyped for SE-alleles. The association between 
SE-alleles, ACPA fine-specificity and radiographic joint damage was assessed using 
radiographic follow-up data. A second cohort of 154 RA patients with 5- and 10-year 
radiographic follow-up was used for replication.
Results: SE alleles predisposed to the recognition of certain citrullinated epitopes. How-
ever, none of the ACPA fine-specificities studied influenced radiographic joint damage. 
Importantly, although SE-alleles associated with radiographic damage in the total RA 
population, this association was no longer detectable after stratification for the presence 
of ACPA.
conclusions: SE-alleles are instrumental in shaping the ACPA repertoire. However, 
ACPA fine-specificities formed under the influence of SE-alleles do not seem to affect 
joint destruction.
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intRoDuction
HLA shared epitope (SE) encoding genes are the most prominent genetic risk factor 
for rheumatoid arthritis (RA). SE-alleles exert their risk effect by predisposing for anti-
citrullinated protein antibody (ACPA)-positive RA1. This and other findings have led 
to the concept that RA represents at least two distinct disease entities (ACPA-positive 
and –negative RA) with different pathogenetic mechanisms2, 3.
The strength of the SE effect on susceptibility to ACPA-positive disease depends on 
the number of SE-alleles present, with two alleles conferring a higher risk of disease than 
one allele. The fact that ACPA are also found in SE-negative patients, albeit in lower 
frequency, indicates that SE alleles are not absolutely required for the development of 
ACPA1. It has been postulated that SE-alleles primarily facilitate priming and activation 
of T helper cells, which can then provide help to ACPA-producing B cells. Such help 
is required for isotype-switching and generation of a potent and long-lasting antibody 
response.
It is conceivable that certain citrullinated antigens are more potent than others in acti-
vating T cells in the context of SE-alleles. Only very few T-cell epitopes have so far been 
found, and no skewing of T-cell responses has been described. However, SE-alleles were 
found to associate with antibodies targeting peptides from citrullinated vimentin, but not 
with the presence of antibodies recognizing citrullinated fibrinogen4. This differential 
modulation of the ACPA response by SE-alleles, and the fact that disease phenotypes 
vary greatly among ACPA-positive patients, has raised the question whether certain 
ACPA fine-specificities might associate with a more severe disease phenotype. If so, 
designing assays that test for these specificities would be of prognostic value and could 
influence treatment decisions in the clinic.
In the present study, we analysed the relation between SE-alleles, different ACPA fine-
specificities and their independent effects on disease outcome.
MethoDs
Patients and Radiographs
ACPA fine-specificity was determined on baseline serum samples of RA patients partici-
pating in the Leiden Early Arthritis Clinic (EAC)5. The present study included patients 
who presented between March 1993 and November 2006 and who fulfilled the 1987 
revised ACR criteria for RA within the first year of follow-up. Annual radiographs of 
hands and feet were assessed as previously described6.
Replication of the association between SE-alleles and radiographic progression in 
relation to ACPA status was performed using data of Norwegian RA patients with a 
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maximum disease duration of 4 years included in 1992-1993 in the European Research 
on Incapacitating Disease and Social Support (EURIDISS) project7-9. Radiographs of the 
hands were available for 154 patients at baseline and assessed according to the Sharp-van 
der Heijde method 10 by one experienced reader with known time order.
Anti-CCP2 assays
Anti-CCP2 antibody levels were measured by ELISA (EAC: Immunoscan RA Mark 
2; Eurodiagnostica, Arnhem, The Netherlands; EURIDISS: INOVA Diagnostics, San 
Diego, CA, USA).
ACPA fine-specificity assays
Antibodies against the citrullinated (Cit) and the arginine-containing form of two pep-
tides derived from vimentin (Vim1-16; Vim59-74), two peptides derived from fibrinogen 
(Fibα 27-43; Fibβ 36-52), one peptide derived from alpha-enolase (Eno 5-20) and against 
citrullinated myelin basic protein (MBP) were determined by in-house ELISA as previ-
ously described4, 11.
Cut-off values were defined as the mean plus three times the standard deviation of the 
values of 30 control subjects (anti-CCP-negative EAC patients diagnosed with gout). 
Recognition was deemed to be citrulline-specific when the following requirements were 
met: 1) OD value citrullinated peptide > cut-off, and 2) OD difference (=OD citrullinated 
peptide – OD arginine-containing peptide) ≥ 0.1. The number of patients recognizing 
both the citrullinated and the arginine-variant above cut-off levels was small (~ 3%).
Statistical analysis
Association between fine-specificity recognition and SE-alleles was assessed using 
chi-square tests. Association of fine-specificities with the rate of joint destruction was 
assessed using a repeated measurement analysis on log-transformed radiological data. 
Adjustments were made for age, gender and treatment strategy used at the time of inclu-
sion as previously described5, 6. No association between inclusion period and recognition 
of separate ACPA fine specificities was found (data not shown). For the EURIDISS co-
hort, non-parametric Mann-Whitney U-test was used because of non-normal distribution 
of the data despite log-transformation. For comparison, Mann-Whitney U-test was also 
applied to the Leiden EAC where indicated.
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Results
HLA SE-alleles associate with several ACPA fine-specificities
SE-alleles associate with the presence of certain ACPA fine-specificities4. We first ex-
tended these findings by analyzing reactivity to more citrullinated epitopes, by increas-
ing the number of patients studied, and by analyzing the effect of the SE gene dose on 
ACPA fine-specificity. Three out of six citrullinated epitopes studied associated with the 
presence of SE-alleles (table 1). Reactivity to citrullinated vimentin 59-74, citrullinated 
alpha-enolase 5-20 and citrullinated MBP was found in significantly increased frequency 
in SE-positive patients, whereas no such effect was observed for the other three antigens. 
The effect was independent of the number of SE-alleles, as patients with one or two 
SE-alleles displayed a comparable profile of ACPA epitope recognition. These data 
indicate that one SE allele is sufficient to facilitate the development of certain ACPA 
fine-specificities, and that presence of a second SE allele does not further skew the ACPA 
profile towards more frequent recognition of a specific epitope.
table 1: Association of HLA SE-alleles with ACPA fine-specificity.
Displayed is the number of patients within the ACPA-positive patient population who harbor ACPA 
recognizing defined citrullinated antigens. Chi-squared test over all 3 allelic groups (Vim 1-16: p = 0.88; 
Vim 59-74: p < 0.001; Fib-α: p = 0.35; Fib-β: p = 0.92; α-enolase: p = 0.022; MBP: p = 0.006).










Vimentin 1-16 8/63 (13%) 25/188 (13%) 8/73 (11%) 41/324 (13%)
Vimentin 59-74 16/64 (25%) 100/190 (53%) 46/73 (63%) 162/327 (50%)
Fibrinogen-α 27-43 20/64 (31%) 51/190 (27%) 15/73 (21%) 86/327 (26%)
Fibrinogen-β 36-52 43/63 (68%) 128/181 (71%) 52/73 (71%) 223/317 (70%)
α-enolase 5-20 12/64 (19%) 70/190 (37%) 27/73 (37%) 109/327 (33%)
MBP 30/64 (47%) 128/190 (67%) 51/73 (64%) 209/327 (64%)
The ACPA fine-specificity repertoire does not predict future radiographic progression
ACPA-positive patients suffer from more severe disease than ACPA-negative patients. 
However, it is unknown whether distinct ACPA fine-specificities are pathogenetically 
driving the inflammatory process and thus lead to a more severe disease outcome. Con-
sidering radiographic joint damage as the most objective sign of disease severity in 
RA, we analyzed the association between baseline recognition of specific citrullinated 
antigens and progression of radiographic joint damage in ACPA-positive patients over 
the course of 5 years (figure 1, panels A and B). The ACPA fine-specificity repertoire 
in individual patients did not change during this time period12. We did not detect a 
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difference in radiographic outcome in patients who harbour ACPA of one of the fine-
specificities tested. Also, patients with ACPA that recognized more citrullinated peptides 
did not suffer from a higher degree of progression of joint damage than patients with a 
limited ACPA repertoire (figure 1, panel C). These data indicate that harbouring ACPA of 
any of the specificities tested has no direct influence on the progression of radiographic 
joint damage.
Stratification for ACPA status abolishes the effect of HLA SE-alleles on radiographic 
joint damage
None of the fine-specificities tested was found to associate with radiographic progres-
sion. A drawback of this analysis is that lack of association does not exclude that the 
investigation of other citrullinated peptides would have revealed a positive association 
with long-term joint damage. As this limitation can persist in case more (non-associating) 
figure 1: Association between different ACPA fine-specificities and radiographic progression.
(A,B) Median Sharp-van der Heijde scores (SHS) during 5 year follow-up of ACPA positive patients 
from the Leiden EAC testing positive or negative for six different ACPA fine-specificities at baseline. (C) 
Median SHS in ACPA-positive patients grouped by the number of ACPA fine-specificities recognized. 
All statistical comparisons (repeated measurement analysis) were non-significant (p>0.05). Numbers 
of patients in each group are given in the table below each figure. The line representing the group of 
patients recognizing six fine-specificities diverts from the rest due to the low number of patients in this 
group. In order to highlight this, this group is depicted with a dotted line. Radiographic data was avail-
able for n=266 ACPA-positive patients at baseline and n=132 at year 5.
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reactivities would be analyzed, we reasoned that an additional way to investigate the 
relationship between the ACPA recognition profile and radiographic outcome is to study 
the effect of SE-alleles on joint damage in ACPA-positive disease only. Since SE-alleles 
affect the recognition of certain citrullinated epitopes (table 1), SE-alleles can be inter-
preted as a surrogate marker for the constitution of the ACPA response.
While SE-alleles associated with the degree of radiographic joint damage in the total 
RA population (figure 2A), they no longer contributed to radiographic joint damage in 
ACPA-positive disease (figure 2B). We sought replication of this observation in the Nor-
wegian EURIDISS cohort. The findings in this cohort with 5 and 10-year radiographic 
follow-up confirmed our results: there was no association between the presence of SE-
alleles and radiographic damage in ACPA-positive disease (figure 2C and D).
figure 2: Shared epitope (SE) alleles exert no effect on radiographic progression after stratification for 
ACPA.
Median Sharp-van der Heijde scores (SHS) in relation to SE positivity in the entire RA population and 
after stratification for ACPA-positive disease in patients of the Leiden Early Arthritis Clinic (A/B) and of 
the EURIDISS cohort (C/D). For the Leiden EAC: radiographic data was available for n=481 patients at 
baseline and n=214 at year 5, of which n=266 were ACPA-positive (data for n=132 available at year 5). 
(A) Repeated measurement analysis: p = 0.013; Mann-Whitney U test p < 0.001 at year 1, p < 0.001 at 
year 2, p = 0.007 at year 3, p = 0.005 at year 4, p = 0.012 at year 5; (B) repeated measurement analysis: p 
> 0.05; all Mann-Whitney U p-values > 0.05. For the EURIDISS cohort: radiographic data was available 
for n=154 patients at baseline and n=142 at year 10, of which n=94 were ACPA-positive (data for n=83 
available at year 10). (C) Mann-Whitney U test p = 0.029 at baseline, p < 0.001 at year 5, p < 0.001 at 
year 10; (D) Mann-Whitney U test p = 0.36 at baseline, p = 0.93 at year 5, p = 0.97 at year 10.
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Discussion
Recent findings on ACPA fine-specificity and its association with SE alleles have fuelled 
a hypothesis in which (a) ACPA are pathogenetically driving the disease and in which 
(b) certain ACPA fine-specificities (developing preferentially under the influence of SE-
alleles) could be more pathogenic than others, leading to more severe joint destruction 
over time 4, 13. Further insights into which ACPA fine-specificities might be associated 
with disease severity could therefore have prognostic value and contribute to our under-
standing of disease pathogenesis.
Here, we could not detect an association between ACPA fine-specificities and radio-
graphic joint damage. An anti-citrulline immune response to 3 out of 6 of the epitopes 
studied developed preferentially in patients harboring SE-alleles, but this did not trans-
late into more severe radiographic outcome. Also, the number of citrullinated epitopes 
recognized by an individual patient did not influence the degree of joint destruction. 
Although we accounted for baseline treatment strategy in this analysis, and although 
no association between year of inclusion and recognition of the separate ACPA fine-
specificities was found, we cannot fully exclude that treatment effects later in the disease 
course could have influenced our results. The number of citrullinated epitopes also limits 
our study, and it cannot be excluded that other epitopes would have been more useful for 
this purpose. We addressed this issue by using SE-alleles as a surrogate marker for those 
ACPA fine-specificities that develop under the influence of SE-alleles. After stratification 
for ACPA, SE-alleles no longer contributed to joint damage. Based on this finding, we 
consider it unlikely that a SE-associated ACPA fine-specificity can be identified that 
predicts disease course in RA. If such a predictive recognition profile exists, antibodies 
recognizing this epitope are likely to be generated independent of SE-alleles.
Our findings are relevant for strategies aimed at identifying patients that are at risk 
for rapidly progressive disease and provide evidence that the recognition profile of the 
ACPA response is unlikely to have a relevant impact on radiographic progression.
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ABstRAct
objective: Two novel genetic polymorphisms on chromosome 6q23 are associ-
ated with susceptibility to rheumatoid arthritis (RA). Both polymorphisms (rs6920220 
and rs10499194) reside in a region close to the gene encoding tumor necrosis factor 
α-induced protein 3 (TNFAIP3). TNFAIP3 is a negative regulator of NFκB and as such 
involved in inhibiting TNF-Receptor mediated signalling effects. Interestingly, the initial 
associations were detected in patients with long-standing RA. However, no association 
was found for rs10499194 in a Swedish early arthritis cohort. As this could be caused by 
overrepresentation of patients with severe disease in cohorts with long-standing RA, we 
analyzed the effect of the 6q23 region on the rate of joint destruction.
Methods: Five single nucleotide polymorphisms (SNPs) in 6q23 were genotyped in 324 
Dutch patients with early RA. Genotypes were correlated to progression of radiographic 
joint damage for a follow-up time of 5 years.
Results: Two polymorphisms (rs675520 and rs9376293) associated with severity of 
radiographic joint damage in ACPA+ patients. Importantly, the effects were present after 
correction for confounding factors such as secular trends in treatment.
conclusions: Our data associate the 6q23 region with the rate of joint destruction in 
ACPA+ RA.
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intRoDuction
Recent whole genome association scans have revealed novel genetic polymorphisms 
associated with susceptibility to ACPA+ RA 1, 2. Among those, two single nucleotide 
polymorphisms (SNPs), rs6920220 (A allele) and rs10499194 (C allele), were found 
to independently associate with ACPA+ disease. Both SNPs map to a single linkage 
disequilibrium block spanning ~60 kb in a region on chromosome 6q23 that lacks known 
genes or transcripts. The closest genes are oligodendrocyte lineage transcription factor 
3 (OLIG3) and tumor necrosis factor α-induced protein 3 (TNFAIP3). The latter is of 
potential importance to RA pathogenesis, as the protein TNFAIP3 acts as a negative 
regulator of NF-κB 3. So far, however, functional relevance of the reported polymor-
phisms is unknown.
Rs6920220 was initially identified in ACPA+ RA patients (minor allele OR 1.38) 
originating from the United Kingdom (UK) 1. It was further replicated in an extended 
UK-based case-control study 4. Rs10499194 was initially identified in North American 
ACPA+ patients (the Brigham Rheumatoid Arthritis Sequential Study, BRASS; minor 
allele OR 0.67) 2. Replication was successful in two additional US cohorts selected from 
the North American Rheumatoid Arthritis Consortium (NARAC). Replication failed, 
however, in ACPA+ patients of a Swedish population-based inception cohort (the Epi-
demiological Investigation of Rheumatoid Arthritis cohort, EIRA)2. This latter finding is 
of interest, as both BRASS and NARAC are cohorts of patients with long-standing RA 
(mean disease duration BRASS: 15.4 ± 12.8 years 5; NARAC: 14.3 ± 11.1 years 6). The 
EIRA study, however, was designed to identify incident cases of RA as soon as possible 
after disease onset, resulting in an estimated mean disease duration at inclusion of only 
10 months 7.
Association of a genetic polymorphism in cohorts of patients with longstanding dis-
ease but absence of this association in an early arthritis cohort led us to hypothesize 
that the 6q23 region would associate with disease severity in ACPA+ patients. Very 
little information is currently available on the effects of genetic variation on outcome 
measures in RA 8. Therefore, we genotyped five SNPs in a Dutch early arthritis cohort 
(the Leiden Early Arthritis Clinic, EAC) and correlated genotyping data to progression 
of radiographic joint damage for a maximum follow up of 5 years.
PAtients AnD MethoDs
Patients
The Leiden EAC is a population-based inception cohort that includes patients with self-
reported symptom duration of ≤ 2 years 9. DNA samples of 324 patients consecutively 
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included between 1993 and 2003 were used for analysis. For further details see supple-
mentary file 1.
SNP selection and genotyping
Five SNPs (rs1878658, rs675520, rs9376293, rs10499194 and rs6920220) were selected 
based on a haplotype analysis across the 6q23 locus published previously.2 All SNPs are 
in imperfect linkage disequilibrium to one another (supplementary table 1). Genotyp-
ing was performed using pre-designed Taqman allelic discrimination probes (Applied 
Biosystems). Each 384 well plate contained 10 ng sample DNA per well and at least 8 
negative and 6 positive controls. Genotype calls and clusters were manually checked for 
discrepancies and doubtful calls were rejected. No SNP deviated from Hardy-Weinberg 
equilibrium. Genotyping call rates were 96.5% (rs1878658), 98% (rs675520), 95% 
(rs9376293), 94% (rs10499194), and 98.1% (rs6920220).
Serology and Radiographs
Serum samples were tested for citrulline-specific IgG antibodies using a commercially 
available ELISA kit (Immunoscan Mark2, Eurodiagnostica, The Netherlands). Radio-
graphs were scored according to the Sharp van der Heijde method 10 with known time 
order by one blinded, independent trained reader (supplementary file 1).
Statistical analysis
Association between genotypes and radiographic scoring data was analyzed using SPSS 
version 16.0 (SPSS Inc., Chicago, IL). P-values < 0.05 were considered significant. All 
p-values reported are two-sided.
Two approaches were chosen for statistical analysis. First, the average increase in 
Sharp van der Heijde scores during the follow-up period was estimated per person by 
regression analysis. Subsequently, the average increase (slope) of scores per genotype 
was compared non-parametrically using the Mann-Whitney rank-sum test.
We observed an influence of the time of inclusion (1993-2003) on the progression of 
radiographic joint damage reflecting most likely an improvement of treatment intensity 
during this 10 year time period. In order to account for this effect, we performed, as a 
second approach, a mixed model analysis described in detail in supplementary file 1.
Results
Radiographic scores of 324 Dutch RA patients (181 ACPA+, 143 ACPA-) were available 
for analysis. At least five radiographic follow-up observations were available in 57% of 
patients. A dominant model was chosen for analysis, as the frequency of patients homo-
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figure 1: Development of median Sharp van der Heijde scores plotted according to genotype/allele in 
ACPA+ (left column) and ACPA- (right column) RA patients. Year 0 equals baseline-values. Regression 
analysis was performed in order to estimate the average increase (slope) in Sharp van der Heijde scores 
over time. Slopes were subsequently compared using the non-parametric Mann-Whitney test (for 
the ACPA+ subgroup: p = 0.37 (rs1878658); p = 0.007 (rs675520); p = 0.021 (rs9376293); p = 0.05 
(rs10499194); p = 0.76 (rs6920220)).
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zygous for the minor allele of rs1878658 (G), rs10499194 (T) and rs6920220 (A) was ≤ 
5%. Figure 1 depicts the influence of genotypes on radiographic joint damage. ACPA+ 
and ACPA- subgroups were analyzed separately. Median scores and interquartile ranges 
(IQR) are provided for ACPA+ patients in table 1 (for ACPA- patients see supplementary 
table 2).
No influence of genotypes on radiographic joint damage was observed in ACPA- pa-
tients (figure 1). In ACPA+ patients, however, two polymorphisms showed reproducible 
association with disease progression over time. Presence of the G allele of rs675520 was 
found to associate with increased Sharp van der Heijde scores, as a significant difference 
was observed when the average increase (slope) in radiographic scores over time was 
compared with G as the dominant allele (median slope AG/GG = 4.6, AA = 2.3; Mann-
Whitney p = 0.007). In order to account for an effect of improving treatment strategies 
on radiographic progression during the 10 year period in which patients were included 
into the study, we next performed a mixed model analysis. This analysis identified the 
year of inclusion as a significant variable influencing the extent of radiographic joint 
damage (p = 0.005). After correcting for the year of inclusion, however, we still observed 
a significant influence of the G allele of rs675520 (AG/GG vs. AA, p = 0.026).
Similar to the G allele of rs675520, we noted an influence of the C allele of rs9376293 
on progression of radiographic joint damage (figure 1). The average increase (slope) 
in Sharp van der Heijde scores over time was significantly higher for C allele carriers 
as compared to T homozygotes (median slope CC/CT = 4.5, median slope TT = 3.0, 
Mann-Whitney p = 0.021). After correcting for the year of inclusion as described above 
a trend effect of the C allele remained (p = 0.097).
For rs1878658, rs10499194 and rs6920220, no significant influence of individual 
genotypes on radiographic joint damage was noted.
Discussion
The 6q23 region has recently been associated with disease susceptibility in RA. This 
region contains no known transcripts. The closest genes with known function are OLIG3 
and TNFAIP3. TNFAIP3 encodes protein A20, a TNF-α induced negative regulator of 
NF-κB 3, 11. Decreased levels of A20 lead to uncontrolled NFκB-activity, resulting in 
increased inflammation. This observation makes TNFAIP3/A20 and the 6q23 region 
interesting candidates that could modulate inflammation also in RA.
We were intrigued by recent differential findings for rs10499194, a SNP on chromo-
some 6q23 close to TNFAIP3, in cohorts with differing disease duration. The major allele 
(C) was found to associate with disease susceptibility in ACPA+ RA patients in three 
cohorts with long-standing disease, but not in an early arthritis cohort 2. This indicated 
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a potential impact of the 6q23 region on disease severity. In order to test for such an 
impact, five SNPs were genotyped in a cohort of Dutch patients with early RA. These 
SNPs had previously been shown to identify common haplotypes in 6q23 2. We identified 
two SNPs for which presence of alleles was associated with increased joint destruction 
in ACPA+ patients. Carriers of the G allele of rs675520 developed increased Sharp van 
der Heijde scores over time. A similar effect, although weaker, was found for the C allele 
of rs9376293. Interestingly, no association was found for any of the SNPs in ACPA- 
individuals. Although this does not exclude a contribution of the 6q23-region to disease 
severity in ACPA- disease, the latter observation is in line with recent reports detecting 
an association of the 6q23 region with disease susceptibility in ACPA+ patients only 4. 
No effect on disease severity was observed for rs10499194 and rs6920220. Based on our 
data we cannot rule out the possibility that either SNP exerts a weak effect that requires 
larger sample numbers for detection or that cannot be observed during the first years of 
disease. Interestingly, we observed nominally higher scores for the risk-conferring A 
allele of rs6920220 without reaching statistical significance. The discrepancy between 
SNPs associating with susceptibility and radiographic progression also indicates that the 
causal variant at this locus has not yet been identified. Given the large area of linkage 
disequilibrium surrounding these SNPs, further fine-mapping and functional character-
ization will have to be performed.
Data linking newly identified genetic polymorphisms to disease outcome in RA are only 
beginning to emerge. Our data are unique, as they cover a long period of radiographic 
follow-up and have been scrutinized for artefacts such as secular trends in treatment 
intensity. Albeit based on relatively low patient numbers, our data indicate a contribution 
of the 6q23 region to the rate of joint destruction in ACPA+ RA, thereby further refining 
our understanding of the effects exerted by this locus. Replication of our findings in other 
cohorts is needed. Nonetheless, this is the first study demonstrating such an effect for 
genetic polymorphisms located outside the HLA-region in ACPA+ RA patients.
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suPPleMentARy infoRMAtion on PAtients AnD MethoDs
Patients
All patients met the American College of Rheumatology 1987 revised classification 
criteria for RA and were of Caucasian origin based on self-reported ethnicity. Written 
informed consent was obtained from all participants, and the study was approved by the 
local institutional review board.
The Leiden Early Arthritis Clinic (EAC) is a population-based inception cohort that 
includes patients with self-reported symptom duration of ≤ 2 years. Follow-up visits are 
performed and radiographs of hands and feet are taken on a yearly basis. DNA samples 
of 324 patients (67.6% female; mean age 56.3 ± 15.4 years) consecutively included be-
tween 1993 and 2003 for who radiographic scoring data and ACPA status were available 
were used for analysis. 2003 as the latest year of inclusion was chosen in order to allow 
a five year follow-up period for all patients.
Radiographic scoring
The number of patients with available radiographs varied per time-point (for ACPA+ 
patients: n = 168 at baseline and n = 153, 154, 134, 119, and 122 at year 1 to 5, respec-
tively; for ACPA- patients: n = 135 at baseline and n = 121, 109, 93, 81, and 65 at year 
1 to 5, respectively). In total, radiographs of 324 patients (181 ACPA+, 143 ACPA-) 
were used for analysis. All radiographs were scored by one experienced reader who was 
blinded with respect to the patient’s autoantibody status, treatment, clinical outcome and 
genotyping results. Scoring was performed with known time order, which is more sensi-
tive to change compared to scoring with unknown time sequence 1. For quality control, 
radiographs of 60 randomly selected RA-patients were rescored by the same reader. 
This selection comprised 499 radiographs, consisting of 149 baseline radiographs and 
350 radiographs during follow-up. Reliability of radiographic scoring was calculated. 
Intraclass-observer correlation coefficients (ICC) were 0.91 for all scored radiographs, 
0.84 for baseline radiographs and 0.97 for the radiographic progression rate.
Statistical analysis
Four different treatment strategies were applied to patients included in the EAC depend-
ing on the year of inclusion. Patients included between 1993 and 1995 were treated 
initially with analgesics and subsequently with chloroquine or sulphasalazine if they 
had persistent active disease (delayed treatment) 2. From 1996 to 1998 patients were 
promptly treated with either chloroquine or sulphasalazine (early treatment) 2, 3. From 
1998 to 2002 patients were promptly treated with either sulphasalazine or methotrexate 
(early treatment) and patients included in 2002 or later were promptly treated with either 
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sulphasalazine or methotrexate combined with treatment adjustments based on disease 
activity (early and disease activity based treatment).
To take advantage of the prospective character of the EAC, consisting of repeated 
measurements, and to avoid multiple testing by performing statistical tests for each time 
point, a linear mixed model for longitudinal data was used, with the log transformed sharp 
score as response variable, to compare the radiological progression between genotype 
groups. We explored different correlation structures between the repeated measurements, 
and based on the Akaike’s information criterion, an autoregressive correlation structure 
with heterogeneous variances was chosen. This model takes missing observations into 
account, assuming that the missing is at random. Differences in progression rates between 
the different genotypes were tested by considering the significance of the interaction 
between genotype and time with time as linear covariate. The year of inclusion into 
the study was entered into the model to correct for possible confounding effects. Inclu-
sion period is a proxy for treatment modalities, because treatment strategies improved 
over time and an influence of the treatment strategy on the progression of radiographic 
joint damage was observed previously 2. The interaction between treatment strategy (i.e. 
inclusion year) and time was significant in all five analyses of the present study (p<0.05).
suPPleMentARy tABle 1:
table 1: Comparison of the LD-parameters obtained from HapMap (CEU population in rel 24 Phase II 
Nov 08) and the Leiden dataset.
hapMap ceu leiden Dataset
snP1 snP2 D’ r^2 D’ r^2
rs1878658 rs675520 1.0 0.112 1.0 0.155
rs1878658 rs9376293 1.0 0.274 1.0 0.263
rs1878658 rs10499194 1.0 0.623 0.98 0.5
rs1878658 rs6920220 1.0 0.028 0.929 0.04
rs675520 rs9376293 0.931 0.356 0.893 0.482
rs675520 rs10499194 1.0 0.191 0.98 0.289
rs675520 rs6920220 1.0 0.209 0.987 0.289
rs9376293 rs10499194 1.0 0.441 0.982 0.478
rs9376293 rs6920220 1.0 0.102 0.985 0.172
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PARt i: t cell contRol of inflAMMAtion
Regulatory T (Treg) cells are an attractive tool for the immunotherapy of autoimmune 
diseases. This is based on the notion that Treg cell deficiency or dysfunction is part 
of the pathogenetic mechanism underlying these conditions, but also on the important 
immunosuppressive properties of these cells 1-3. Crucial to this belief is the observation 
that severe multiorgan autoimmunity develops in the complete absence of Treg cells, 
for which examples exist in both mice and men 4, 5. Isolating T cells from peripheral 
blood of a diseased patient, generating or expanding a regulatory T cell subset in vitro, 
and re-infusing functional Treg cells in high quantity as cellular components that sup-
press inflammation comes close to the perception of an ideal, patient tailored therapeutic 
concept. Enticing is the use of the patient’s own cells, which excludes graft rejection. 
Prerequisite for such an approach, however, is detailed knowledge on how Treg cells 
suppress inflammation, which subsets are responsible for the suppressive effects, and 
which role Treg cells play in the development and chronicity of the respective disease.
Collagen induced arthritis (CIA) is a mouse model that shares many clinical, sero-
logical and histological characteristics with human RA 6. Amongst other features, the 
development of antibodies to collagen type II (CII) and to self-antigens is considered 
crucial to its pathogenesis 7, 8. These antibodies develop upon immunization of suscep-
tible mice with heterologous CII in combination with an adjuvant 7. T cells in this model 
are thought to mainly provide help to B cells during their development into antibody 
producing plasma cells. Indeed, depletion of Treg cells before disease induction leads 
to increased titers of collagen type II specific antibodies and to enhanced disease sever-
ity 9. This is in line with the direct suppressive effects of Treg cells on effector T cells 
described in in vitro studies 10. Conversely, one would expect that effective inhibition of 
effector T cell function would lead to a reduction in antibody titers, as less B cells receive 
the T cell help needed to differentiate into plasma cells. Earlier work has demonstrated 
that a single adoptive transfer of Treg cells in established CIA can indeed effectively 
inhibit arthritis 11. Of interest, however, this effect was not paralleled by a reduction of 
the CII-specific antibody response. This intriguing observation indicates that Treg cells 
can dampen inflammation by mechanisms other than the inhibition of effector T cells. 
As a proof of principle, we injected mice with complete Freund’s adjuvant to induce a T 
cell independent acute phase response, as evidenced by the production of serum amyloid 
P. Also here, adoptive transfer of Treg cells could inhibit inflammation, underlining the 
ability of Treg cells to inhibit not only effector T cells, but also T cell independent im-
mune responses (unpublished observation). chapter 2 describes experiments dedicated 
at elucidating the mechanism underlying this observation.
We hypothesized that the inhibition of T cell independent immune responses is likely 
to require a Treg cell derived soluble factor able to interfere with acute phase reactants. 
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Injection of adjuvants induces high levels of TNF-α, making soluble TNF receptors 
likely candidates for the effects observed 12. In addition, Treg cells had previously been 
shown to express high levels of TNFRII 13. Our studies indeed revealed that Treg cells, 
but not effector T cells, shed TNFRII from the surface upon stimulation, and that this 
soluble TNFRII is able to interfere with TNF-mediated effects both in vitro and in vivo. 
Importantly, the ability to shed TNFRII was also found for human Treg cells. Although 
CD25+FoxP3- human effector T cells constitutively expressed TNFRII, only the regula-
tory population expressing high levels of FoxP3 was capable of shedding the receptor 
upon stimulation. Additional analysis of the human Treg cell population showed that 
the HLA-DR expressing subgroup, which is known for its strong suppressive effects on 
effector T cells 14, also possessed the strongest TNFRII shedding capacity.
Several aspects of this observation have implication for Treg cells in RA. First, due to 
the important role of TNF-α in RA pathogenesis, TNFR shedding might be an important 
feature that could be exploited for optimizing Treg cell based immunotherapy. In fact, 
Etanercept, a soluble TNFRII fused to a human Fc tail, is a highly effective therapeutic 
in active RA 15. Enrichment for the TNFR shedding population could therefore yield Treg 
cells with enhanced anti-inflammatory capacity for therapeutic use.
Second, our finding contributes to a better understanding of the interplay between 
TNF-α and TNFR expression with regard to Treg cell function in RA. In this context, two 
concepts are being debated that try to explain why Treg cells fail to control inflammation 
in this disease: impaired Treg cell function versus increased resistance of effector T cells 
to Treg mediated suppression 16. Data on this issue are conflicting, as are data concerning 
the number and functionality of Treg cells in RA. Supporting the first concept, several 
studies have demonstrated inhibiting effects of TNF-α on Treg cells mediated by TN-
FRII, and found an expansion of Treg cells in RA patients upon treatment with TNF 
inhibitors 17-19. These data are in contrast to more recent studies showing that TNF-α can 
promote, by signaling via TNFRII, expansion, proliferation and survival of Treg cells 20. 
In fact, TNF-α even induced expression of TNFRII and, as in our study, constitutive TN-
FRII expression was found highest on those Treg cells that also most strongly expressed 
FoxP3. In line with this, TNFRII positive Treg cells possessed strong suppressive capac-
ity 21, indicating that TNFRII expression is closely linked to suppressive function. Based 
on our study, it is likely that part of the anti-inflammatory effects exerted by these cells is 
mediated by shedding of soluble TNFRII. In line with these stimulatory effects of TNF-α 
for Treg cell function, and in keeping with the second concept, TNF-α was also found to 
induce resistance of effector T cells to suppression by Treg cells 22. This concept fits with 
the finding of elevated TNFRII expression by synovial fluid Treg cells in RA, which also 
showed increased suppressive function in vitro 23-25. Treatment with TNF-α inhibitors 
could, therefore, lead to sensitization of effector T cells for Treg mediated suppressive 
effects, partly explaining the beneficial effects of this treatment in RA. However, as the 
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network of molecules involved in these interactions is actually much larger, including 
the TNF superfamily member lymphotoxin (TNFβ) that can bind TNFRII, further study 
is warranted to fully understand the effects.
In summary of chapter 2, we demonstrated a novel mechanism by which Treg cells 
can inhibit T cell independent inflammation. This functional feature could be exploited 
for Treg cell based immunotherapy, while it contributes to the understanding of Treg cell 
function in RA.
PARt ii: chARActeRistics of the iMMune ResPonse to 
citRullinAteD AntiGens
RA develops on the basis of a heterogeneous, complex interplay of different factors 
that eventually determine its clinical presentation. Among the available biomarkers that 
help in diagnosis and risk assessment, anti citrullinated protein antibodies (ACPA) have 
proven most useful 26. This is mainly due to their unique specificity and their prognostic 
value, both for disease development in the pre-RA period and for disease progression in 
established RA. Several aspects of the ACPA immune response remain puzzling, howev-
er, and raise the question as to what extent ACPA are truly involved in RA pathogenesis. 
Most striking is the observation that ACPA titers do not reflect disease activity, at least 
in established disease 27, 28. In fact, patients can undergo complete, drug free remission 
despite high ACPA serum titers. Also pre-disease, ACPA can be present for many years 
without causing apparent pathology. This indicates that ACPA could themselves be non-
pathogenic but surrogate markers of a yet unknown, underlying immune response. Next 
to data from murine studies, however, several recent lines of evidence show a role of 
human ACPA in complement activation, mast cell degranulation and osteoclast activa-
tion 29-31. These observations make it likely that ACPA do in fact contribute to the disease 
process. However, ACPA might require one or several additional components to acquire 
pathogenic effector functions, or could possess specific, variable features that determine 
pathogenicity. Part II of the thesis focuses on this latter aspect, with emphasis on features 
of the ACPA Fc tail and of the interaction between ACPA and its antigen.
Characteristics of the ACPA Fc tail
The Fc tail of human antibodies can activate complement and bind to specific cell surface 
receptors. In addition, the Fc tail of IgG can itself serve as antigen for rheumatoid factors 
(RF). The degree to which the Fc tail interacts with the immune system depends, in part, 
on the isotype. IgM and IgG3 are potent activators of complement, while IgG1 more 
strongly binds to activating Fc receptors on, for example, macrophages 32. In addition, 
the Fc tail of IgG carries two highly variable glycan moieties, which can modulate its 
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inflammatory potential. Based on this, we hypothesized that the degree of ACPA patho-
genicity could, in part, depend on its Fc specific glycosylation profile. This notion was 
fuelled by early studies that showed aberrant glycosylation of IgG molecules in RA 33.
An obstacle in the ACPA specific analysis of Fc linked glycans was the lack of methods 
to isolate ACPA to high purity. Therefore, we first developed a technique that allowed 
purification of ACPA from small quantities of serum samples in a high throughput man-
ner (chapter 3). This was achieved by purifying ACPA based on affinity to plate bound 
citrullinated antigen using commercially available ELISA plates. Eluting ACPA from 
these plates yielded sufficient amounts of IgG for Fc glycosylation analysis, while no 
non-specific IgG was found in eluates from plates incubated with ACPA negative serum. 
Subsequent to elution, IgG ACPA were digested with trypsin to peptide fragments of 
known mass, which allowed for the analysis of peptides carrying Fc-linked glycans by 
mass spectrometry. We noted, however, that not all ACPA were eluted from the plate 
under the conditions employed. As this could bias the analysis towards ACPA of low 
avidity, we additionally digested ACPA on plate while still bound to the antigen, and ana-
lyzed the resulting Fc glycopeptides in the same manner. Importantly, no difference was 
noted in the Fc glycosylation profile between eluted ACPA and those digested in-plate, 
indicating that the eluted fraction was representative of the overall ACPA glycan profile. 
In later studies on ACPA avidity (see below), we additionally analyzed Fc glycosylation 
profiles of high and low avidity ACPA separately, without observing specific differences 
(unpublished observation).
As a second step, we employed this technique to a set of serum and synovial fluid 
samples of patients with ACPA positive arthritis (chapter 4). ACPA specific Fc glyco-
sylation profiles and Fc glycosylation of total, non-specific IgG from individual patients 
were studied in parallel. This analysis revealed that ACPA indeed display a specific, pro-
inflammatory glycan profile, characterized by a lack of sialic acid and galactose residues. 
This feature was most prominent in synovial fluid, i.e. the site of inflammation. This 
latter finding is of interest, as it shows qualitative differences between ACPA in different 
compartments. Importantly, the Fc glycosylation profile of the non-specific IgG fraction 
in serum and synovial fluid was comparable, making it unlikely that the lack of sialic 
acid and galactose residues was due to enzymatic modification of the antibodies post-
secretion. It also indicates that ACPA specific B cells possess distinct features, which 
are not, or to a lesser extent, present in “conventional” B cells. Similar conclusions are 
supported by the observation that ACPA are primarily of low affinity (chapter 6), which 
could point to a distinct developmental pathway of these B cells. We also noted that the 
agalactosylated G0 form of ACPA was particularly frequent in patients that harbored 
rheumatoid factor (RF). This is intriguing, as it suggests an interaction between ACPA 
and RF. Such an interaction is also suggested by observations from cohort studies, which 
report increased risk for RA development in individuals positive for both autoantibodies 
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as compared to patients positive for only ACPA 34. Most RF bind to the CH2 domain of 
human IgG, which also harbors the Fc-glycosylation site 35. Therefore, it is not unlikely 
that Fc-linked glycans can modulate RF binding. In fact, several studies have shown that 
RF bind preferentially to Fc domains with G0 glycans 36-39. IgG molecules isolated from 
synovial fluid derived immune complexes also showed a high G0 content 40. However, 
while these considerations could point to a facilitated formation of immune complexes 
containing ACPA and RF, they do not explain why individuals with G0-ACPA were 
found to be more frequently RF positive. To answer this question, it will be intrigu-
ing to analyze whether lack of galactoses on the ACPA Fc tail exposes immunogenic 
neoantigens that could trigger the development of RF.
In summary, in chapters 3 and 4, we describe characteristic features of ACPA, which 
are relevant to their inflammatory potential. As Fc glycosylation of human IgG can be 
modulated ex vivo 41, this offers interesting options for therapeutic intervention.
Characteristics related to antigen recognition
ACPA specific for a mutated form of citrullinated vimentin have recently been shown to 
bind to osteoclasts, thereby inducing osteoclast activation 31. In line with this, human anti 
citrulinated vimentin antibodies, but not control IgG, enhanced bone degradation in the 
mouse. Although it was not examined if ACPA of other specificities would have similar 
effects, this finding raises the question as to whether certain ACPA fine specificities might 
be more pathogenic than others. In such a scenario, the composition of the ACPA fine 
specificity repertoire could variably change, while overall ACPA serum levels remain 
stable. In fact, the number of epitopes recognized by ACPA was found to broaden prior to 
disease onset and showed association with early disease progression 42, 43. Patients with 
undifferentiated arthritis that progressed to RA within one year recognized more citrul-
linated epitopes, including vimentin-derived peptides, than patients that remained in the 
undifferentiated state in the same period of time 43. However, once RA had developed, no 
further broadening of the epitope recognition profile was noted. Also, no specific pattern 
or sequence of antigen recognition could be discerned that differentiated progressing 
from non-progressing patients 42, 43. This finding suggests that epitope spreading, without 
preference for a certain fine specificity, reflects merely a general progression of the 
ACPA specific immune response in the early stage of disease. Still, it was not possible to 
exclude increased pathogenicity of individual ACPA reactivity’s based on these data. To 
address this question, we studied whether recognition of specific citrullinated antigens 
would relate to increased radiographic joint destruction over time (chapter 6). Analyz-
ing the ACPA recognition profile at the time of diagnosis was considered feasible, as no 
further broadening of the fine specificity repertoire at later stages had previously been 
noted 43. Of interest, our analysis revealed that none of the fine specificities tested showed 
preferential association with the degree of joint destruction during 5-year follow-up. 
134 Chapter 8
Also the number of epitopes recognized did not relate to an increase in joint damage. 
As the number of epitopes analyzed was limited in this study, we additionally analyzed 
whether SE-alleles, which can serve as a surrogate marker for the composition of the 
ACPA fine specificity repertoire, would themselves favor a profile with increased risk 
for joint destruction. Also here, however, no effect of the SE-allele was noted within the 
ACPA positive patient group. Therefore, based on these data, we consider it unlikely that 
ACPA exert differential pathogenic effects due to recognition of specific epitopes.
Little is known on the origin of ACPA producing B cells, on their development and on 
the stage at which tolerance to citrullinated antigens is broken. Similar to the epitope 
recognition profile, also the number of ACPA isotypes present in RA sera is increased at 
the time of disease onset as compared to the pre-disease state 34, 44. Also here, no further 
spreading of the isotype profile was observed in established disease 45. The continuous 
presence of ACPA IgM in some patients, however, points to a continuously regenerating 
immune response 44. While these data underline the notion that mainly the magnitude 
of the ACPA response contributes to disease development, they also indicate that ACPA 
producing B cells undergo extensive isotype switching. Isotype switching is part of the 
B cell maturation process, requires T cell help, and occurs in parallel to affinity matura-
tion in germinal centers 46. Affinity maturation requires B cells to compete for antigen 
presented by follicular dendritic cells, and only those B cells that express high affinity 
B cell receptors receive sufficient survival signals to develop into antibody secreting 
plasma cells or memory cells 47. As a result, classical germinal center reactions generate 
high affinity, class-switched B cells. While it is generally accepted that this applies to 
B cells that develop upon encounter of foreign antigens, e.g. upon vaccination or infec-
tion, it is uncertain whether the same holds true for autoreactive B cells. An important 
difference could be the abundant and continuous presence of self-antigen in autoimmune 
diseases, which could impair affinity maturation due to a lack of competition for antigen 
between B cells. To test this hypothesis in the context of the ACPA response, and in order 
to gain insight into the development of ACPA specific B cells, we studied the avidity of 
polyclonal ACPA, and compared it to the avidity of antibodies against recall antigens in 
the same patients (chapter 5). Of interest, ACPA avidity was significantly lower than 
that of tetanus or diphtheria toxoid specific antibodies, with no difference between ACPA 
isolated from serum or synovial fluid. Moreover, ACPA avidity was low irrespective of 
ACPA titer, disease activity and the number of isotypes used. Also, no avidity maturation 
could be detected over time, and based on an additional limited number of citrullinated 
antigens studied no difference was noted with regard to antibodies of differing specific-
ity. These data indicate that ACPA specific B cells undergo a different developmental 
process than “conventional” B cells, in that affinity maturation and isotype switching are 
uncoupled.
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Taken together, based on the considerations above, we understand the ACPA response as 
a continuous, polyclonal reaction to self-antigens that broadens before disease onset and 
generates low avidity antibodies of all isotypes. Of those, IgG ACPA harbor Fc tails with 
a distinct, pro-inflammatory glycan profile, which might facilitate their interaction with 
RF. Once established, ACPA isotype usage, fine specificity repertoire and avidity remain 
stable. In this context, neither the number of antigens recognized, nor ACPA specific for 
a particular antigen known so far, seem to specifically drive the disease process.
PARt iii: Genetic contRiBution to joint DestRuction
Genetic variation, in part, contributes to RA susceptibility. Although more than 30 ge-
netic polymorphisms have so far been identified that show this association in patients 
of European descent 48, little is known on the underlying mechanisms by which genetic 
risk translates to biologic effects. Analysis is often difficult, as some of these polymor-
phisms are part of an inherited haplotype and do not necessarily represent the causal 
genetic variant. Other polymorphisms reside in intergenic regions with unknown func-
tion, rendering it difficult to predict their potential effects. Some indications, however, 
can come from careful analysis of the cohorts in which a polymorphism is found. We 
were intrigued by the observation that a single nucleotide polymorphism (SNP) that had 
been reported as a risk factor for ACPA positive RA, showed significant association with 
disease susceptibility in a cohort of patients with established RA but failed to associate 
with early RA 49-51. We hypothesized that this could indicate a genetic contribution of the 
6q23 region to disease severity. To this end, we studied association of this region with 
the degree of joint destruction in patients of the Leiden Early Arthritis Clinic (chapter 7). 
The SNP initially identified resides in an intergenic region on chromosome 6q23, close to 
the gene coding for TNFAIP3 (A20). A20 is a protein involved in negative regulation of 
NFκB 52. Variation in A20 gene expression or protein function could, therefore, directly 
impact on inflammation. In fact, mice deficient for A20 expresssion in myeloid cells 
spontaneously develop severe destructive polyarthritis with high levels of inflammatory 
cytokines in serum 53. In analogy, overexpression of A20 by viral transfer of A20 cDNA 
to mice with collagen-induced arthritis via intra-articular injection induced sustained 
reduction in disease severity, also in non-injected joints 54.
When analyzing five SNPs that identify common haplotypes in the 6q23 region, two 
(rs675520 and rs9376293) significantly associated with joint damage in our study. Car-
riers of the G allele of rs675520 and of the C allele of rs9376293 showed increased joint 
destruction over time (5 years). Of interest, the SNPs associating with disease severity 
were not identical to the SNPs associating with disease susceptibility. This could partly 
be due to small sample size of our study, but also suggests that the causal variant in 
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this region has yet to be defined. Similarly, different SNPs in this region were found to 
associate with disease susceptibility in different ethnic groups (rs6920220 in Europeans 
and rs10499194 in Asians), pointing in the same direction 55.
Taken together, our study linked genetic variation in the 6q23 region to disease out-
come in RA. While the causal variant is yet unknown, accumulating evidence on the 
protein level underlines that A20, encoded by TNFAIP3, the gene closest to the poly-
morphisms described, could indeed be involved in regulating inflammation in RA. Of 
interest, association of the 6q23 region with the degree of joint destruction has recently 
been replicated in another study, confirming our results 56.
Summary and Discussion 137
8
RefeRences
1 Sakaguchi S, Wing K, Miyara M. Regulatory T cells - a brief history and perspective. Eur J 
Immunol. 2007; 37 Suppl 1: S116-123.
2 Sarkar S, Fox DA. Regulatory T cell defects in rheumatoid arthritis. Arthritis Rheum. 2007; 
56: 710-713.
3 Chavele KM, Ehrenstein MR. Regulatory T-cells in systemic lupus erythematosus and rheu-
matoid arthritis. FEBS Lett. 2011; 585: 3603-3610.
4 Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) 
mutant mouse. Am J Pathol. 1991; 138: 1379-1387.
5 Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immuno-
dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet. 
2002; 39: 537-545.
6 Asquith DL, Miller AM, McInnes IB, et al. Animal models of rheumatoid arthritis. Eur J 
Immunol. 2009; 39: 2040-2044.
7 Holmdahl R, Jansson L, Gullberg D, et al. Incidence of arthritis and autoreactivity of anti-
collagen antibodies after immunization of DBA/1 mice with heterologous and autologous 
collagen II. Clin Exp Immunol. 1985; 62: 639-646.
8 Holmdahl R, Jansson L, Larsson A, et al. Arthritis in DBA/1 mice induced with passively 
transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-
type II collagen auto-antibodies. Scand J Immunol. 1990; 31: 147-157.
9 Morgan ME, Sutmuller RP, Witteveen HJ, et al. CD25+ cell depletion hastens the onset of 
severe disease in collagen-induced arthritis. Arthritis Rheum. 2003; 48: 1452-1460.
10 Suri-Payer E, Amar AZ, Thornton AM, et al. CD4+CD25+ T cells inhibit both the induction 
and effector function of autoreactive T cells and represent a unique lineage of immunoregula-
tory cells. J Immunol. 1998; 160: 1212-1218.
11 Morgan ME, Flierman R, van Duivenvoorde LM, et al. Effective treatment of collagen-
induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum. 2005; 
52: 2212-2221.
12 Fattori E, Cappelletti M, Costa P, et al. Defective inflammatory response in interleukin 
6-deficient mice. J Exp Med. 1994; 180: 1243-1250.
13 Annunziato F, Cosmi L, Liotta F, et al. Phenotype, Localization, and Mechanism of Suppres-
sion of CD4+CD25+ Human Thymocytes. Journal of Experimental Medicine. 2002; 196: 
379-387.
14 Baecher-Allen C, Wolf E, Hafler DA. MHC Class II Expression Identifies Functionally 
Distinct Human Regulatory T Cells. The Journal of Immunology. 2006: 4622-4631.
15 Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of 
etanercept and methotrexate compared with each treatment alone in patients with rheumatoid 
arthritis: double-blind randomised controlled trial. The Lancet. 2004; 363: 675-681.
16 Chen X, Oppenheim JJ. The phenotypic and functional consequences of tumour necrosis 
factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. Immunology. 2011; 
133: 426-433.
138 Chapter 8
17 Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in 
rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004; 200: 277-285.
18 Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of 
human CD4+CD25hi T-regulatory cells. Blood. 2006; 108: 253-261.
19 Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T 
cell population in patients with rheumatoid arthritis via TGF-β. Journal of Experimental 
Medicine. 2007; 204: 33-39.
20 Chen X, Baumel M, Mannel DN, et al. Interaction of TNF with TNF receptor type 2 pro-
motes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007; 
179: 154-161.
21 Chen X, Subleski JJ, Hamano R, et al. Co-expression of TNFR2 and CD25 identifies more of 
the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol. 
2010; 40: 1099-1106.
22 Chen X, Hamano R, Subleski JJ, et al. Expression of costimulatory TNFR2 induces resistance 
of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. J 
Immunol. 2010; 185: 174-182.
23 Nagar M, Jacob-Hirsch J, Vernitsky H, et al. TNF activates a NF-kappaB-regulated cellular 
program in human CD45RA- regulatory T cells that modulates their suppressive function. J 
Immunol. 2010; 184: 3570-3581.
24 van Amelsfort JM, Jacobs KM, Bijlsma JW, et al. CD4(+)CD25(+) regulatory T cells in 
rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral 
blood and synovial fluid. Arthritis Rheum. 2004; 50: 2775-2785.
25 Cao D, Malmstrom V, Baecher-Allen C, et al. Isolation and functional characterization 
of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid 
arthritis. Eur J Immunol. 2003; 33: 215-223.
26 Scherer HU, Burmester GR. A clinical perspective of rheumatoid arthritis. Eur J Immunol. 
2009; 39: 2044-2048.
27 Landmann T, Kehl G, Bergner R. The continuous measurement of anti-CCP-antibodies 
does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with 
rheumatoid arthritis. Clin Rheumatol. 2010; 29: 1449-1453.
28 Shiozawa K, Kawasaki Y, Yamane T, et al. Anticitrullinated protein antibody, but not its 
titer, is a predictor of radiographic progression and disease activity in rheumatoid arthritis. J 
Rheumatol. 2012; 39: 694-700.
29 Trouw LA, Haisma EM, Levarht EW, et al. Anti-cyclic citrullinated peptide antibodies 
from rheumatoid arthritis patients activate complement via both the classical and alternative 
pathways. Arthritis Rheum. 2009; 60: 1923-1931.
30 Schuerwegh AJ, Ioan-Facsinay A, Dorjee AL, et al. Evidence for a functional role of IgE 
anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2010; 
107: 2586-2591.
31 Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human 
autoantibodies against citrullinated vimentin. J Clin Invest. 2012; 122: 1791-1802.
32 Janeway CA, Travers P. Immunobiology. The Immune System in Health and Disease. 3 ed. 
London: Current Biology Ltd./Garland Publishing Inc.; 1997.
Summary and Discussion 139
8
33 Parekh RB, Dwek RA, Sutton BJ, et al. Association of rheumatoid arthritis and primary 
osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985; 316: 
452-457.
34 Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity 
and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis 
Rheum. 2008; 58: 3000-3008.
35 Corper AL, Sohi MK, Bonagura VR, et al. Structure of human IgM rheumatoid factor Fab 
bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. 
Nature Structural Biology. 1997; 4: 8.
36 Soltys AJ, Hay FC, Bond A, et al. The binding of synovial tissue-derived human monoclonal 
immunoglobulin M rheumatoid factor to immunoglobulin G preparations of differing galac-
tose content. Scand J Immunol. 1994; 40: 135-143.
37 Matsumoto A, Shikata K, Takeuchi F, et al. Autoantibody activity of IgG rheumatoid factor 
increases with decreasing levels of galactosylation and sialylation. J Biochem. 2000; 128: 
621-628.
38 Chou CT. Binding of rheumatoid and lupus synovial fluids and sera-derived human IgG 
rheumatoid factor to degalactosylated IgG. Arch Med Res. 2002; 33: 541-544.
39 Imafuku Y, Yoshida H, Yamada Y. Reactivity of agalactosyl IgG with rheumatoid factor. 
Clinica Chimica Acta. 2003; 334: 217-223.
40 Leader KA, Lastra GC, Kirwan JR, et al. Agalactosyl IgG in aggregates from the rheumatoid 
joint. British Journal of Rheumatology. 1996; 35: 6.
41 Wang J, Balog CI, Stavenhagen K, et al. Fc-glycosylation of IgG1 is modulated by B-cell 
stimuli. Mol Cell Proteomics. 2011; 10: M110 004655.
42 van de Stadt LA, van der Horst AR, de Koning MH, et al. The extent of the anti-citrullinated 
protein antibody repertoire is associated with arthritis development in patients with seroposi-
tive arthralgia. Ann Rheum Dis. 2011; 70: 128-133.
43 van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the 
anti-citrullinated protein antibody response occurs before disease onset and is associated 
with the disease course of early arthritis. Ann Rheum Dis. 2010; 69: 1554-1561.
44 Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, et al. Isotype distribu-
tion of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid 
arthritis reflects an ongoing immune response. Arthritis Rheum. 2006; 54: 3799-3808.
45 van der Woude D, Syversen SW, van der Voort EI, et al. The ACPA isotype profile reflects 
long-term radiographic progression in rheumatoid arthritis. Ann Rheum Dis. 2010; 69: 1110-
1116.
46 DiSanto JP, Bonnefoy JY, Gauchat JF, et al. CD40 ligand mutations in x-linked immunodefi-
ciency with hyper-IgM. Nature. 1993; 361: 541-543.
47 Goodnow CC, Vinuesa CG, Randall KL, et al. Control systems and decision making for 
antibody production. Nat Immunol. 2010; 11: 681-688.
48 Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis 
identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010; 42: 508-514.
49 WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 
3,000 shared controls. Nature. 2007; 447: 661-678.
140 Chapter 8
50 Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk 
of rheumatoid arthritis. Nat Genet. 2007; 39: 1477-1482.
51 Thomson W, Barton A, Ke X, et al. Rheumatoid arthritis association at 6q23. Nat Genet. 
2007; 39: 1431-1433.
52 Wertz IE, O’Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of 
A20 downregulate NF-kappaB signalling. Nature. 2004; 430: 694-699.
53 Matmati M, Jacques P, Maelfait J, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers 
erosive polyarthritis resembling rheumatoid arthritis. Nat Genet. 2011; 43: 908-912.
54 Hah YS, Lee YR, Jun JS, et al. A20 suppresses inflammatory responses and bone destruction 
in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis 
Rheum. 2010; 62: 2313-2321.
55 Lee YH, Bae SC, Choi SJ, et al. Associations between TNFAIP3 gene polymorphisms and 
rheumatoid arthritis: a meta-analysis. Inflamm Res. 2012; 61: 635-641.
56 Maxwell J, Marinou I, Kuet KP, et al. Rheumatoid Arthritis-associated Polymorphisms at 










Het ziektebeeld reumatoïde artritis (RA) ontstaat door een complex samenspel van 
verschillende factoren. Genetische aanleg vormt een belangrijke basis. Vervolgens zijn 
er effecten van omgevingsfactoren waarna autoantistoffen, afweercellen, hormonen en 
lokale factoren uit bot en kraakbeen leiden tot een karakteristieke vorm van gewrichts-
ontsteking. Hoewel het klinisch beeld van RA bij patiënten met lang bestaande ziekte 
typisch en onmiskenbaar is, is de presentatie van de patiënt in een vroeg stadium heel 
variabel. In deze fase is het beloop van het ziektebeeld vaak moeilijk in te schatten, omdat 
zowel rustige, zich sluipend verslechterende vormen als vormen met een agressief, snel 
tot gewrichtsschade leidend beloop voorkomen. Recent onderzoek heeft laten zien dat, 
op basis van de aanwezigheid van autoantistoffen tegen gecitrullineerde eiwitten (anti-
citrullinated proteïne antistoffen, ACPA), het ziektebeeld valt in te delen in ten minste 
twee vormen: ACPA-negatieve en ACPA-positieve RA. ACPA zijn vaak al jaren voor de 
eerste klachten in het serum van patiënten aanwezig, ze voorspellen het ontstaan van RA 
en zijn markers voor een ernstiger beloop met veel gewrichtsschade. Ook ontwikkelen 
ACPA zich bij voorkeur bij patiënten met een specifieke genetische achtergrond. Vooral 
de aanwezigheid van bepaalde bloedgroepen op witte bloedcellen, de HLA allelen die als 
“shared epitope” allelen bekend staan, spelen een belangrijke rol bij RA. Aanvankelijk 
dacht men dat deze bloedgroep een risicofactor was voor het ontstaan van RA, maar het 
is duidelijk dat deze erfelijke factor alleen een risico vormt voor het ontstaan van ACPA-
positieve ziekte. Gezien deze associaties is er grote belangstelling voor een beter begrip 
van de door ACPA veroorzaakte biologische effecten. Ook is het van belang kennis te 
hebben van de bijdrage die andere genetische risicofactoren of bepaalde afweercellen 
zoals T-cellen leveren aan het ontstaan van het ontstekingsproces. Het in dit proefschrift 
gepresenteerde promotieonderzoek omvat deze aspecten en is daarom onderverdeeld in 
drie delen. Deel I beschrijft het onderzoek naar een mechanisme waardoor de activiteit 
van ontsteking door zogenaamde regulatoire T-cellen kan worden geremd. Deel II be-
schrijft het onderzoek naar de eigenschappen van ACPA die deze ziekteactiviteit zouden 
kunnen beïnvloeden. Ten slotte beschrijft deel III het effect dat een recent gevonden 
genetisch variant kan hebben op radiologische gewrichtsschade ten gevolge van RA.
Deel i: contRole vAn ontstekinG DooR ReGulAtoiRe t-cellen
Regulatoire T (Treg)- cellen hebben als voornaamste eigenschap dat zij de functie van 
effector T-cellen kunnen remmen. Hierdoor kunnen Treg-cellen het ontstaan van auto-
immuniteit voorkomen. Dit wordt duidelijk in situaties waarbij door een genetisch defect 
geen Treg-cellen aanwezig zijn. In de muis, maar ook in de mens leidt een gebrek aan 
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Treg-cellen tot ernstige auto-immuun ziekte waarbij van bijna alle organen, inclusief 
de gewrichten, zijn betrokken. Gebaseerd op deze observatie is de gedachte geuit dat 
Treg-cellen bij patiënten met RA ontbreken of onvoldoende werkzaam zijn, dan wel dat 
effector T-cellen ongevoelig zijn geworden voor de remmende effecten van Treg-cellen.
In een proefdiermodel voor artritis spelen effector T-cellen een belangrijke rol bij het 
ontwikkelen van de ziekte doordat ze hulp verlenen aan B-cellen. Hierdoor kunnen deze 
B-cellen de juiste autoantistoffen aanmaken. Deze autoantistoffen zijn pathogeen en 
kunnen de ziekte overdragen aan een gezonde muis. De therapeutische toediening van 
Treg-cellen in dit model remt het beloop van artritis. Hierbij valt echter op dat de Treg-
cellen geen invloed hebben op de hoeveelheid autoantilichamen. Deze bevinding gaf 
aanleiding tot de hypothese dat Treg-cellen ontsteking ook op een andere, effector T-cel 
onafhankelijke, wijze kunnen remmen. In hoofdstuk 2 wordt een nieuw, hierbij passend, 
mechanisme beschreven. Geactiveerde Treg-cellen kunnen een oplosbare factor produce-
ren die de effecten van TNF-α, een ontsteking veroorzakend eiwit, remt. TNF-α is een van 
de meest belangrijke mediatoren van ontsteking bij patiënten met RA, en therapeutische 
remming van TNF-α hoort bij de standaard behandelingen van deze ziekte. Treg-cellen 
dragen een receptor voor TNF-α, TNFRII, op hun oppervlak. Deze receptor wordt bij 
activering afgesplitst van de celwand. Dit geldt niet alleen voor Treg-cellen van de muis, 
maar werd ook voor humane Treg-cellen gevonden. Door de secretie van TNFRII wordt 
TNF-α weggevangen waardoor de ontsteking wordt geremd. Hoewel deze bevinding een 
verklaring kan zijn voor de positieve effecten van Treg-cellen op het beloop van artritis in 
de muis blijft het onduidelijk waarom dit mechanisme niet voldoende is om activiteit van 
RA in de mens te remmen. Uit verder onderzoek zal moeten blijken waarom Treg-cellen 
in patiënten met RA de ziekte niet kunnen voorkomen of onder controle kunnen brengen.
Deel ii: eiGenschAPPen vAn De AfweeRReActie teGen 
GecitRullineeRDe eiwitten
Zoals beschreven hebben ACPA een grote diagnostische maar ook voorspellende waarde 
in het kader van RA. Recente data laten zien dat ACPA directe ziektebevorderende 
eigenschappen hebben waardoor ontsteking mede veroorzaakt of versterkt kan worden. 
ACPA kunnen echter ook in hoge concentratie aanwezig zijn zonder dat er sprake is 
van actieve gewrichtsontsteking. ACPA zijn in het bloed van gezonde mensen gevonden 
jaren voordat deze mensen klachten ontwikkelden. Deze bevindingen suggereren dat 
naast de aanwezigheid van ACPA nog een cofactor nodig is om ontsteking te veroorza-
ken, of dat ACPA variabele eigenschappen bezitten die betrokken zijn bij (het ontstaan 
van) de gewrichtsontsteking. Hierbij kan ondermeer gedacht worden aan een structurele 
eigenschap aanwezig op deze antistoffen.
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Antilichamen zijn eiwitten die suikerstructuren dragen. Het Fc gedeelte van IgG mo-
leculen bevat twee suikers die in vorm en samenstelling variëren. Afhankelijk van deze 
samenstelling varieert de halfwaardetijd van het antilichaam en kan IgG in verschillende 
mate met cellen van het afweersysteem in contact treden, deze activeren of remmen en 
het complement systeem activeren. Er is al langer bekend dat IgG moleculen in serum 
van RA-patiënten minder galactose dragen dan IgG moleculen van gezonde donoren. 
Gebaseerd op deze bevinding gaan de hoofdstukken 3 en 4 in op de vraag in hoeverre 
de suikerstructuren op het Fc gedeelte van ACPA ontsteking kunnen bevorderen. hoofd-
stuk 3 beschrijft de ontwikkeling van een techniek waardoor het mogelijk werd ACPA 
uit een kleine hoeveelheid serum op te zuiveren en aansluitend het suikerprofiel te meten. 
hoofdstuk 4 maakt gebruik van deze methode voor het bepalen van ACPA Fc suiker-
profielen van een groter aantal patiënten met ACPA positieve artritis. Interessant genoeg 
werd gevonden dat ACPA inderdaad een ontsteking bevorderend suikerprofiel dragen 
omdat ACPA veelal de suikers siaalzuur en galactose missen. Het ontbreken van deze 
suikers maakt de communicatie met afweercellen via activerende Fc receptoren makke-
lijker. Opvallend was de bevinding dat ACPA in synoviaal vocht het meest inflammatoire 
profiel hadden. Deze eigenschap is specifiek voor ACPA omdat dit niet werd gevonden 
voor het “niet-specifieke” IgG in het synoviale vocht. Deze observatie suggereert dat 
ACPA producerende B-cellen antilichamen maken met een specifieke suikerstructuur die 
mogelijk extra kunnen bijdragen aan het ziekteproces. Inderdaad werd een sterke corre-
latie gevonden tussen activiteit van de ziekte en gebrek aan galactose. Nader onderzoek 
moet nu laten zien of de verandering van de suikerstructuur aan ACPA voorafgaat aan 
de stijging van ziekteactiviteit. Dit zou kunnen worden verwacht indien er een causale 
relatie aanwezig zou zijn.
Deze data geven ook aanleiding tot de vraag of ACPA producerende B-cellen mogelijk 
een aparte ontwikkeling ondergaan. ACPA bestaan in alle isotypes. Dit geeft aan dat 
ACPA zeer waarschijnlijk de klassieke stappen van ontwikkeling in het germinal center 
doorlopen. Hier gaan B-cellen o.a. over van de productie van het IgM isotype naar de 
productie van het IgG, A of E isotype. Ook ondergaat de B-cel in een germinal center 
verdere uitrijping waardoor de geproduceerde antistoffen antigenen beter, met een ho-
gere affiniteit, kunnen herkennen. Deze rijping vindt plaats indien na competitie tussen 
B-cellen voor het antigeen dat ze herkennen. De B-cel met de hoogste affiniteit zal in dit 
proces overleven. Daar autoantigenen zoals gecitrullineerde eiwitten overal aanwezig 
zijn, is het de vraag of er competitie tussen B-cellen optreedt nodig voor affiniteitrijping 
van antistoffen. Inderdaad vonden wij, zoals beschreven in hoofdstuk 5, dat dit niet 
het geval blijkt te zijn. ACPA bleken, op groepsniveau, vooral een lage aviditeit te heb-
ben. De aviditeit veranderde niet in de loop van de tijd en verschilde significant van de 
aviditeit die werd gevonden voor anti-tetanus of anti-diphteria toxine antilichamen. Alles 
overwegende impliceert dit dat ACPA producerende cellen een proces van ontwikke-
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ling doorlopen dat verschilt van dat van conventionele B-cellen. Dit zou in de toekomst 
aanknopingspunten kunnen geven voor een gerichte interventie in dit proces.
Tevens staat in deel II beschreven in hoeverre het herkenningsprofiel van ACPA, ge-
bruikmakend van verschillende gecitrullineerde antigenen, correleert met verschillende 
stadia van het ziekteproces. De ACPA-reactie is polyclonaal. Dit betekent dat ACPA 
verschillende gecitrullineerde antigenen herkennen. Dit maakt de aanname mogelijk 
dat bepaalde antigenen “belangrijker” zijn voor de ziekte dan andere, waardoor vari-
atie in het herkenningsprofiel van ACPA zou kunnen correleren met stadia van ziekte. 
Gebaseerd op deze overweging is in hoofdstuk 6 beschreven of de fijn-specificiteit van 
ACPA relateert met het ontstaan van radiologische schade. Analyse van vijf verschil-
lende fijn-specificiteiten liet ook na stratificatie van de onderliggende genetische variatie 
geen aanwijzing zien dat het herkenningsprofiel geassocieerd is met de mate van radiolo-
gische gewrichtsdestructie. Dit betekent, dat het onwaarschijnlijk is dat herkenning van 
de aanwezigheid van een bepaalde specificiteit binnen de groep van ACPA bijdraagt aan 
het ziekteproces.
Deel iii: BijDRAGe vAn Genetische vARiAnten AAn 
RADioloGisch GewRichtsDestRuctie
Er zijn inmiddels meer dan 30 genetische polymorfismen geïdentificeerd die het risico 
verhogen om RA te ontwikkelen. Het blijkt tot nu toe echter uiterst moeilijk het onder-
liggende mechanisme voor elk factor te bepalen. Een recent ontdekte risicofactoor ligt 
in een regio tussen twee genen op chromosoom 6q23, waarbij associatie met het gen 
dat codeert voor TNF-AIP3 (A20) het meest waarschijnlijk lijkt. A20 is een eiwit dat 
zorgt voor de negatieve regulatie van NFκB, een transcriptiefactor die o.a. de expressie 
van TNF-α bevordert. In het kader van RA is A20 interessant, omdat bij muizen de 
afwezigheid van A20 tot ernstige artritis leidt, terwijl de overexpressie van A20 artritis 
kan remmen. Opvallend was dat het risico bevorderende genetische polymorfisme al-
leen gevonden werd in een cohort van patiënten met lang bestaande ziekte, maar niet 
in cohorten met kort bestaande RA. Dit gaf aanleiding tot de aanname dat deze variant 
mogelijk invloed heeft op ernst van die ziekte. In hoofdstuk 7 is beschreven of in totaal 
5 genetische polymorfismen in de 6q23 regio de kans verhogen op het ontstaan van 
gewrichtsschade. Interessant genoeg werd gevonden dat twee polymorfismen inderdaad 
significant geassocieerd zijn met een ernstig beloop van RA. In combinatie met de data 
op eiwitniveau dragen deze bevindingen bij aan de hypothese dat de 6q23 regio direct 










Hans Ulrich Scherer werd in 1975 geboren in München. Vanaf 1986 woonde hij in 
Berlijn. In 1991/1992 bezocht hij voor een jaar Northfield Mount Hermon School in 
Massachusetts, Verenigde Staten in het kader van het programma ASSIST (American 
Secondary Schools for International Students and Teachers). Hij slaagde in 1994 voor 
het eindexamen gymnasium in Berlijn. Vervolgens voltooide hij gedurende 17 maanden 
de vervangende dienstplicht in Avignon, Frankrijk in het kader van het vrijwilligers 
programma ICE (Initiatief Christenen voor Europa). In 1995 begon hij aan zijn studie 
geneeskunde aan de Vrije Universiteit Berlijn, die hij vervolgens voortzette aan de 
Eberhard Karls Universiteit Tübingen en de Humboldt Universiteit Berlijn. Zijn eerste 
contact met basaal biomedisch wetenschap kwam tot stand tijdens een stage aan de 
International Agency for Research on Cancer in Lyon, Frankrijk. Vervolgens deed hij 
twee jaar lang onderzoek in het immunologisch laboratorium van de afdeling cellulaire 
biologie van de Universiteit Tübingen. In deze tijd ontving hij een studiebeurs en was hij 
lid van het Graduiertenkolleg “Zellbiologie in der Medizin” van de Duitse Organisatie 
voor Wetenschappelijk Onderzoek (DFG). Met de resultaten van het onderzoek verricht 
in Tübingen behaalde hij zijn Duitse doctorstitel met het predicaat “magna cum laude”. 
Hij studeerde af in 2002.
In 2003 begon hij aan zijn opleiding tot specialist interne geneeskunde / reumatologie 
aan het Charité Universitair Medisch Centrum te Berlijn. Als ontvanger van een Articu-
lum Fellowship heeft hij in 2006/2007 14 maanden onderzoek verricht bij de afdeling 
reumatologie van het Leids Universitair Medisch Centrum (LUMC). Na het afronden 
van zijn opleiding tot internist in Berlijn keerde hij in 2010 terug naar Leiden voor 
het voortzetten van wetenschappelijk onderzoek. Daarnaast volgt hij zijn opleiding tot 
reumatoloog. Voor zijn wetenschappelijk onderzoek won hij diverse reisbeurzen evenals 
de Abstract Award en de Young Investigator Award van de European League Against 
Rheumatism (EULAR). Hij werd uitgenodigd deel te nemen aan het ACR/EULAR 
Exchange Programma in 2012.
Hij woont samen met Ute Braig-Scherer en zijn twee dochters Anouk en Milou in 
Leiden.

List of publications 155
&
list of PuBlicAtions
* : included in this thesis
# : these authors contributed equally
van der Woude D, scherer hu, Huizinga TW, Toes RE. Pathogenic relevance of 
anti-citrullinated vimentin antibodies: comment on the article by Montes et al. Arthritis 
Rheum. 2013;65:541-542.
Suwannalai P, Britsemmer K, Knevel R, scherer hu, Levarht EW, van der Helm-van Mil 
AH, van Schaardenburg D, Huizinga TW, Toes RE, Trouw LA. Low-avidity anticitrul-
linated protein antibodies (ACPA) are associated with a higher rate of joint destruction 
in rheumatoid arthritis. Ann Rheum Dis. 2013. DOI 10.1136/annrheumdis-2012-202615
scherer hu, Burmester GR, Haupl T. [Biomarkers and personalized medicine]. Z 
Rheumatol. 2013;72:20-26.
Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ, Baum 
W, Nimmerjahn F, Szarka E, Sarmay G, Krumbholz G, Neumann E, Toes R, scherer 
hu, Catrina AI, Klareskog L, Jurdic P, Schett G. Induction of osteoclastogenesis 
and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 
2012;122:1791-1802.
Wang J, Balog CI, Stavenhagen K, Koeleman CA, scherer hu, Selman MH, Deelder 
AM, Huizinga TW, Toes RE, Wuhrer M. Fc-glycosylation of IgG1 is modulated by B-
cell stimuli. Mol Cell Proteomics. 2011;10:M110 004655.
van der Linden MP, Batstra MR, Bakker-Jonges LE, Detert J, Bastian H, scherer hu, 
Toes RE, Burmester GR, Mjaavatten MD, Kvien TK, Huizinga TW, van der Helm-van 
Mil AH. Toward a data-driven evaluation of the 2010 American College of Rheumatol-
ogy/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible 
to look at levels of rheumatoid factor? Arthritis Rheum. 2011;63:1190-1199.
* Suwannalai P, scherer hu, van der Woude D, Ioan-Facsinay A, Jol-van der Zijde CM, 
van Tol MJ, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA. Anti-citrullinated protein 
antibodies have a low avidity compared with antibodies against recall antigens. Ann 
Rheum Dis. 2011;70:373-379.
156 List of publications
* scherer hu#, van der Woude D#, Willemze A, Trouw LA, Knevel R, Syversen SW, 
van der Linden MP, Lie B, Huizinga TW, van der Heijde DM, van der Helm-van Mil 
AH, Kvien TK, Toes RE. Distinct ACPA fine specificities, formed under the influence of 
HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid 
arthritis. Ann Rheum Dis. 2011;70:1461-1464.
scherer hu, Burmester GR. Adaptive immunity in rheumatic diseases: bystander or 
pathogenic player? Best Pract Res Clin Rheumatol. 2011;25:785-800.
Ioan-Facsinay A, el-Bannoudi H, scherer hu, van der Woude D, Menard HA, Lora 
M, Trouw LA, Huizinga TW, Toes RE. Anti-cyclic citrullinated peptide antibodies are 
a collection of anti-citrullinated protein antibodies and contain overlapping and non-
overlapping reactivities. Ann Rheum Dis. 2011;70:188-193.
Becker MO, Bruckner C, scherer hu, Wassermann N, Humrich JY, Hanitsch LG, 
Schneider U, Kawald A, Hanke K, Burmester GR, Riemekasten G. The monoclonal 
anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an 
open-label study. Ann Rheum Dis. 2011;70:1340-1341.
scherer hu, van Pel M, Toes RE. Mesenchymal stem cells in autoimmune diseases: 
hype or hope? Arthritis Res Ther. 2010;12:126.
* scherer hu, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA, Wang 
J, Haupl T, Burmester GR, Deelder AM, Huizinga TW, Wuhrer M, Toes RE. Glycan 
profiling of anti-citrullinated protein antibodies isolated from human serum and synovial 
fluid. Arthritis Rheum. 2010;62:1620-1629.
* scherer hu, van der Linden MP, Kurreeman FA, Stoeken-Rijsbergen G, Cessie S, 
Huizinga TW, van der Helm-van Mil AH, Toes RE. Association of the 6q23 region with 
the rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2010;69:567-570.
scherer hu, Dorner T, Burmester GR. Patient-tailored therapy in rheumatoid arthritis: 
an editorial review. Curr Opin Rheumatol. 2010;22:237-245.
Hoffmann C, Hoffmann P, Lun A, Buning C, Hiepe F, scherer hu, Steinhagen-Thiessen 
E, Weimann A. Is there a role for mannan-binding lectin in the diagnosis of inflammatory 
bowel disease? Immunogenetics. 2010;62:231-235.
List of publications 157
&
Brueckner CS, Becker MO, Kroencke T, Huscher D, scherer hu, Worm M, Burmester 
G, Riemekasten G. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis 
from a single centre pilot study. Ann Rheum Dis. 2010;69:1475-1478.
* scherer hu, Wang J, Toes RE, van der Woude D, Koeleman CA, de Boer AR, Huiz-
inga TW, Deelder AM, Wuhrer M. Immunoglobulin 1 (IgG1) Fc-glycosylation profil-
ing of anti-citrullinated peptide antibodies from human serum. Proteomics Clin Appl. 
2009;3:106-115.
scherer hu, Burmester GR. A clinical perspective of rheumatoid arthritis. Eur J Im-
munol. 2009;39:2044-2048.
Wang J, van Dongen H, scherer hu, Huizinga TW, Toes RE. Suppressor activity among 
CD4+,CD25++ T cells is discriminated by membrane-bound tumor necrosis factor alpha. 
Arthritis Rheum. 2008;58:1609-1618.
* scherer hu#, van Mierlo GJ#, Hameetman M#, Morgan ME, Flierman R, Huizinga 
TW, Toes RE. Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits 
the induction of inflammatory mediators. J Immunol. 2008;180:2747-2751.
scherer hu, van Landeghem FK, Buttgereit F. [Polyarteritis nodosa - a “classical” 
case]. Z Rheumatol. 2006;65:311-314.
scherer hu, Burmester GR, Riemekasten G. Targeting activated T cells: successful use 
of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis. Ann 
Rheum Dis. 2006;65:1245-1247.
scherer hu, Burmester GR. [Biologicals in the treatment of rheumatic diseases]. Dtsch 
Med Wochenschr. 2006;131:2279-2285.
scherer hu, Burmester GR. [Rheumatology]. Internist (Berl). 2005;46:882-891.
Kary S, Fritz J, scherer hu, Burmester GR. Do we still miss the chance of effectively 
treating early rheumatoid arthritis? New answers from a new study. Rheumatology 
(Oxford). 2004;43:819-820.
Singh-Jasuja H, scherer hu, Hilf N, Arnold-Schild D, Rammensee HG, Toes RE, 
Schild H. The heat shock protein gp96 induces maturation of dendritic cells and down-
regulation of its receptor. Eur J Immunol. 2000;30:2211-2215.
158 List of publications
Singh-Jasuja H, Hilf N, scherer hu, Arnold-Schild D, Rammensee HG, Toes RE, Schild 
H. The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator 
of dendritic cells. Cell Stress Chaperones. 2000;5:462-470.
Non indexed publications and Chapters in Books
Burmester GR, Feist E, scherer hu, Villiger PM. 2012. Biologika Therapie. In Klinische 
Immunologie. Peter, Pichler, Müller-Ladner, Editors; Elsevier Publishers, 154-161.
Kvien TK, scherer hu, Burmester GR. 2009. Rheumatoid Arthritis. In EULAR Com-
pendium on Rheumatic Diseases. J.W.J. Bijlsma, Editor; BMJ Publishing Group Ltd, 
61-80.
scherer hu, Burmester GR. 2008. New Thoughts on the Pathogenesis of Rheumatoid 
Arthritis. Int J Adv Rheumatol. 5(4):106-14.
scherer hu, Burmester GR. 2004. Practical Issues surrounding the Use of Biological 
Therapies in Patients with Rheumatic Diseases. Int J Adv Rheumatol. 2:2-8.
scherer hu, Scholze S, Burmester GR. 2004. [Immunopathology of rheumatoid arthri-
tis - Cytokines and new cellular targets]. In Zytokinwirkung und Zytokinhemmstoffe in 
der Rheumatologie - Klinischer Einsatz von Immunmodulatoren. H. Nüßlein, Editor; 




A frequently quoted statement at the Leiden Department of Rheumatology is accredited 
to former head of department professor Ferry Breedveld and claims: “science is a social 
affair”. Looking back on how this thesis came about, no delineation would fit better.
2005, EULAR congress in Vienna: Dear René (professor Toes), had you not suddenly 
been standing in front of my poster at this meeting, six years after we had met in the 
lab of professor Hans-Georg Rammensee in Tübingen and later lost sight of each other, 
neither would I live in Leiden today nor would this thesis have ever been written. Since 
then, you have been invaluable mentor, ever-optimistic motivator, unreserved promoter, 
and, at the same time, good friend – a combination I cannot esteem high enough and 
for which I sincerely thank you! Professor Huizinga, dear Tom, you granted me the op-
portunity to become part of your vivid department, you gave me the chance to experience 
its stimulating, enthusiastic atmosphere, to learn and grow within its shell and to profit 
from its clinical and scientific potential. This confers pride and challenge every day and 
I am deeply grateful for your outright confidence and commitment, for the perspectives 
you offer, and for your willingness to help wherever you can.
I am deeply indebted to many colleagues, basic researchers and clinicians, who have 
helped and supported me with much patience and comprehension. Not all can I mention 
by name, and I apologize to those I might miss. Leendert, Andreea and Fina, you are 
and have been tremendously important, offering help on many scientific issues, provid-
ing knowledge, suggestions and criticism. I take much motivation and inspiration from 
working with you! Ellen, it is a particular privilege that I may rely on your experience 
and advice. Your contribution to this thesis has been invaluable! Gerrie, your help with 
genotyping (chapter 7) needs acknowledgment, thank you! Others from my “early” 
days at D3: Wang, Wanda, Geertje, Anouk, Onno and those who are still there: Aleida, 
Annemarie, Nivine, Marjolijn, Joris. All of you generate an atmosphere, which makes it 
worth taking the effort to squeeze basic research in between clinical duties.
Annemie, you are both excellent clinician and committed scientist with a research 
line that is truly translational. Thank you for frequent advice, for clinical teaching and 
mentoring. Liebe Diane, ein Wort von besonderem Dank! Oft hilfst Du mir, die kleinen 
Unterschiede zwischen den Niederlanden und Deutschland zu überbrücken. Dies bedeu-
tet mir viel, ebenso wie Deine Freundschaft! Jullie twee, hartelijk dank voor jullie rol 
als paranimfen!
I am grateful to all members of the staff, the fellows in training, the research nurses and 
secretaries for a warm welcome and a pleasant atmosphere, for continuous supervision, 
help in sample collection and commitment to research.
Manfred, had it not been for you and your team, amongst which I sincerely thank 
Carolien, never would I have started to dig into the fascinating world of carbohydrates. 
160 Dankwoord
Thank you for this fruitful collaboration! Yoann, je suis très content que tu sois venu 
travailler avec nous. Merci pour le soutien au laboratoire et les discussions vivantes sur 
la glycobiologie des anticorps !
Professor Burmester, in Ihrer Klinik konnte ich über Jahre spannende Rheumatolo-
gie und klinisch angewandte Forschung erleben. Für Ihre Unterstützung, Ausbildung, 
Förderung und nicht zuletzt für den Vorschlag zum Articulum Fellowship möchte ich 
Ihnen sehr herzlich danken. Auch Professor Dörner, Hiepe, Buttgereit und Riemekasten 
sei gedankt für wertvollen Rat bei der Wahl meines wissenschaftlichen und klinischen 
Weges. Lieber Henrik, Dir sei gedankt für Freundschaft und wertvolle Unterstützung. 
Meinen Berliner Kollegen, allen voran Udo, aber auch Anne, Konstanze, Conny, Bimba, 
Tobias und Mike sei dafür gedankt, dass sie die freundschaftliche Verbindung nicht 
abreißen lassen.
Ich habe das besondere Glück, in eine Familie eingebettet zu sein, die viel Anteil nimmt 
an meiner Arbeit und unserem Leben in den Niederlanden. Mama und Papa: Ihr habt 
durch viel Arbeit und Voraussicht Bedingungen geschaffen, die mir das unbeschwerte 
Folgen eines eigenen Weges ermöglichen. Nie habt Ihr gezögert, mich zu unterstützen, 
egal auf welche Entfernung, und immer habt Ihr ein untrügliches Gespür dafür, wie es 
uns geht. Habt vielen Dank dafür! Liebe Kathrin, ich durfte viel davon profitieren, der 
kleine Bruder zu sein. Du stehst mir oft mit Rat und Verständnis zur Seite. Ich bin sehr 
stolz auf meine große Schwester!
Zu guter Letzt, liebe Ute! Du hast mich für diese Promotion mehr als ein Jahr lang 
entbehrt, Dich auf das Experiment Niederlande eingelassen und viele Unsicherheiten in 
Kauf genommen. Für dieses Vertrauen möchte ich Dir sehr danken! Durch Dich haben 
wir zwei wunderbare Kinder, Ihr alle sorgt dafür, dass ich nicht vergesse, ein Leben 
außerhalb der Klinik zu leben. Seid herzlich und fest umarmt dafür! Und ja, Anouk, Du 











Basic Disease Mechanisms 
in Rheumatoid Arthritis
HAnS UlRicH ScHeReR
